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THE SYNTHESIS AND CHARACTERIZATION OF MULTIFUCNTIONAL
NANOPARTICLES OF ELASTIN-LIKE POLYPETIDES FOR THERANOSTIC
APPLICATIONS
JAMES T. COLE
ABSTRACT
Theranostics is a promising field that aims to combine therapeutics and
diagnostics into single multifunctional formulations. This field is driven by advancements
in nanotechnology and specifically in the creation of multifunctional nanoparticles
capable of providing the necessary functionalities. Elastin-like polypeptides (ELPs) are a
class of environmentally responsive biopolymers that are known to undergo a transition
in response to various stimuli. The organic nature of ELPs along with the ability to
control their design at the gene level and the aforementioned responsive behavior make
them a promising candidate for use in theranostic systems. The system presented here is
one of the first examples of using ELPs as the base for multifunctional theranostic
nanoparticles.
Presented in this study is a fully protein based self-assembling nanoparticle
system based on micelles of ELPs for use in theranostic applications. Micelle forming
ELP constructs have been modified through the fusion of the protein based MRI contrast
agent CA1.CD2 to the C terminal of existing protein constructs. Micelles were then
crosslinked into stable nanoparticles that relied only on changes in temperature to drive
the transition. In addition to that, a targeting peptide has been added to the system as well
to provide active targeting to cancer cells. As a contrast agent the system has been shown
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to bind and retain gadolinium while effectively providing contrast in T1 weighted
imaging and having higher relaxivity values than clinical contrast agents. Modification
of the architecture of the construct through changes of the tail length, and through
creation of mixtures did not drastically affect the behavior of the system demonstrating
its flexibility. Here I detail, the design, synthesis of the expression, purification and
characterization of all the required properties of the constructs.
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CHAPTER I
INTRODUCTION AND BACKGROUND
(Modified from publication with N.B. Holland, Drug Delivery and Translational Research, 5,
2015, 295-309)

1.1. Multifunctional nanoparticle theranostic systems
Cancer is the second leading cause of death in the United States with projections
estimating 1,665,540 new cases occurring with 588,720 deaths or 1,600 deaths per day1.
Despite advances in treatment, diagnosis and prevention options, cancer mortality rates
however have only dropped 1.6%, which given the total number of cases, is not a
significant improvement2. These statistics indicate that there is a pressing need to develop
novel treatments and approaches that will enhance the survival rates.
Chemotherapeutics, although successful in reducing deaths directly related to
cancer, suffer from very poor pharmacokinetic profiles as well as non-specific
mechanisms of action, which in turn leads to a tremendous amount of systemic toxicity
for the patient. These drugs also are known to target any highly proliferative cell, not just
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cancer, and the non-specific mechanism of action exposes all of these cells to the drug
and causes damage to these as well, such as hair follicles, stomach lining and bone
marrow3. The non-specific mechanism of action also reduces the amount of drug that is
actually delivered to the cells of interest, which results in the need for higher and
continuous doses.
In recent years nanoscale materials have been developed for a wide range of
purposes related to drug delivery, cancer treatment and diagnosis. These materials present
numerous opportunities to improve the current state of cancer diagnosis and treatment
available to patients. Currently there are numerous clinically approved formulations that
are comprised of nanoparticle drug delivery systems which have been shown to reduce
the toxic side effects associated with traditional chemotherapy regimens4. These
therapeutic loaded nanoparticles have displayed limited long-term success clinically,
which has led to the need to attempt to develop new strategies to improve the efficacy of
nanoscale treatments through addition of numerous functional elements. Active targeting
enhancements as well as imaging modalities have been imparted into the nanoparticles to
create truly multifunctional formulations.
Theranostic nanoparticles represents the culmination of all the strategies that have
been imparted onto multifunctional nanoparticles into one package. The traditional
definition of theranostics is that they are a therapeutic (Thera-) and diagnostic (nostic) in
the same formulation5. In order to achieve this multi-functionality typically 4 components
are include in the formulation (Figure 1-1).
1) Nanoparticle base
2) Diagnostic imaging domain
2

3) Targeting ligand
4) Therapeutic
Once the interplay between all of the components has been optimized the field of
theranostics holds the ability to potentially drive the field of nano-medicine into the area
of “personalized medicine”6. The concept of personalized medicine is to attempt to tailor
medicinal regiments and treatments to the specific characteristics of each individual
patient7 due to the idea that no single individual undergoes the same response to any
therapeutic agent. This therapy may aid in reducing undesirable side effects of treatment
and potentially produce better results.
The diagnostic imaging domain component can be utilized before starting
treatments, which can potentially allow for the exact nature, phenotype and stage of the
disease state to aid in guiding treatment. This capability allows theranostic compound to
act as a guided biomarker to support the treatment regimen chosen, the efficacy of the
dosage as it’s delivered or predict the response to treatment8. In theory this powerful
technique can help to maximize drug efficacy and reduce the guesswork associated with
development of cancer treatments. In order to take advantage of these techniques
however, it is necessary for a sufficient amount of contrast to accumulate in the region of
interest. The usage of the nanoparticle platform becomes quite advantageous in this
regard because of the ability to decorate or functionalize the surface of the particles with
these domains. Commonly included imaging modalities include magnetic resonance
imaging (MRI), computed tomography (CT), optical imaging (fluorescence and
bioluminescence) and radionuclide imaging (PET and SPECT).
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There are a large number of nanoparticle formulations that can be used as the base
for a theranostic system, and these include both organic and inorganic nanoparticles.
Common materials used to synthesize or form nanoparticle systems include proteins,
polymers, lipids, gold and iron oxides. Each class of particles will have a size of less than
150 nm in diameter, with highly heterogeneous particle distributions and sufficient
stability in vivo. Further these particles must be able to be functionalized with imaging,
therapeutic cargo and targeting elements while retaining their nanoparticle nature upon
the addition of components. The use of targeting ligands decorated on the surface of the
theranostic nanoparticles, allows for direct binding of the system to receptors that are
overexpressed on tumors. Finally therapeutics can be encapsulated within these particles
and be designed to either have slow release properties, which is typical of most
therapeutic drug combinations or designed to have triggered release capabilities, such that
upon endocytosis of the nanoparticle release occurs due to change in the environment.
What follows are examples of possibilities for the different components in a theranostic
system as well as useful examples.
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Figure 1.1. Schematic of theranostic nanoparticle. Included in a single system is a
nanoparticle, an imaging component, a targeting moiety and a therapeutic component.
1.1.2. Components of multifunctional nanoparticle systems
Nanoparticle drug delivery vehicle
The nanoparticle forming material that is used for the base of the theranostic
particle delivery vehicles can vary in composition, size, shape, charge and
hydrophobicity. Using any composition of nanoparticles as the drug delivery vehicle can
overcome the following series of limitations associated with traditional drug
administration routes. The first is the problem of solubility of the therapeutic which
occurs due to the fact that most chemotherapeutics are hydrophobic and subsequently
require the use of solubilization agents such as Cremophor EL, which has been associated
with hypersensitivity reactions9. The use of nanoparticles such as polymeric micelles, or
liposomes can provide both a hydrophobic and hydrophilic environment which can
enhance solubility10. The second is burst release upon administration, which can cause
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significant damage to surrounding tissues or rapid degradation of the drug in vivo. To be
considered a successful drug carrier nanoparticle drug delivery vehicles must stably
encapsulate the therapeutic, which has the effect of delaying the release of in the body
and protecting the payload from environmental effects in vivo11. The third limitation is
traditional drug delivery routes have unfavorable pharmacokinetic profiles due to rapid
clearance, which subsequently requires repeated high dosages. This is overcome using
nanoparticles, which provide slower drug release, and a lower overall dosage to achieve a
greater effect of the therapeutic12. Poor bio-distribution also occurs in these systems due
to the non-specific nature of the formulation. Due to the ability to control the design of
the particles either from the gene level, or through chemical reactions, targeting elements
can be decorated on the surface on the nanoparticles, reducing systemic toxicity and
enhancing the delivery of therapeutic at the site of interest13. It is clear that the use of
nanoparticles as drug delivery systems offer an enormous amount of advantages as well
as great potential for the future.
1.1.3. Compositions of nanoparticles
The physiochemical properties of the nanoparticles used for theranostic
applications plays a very important role in determining the success of the uptake and
interaction with cancer cells14. Factors that play a role in the ultimate success of the
theranostic system include size, shape, charge, hydrophobic / hydrophilic character, and
surface chemistry. The size of the nanoparticles is directly related to the cellular uptake
rate of the nanoparticles15 and is related to time the nanoparticle remains in circulation.
The mechanism of uptake is known as pinocytosis16 and can occur in two ways; the first
is through passive targeting or adsorptive mechanisms and the second is through active
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targeting and receptor-mediated endocytosis. In order for the particles to undergo cellular
internalization it has been found that particles of the size 40 to 50 nm have maximum
uptake in vitro17, while a general range of 10 to 100 nm has been established for in vivo
applications18. Smaller nanoparticles, such as those less than 10 nm in size, are cleared
via glomerular filtration in the kidneys19. Larger particles are cleared through the Kupffer
cells of the liver and through the spleen20. When targeting to solid tumors for the purpose
of nanoparticle accumulation the size ranges are between 70 to 200 nm for passive
targeting purposes21, while anything larger than 400 nm is considered too large14. While
these general size ranges have been established, there are also examples of contradictory
reports and each class of nanoparticle and cell type interaction appears to needs to be
investigated individually.
The shape of the nanoparticles also plays a critical role in the internalization interaction
between the particles and cells. Due to the role of hydrodynamic forces in the transport of
nanoparticles, the symmetry of the particles dictates the trajectory as they travel through
the body22. Shapes that can accommodate cellular membrane wrapping are most effective
at cellular uptake and between rods and spheres, spheres are more effectively taken up23.
Spheres are symmetrical in shape and because of this the distribution of forces acting on
it are constant, which will allow them to remain in the center of the blood vessel as they
circulate24. Rods, which are asymmetrical in shape are susceptible to drag forces and
torques as they circulate, which leads to alteration of the particle motion and a propensity
to head towards and accumulate at the vessel walls25. Shape also plays a role in the
circulation time and bio-distribution of the particles. It has been reported that spherical
particles have shorter circulation times than non-spherical particles26.
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The charge on the surface of the nanoparticles plays a role in whether or not the
particles bind to the target of interest or undergo non-specific binding elsewhere while in
circulation. Cationic nanoparticles will interact with negatively charged proteins, glycans,
and phospholipid head groups on the surface of cells27, which will in turn enhance
nanoparticle uptake due to increased cellular binding. Anionic particles have been shown
to display enhanced uptake compared to neutral particles28. The charge further plays a
role in the mechanism of uptake that takes place with negatively charged particles being
internalized in a dynamin independent manner and positively charged particles being
internalized using dynamin and F-actin29. Positively charged particles will be cleared via
the mononuclear phagocyte system and suffer from short half-life due to interactions with
blood proteins. When these interactions occur, it activates the complement pathway30. If
the designed nanoparticles are more hydrophobic than the cell surface they are binding to,
there is an enhancement of uptake27, as well as experiencing an enhancement of protein
adsorption on their surfaces31. Hydrophilic nanoparticles on the other hand, will attract
fewer of these proteins. For this reason nanoparticles are often PEGylated, which is the
process of coating the surface of the particles with polyethylene glycol (PEG)32, a highly
hydrophilic polymer coating that increases in vivo circulation and half-life times. The
optimal level of PEGylation, such as the thickness of the coating, the coverage
configuration and the chain length has yet to have been established and is an important
factor to investigate in each nanoparticle cell pairing.
Clearly there are many factors that interplay in the design of the nanoparticles for
use in theranostic systems. Despite the wealth of information available and reported,
there is no way to predict the interactions that may take place in a given system.
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Therefore, it is critical to determine each of these factors experimentally for a given
system.
Polymers
Polymeric nanoparticles are comprised of a broad class of materials that are
characterized by shapes that are either nanospeheres or nanocapsules and are composed
of a backbone that is polymeric in nature with a biodegradable monomer33. The most
common materials used to make polymeric nanoparticles are poly(lactic acid) /
poly(lactic-co-glycolic acid) PLA/PGLA, block copolymers, and chitosan. Chitosan are
semi-synthetic polysaccharides that have been used extensively as multi-functional
nanoparticle systems, and especially in gene delivery applications34 due to their strong
polycationic properties. PLA / PLGA is an attractive polymer for encapsulating
hydrophobic and hydrophilic drugs without degradation35 and providing a mechanism for
their release into the target of interest. The manner through which the drugs are loaded
into the particles greatly affect the rate of release. PLGA nanoparticles undergo
hydrolysis of ester linkages throughout its matrix and advantageously the resulting by
products are easily cleared from the body. Tunability of these nanoparticles can be
achieved via changing the ratios of lactic and glycolic acid in the synthesis36. Overall
polymeric nanoparticles offer a great deal of advantages including biocompatibility, low
clearance in the body and ease of customization.
Liposome
Liposomes are concentric closed bilayer membranes of water-insoluble polar
lipids, which are an important structural component of the cell membrane. Liposomes are
amphiphillic in nature, due to being composed of both hydrophobic and hydrophilic
9

components which leads to the self-assembly into the bi-layer structures37. These
materials possess many advantages for use as drug delivery systems the first of which is
that the surface properties can be easily modified to suit the needs of the system being
developed through the addition of targeting functionalization38 and their size can be
precisely controlled39. They can also stably encapsulate and protect both water soluble or
insoluble therapeutics in the core40. Finally due to their organic nature, liposomes are
generally biocompatible. Despite these advantages there are drawbacks to using
liposomes, including poor stability, low loading efficiency, and poor release profiles.
Dendrimers
Dendrimers41 are spherical, synthetic structures that are typically composed of a
core molecule that branches out into tree like extensions with terminal ends that are
available for functionalization. In terms of diameter, dendrimers are the smallest
nanoparticle system42 with radius ranging from 2.5 to 8 nm. Due to the nature of their
synthesis, dendrimers offer a high level of control of their branching, molecular weight,
charge and functionalization. This allows for drugs to be attached to the branches via the
functional groups, can fill in the void spaces between the branches or can be encapsulated
in the core presuming it is hydrophobic. Targeting or imaging domains can be attached to
the ends through the functionalized groups and because of the shape of the dendrimers
these are highly available. These highly customizable features are the most desirable
properties of using dendrimers as drug delivery vehicles.
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Polymeric Micelle
Nanoparticle micelles are colloids consisting of amphiphillic macromolecules
with both hydrophobic and hydrophilic segments43. The segments lead to a distinct
segmentation of the particles into two regions, a hydrophobic core consisting of polymer
tails and a hydrophilic headgroup. Typically the micelles are formed through a process of
self-assembly that occurs in a concentration dependent manner known as a critical
micelle concentration (CMC). Below this concentration micelles exist as monomers in
solution. Micelle nanoparticles typically have a size that ranges from 5-100 nm in
diameter. As drug delivery vehicles there are numerous advantages to using micelles as
the base particle. Chemotherapeutics can be encapsulated in micelles in multiple ways,
including during self-assembly for hydrophobic drugs in aqueous solution, or selfassembly of hydrophilic drugs in non-aqueous solutions. This core shell structure is
highly advantageous for using micelles in drug delivery, due to the hydrophobic core
which solubilizes drugs and the hydrophilic shell which protects the particles as they
travel through the body. Addition of targeting fragments or imaging domains is
achievable using micelles, and various studies have shown that micelles are endocytosed
via EPR effect or through receptor mediated interactions. Micelles are generally
composed of biocompatible materials, which aids in their presence and eventual
clearance in the body.
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Figure 1.2. Multifunctional nanoparticles used in theranostic systems. A) liposome B)
dendrimer C) functionalized polymer D) micelle
1.2. Nanoparticle Drug Delivery Systems
1.2.1. Chemotherapeutics
Choice of the therapeutic agent used plays a very large role in the development of
multifunctional nanoparticle systems. A large amount of the design in encapsulating the
compound depends on the solubility of the therapeutic, which can either need to be
protected or need to have its solubility enhanced. Two of the most common therapeutics
that have been encapsulated into micelles are doxorubicin and paclitaxel.
Doxorubicin which is commercially available in a PEGylated liposomal form44 is
a chemotherapeutic drug used in numerous forms of cancer chemotherapy. Due to its
wide range of indications, it is one of the most widely used anti-cancer drugs on the
market. However, even though it is approved for usage there are a number of adverse side
effects associated with its administration. These include common symptoms such as hair
loss and vomiting as well as hand- foot syndrome45 and cardiomyopathy46. Doxorubicin’s
mechanism of action is through interaction with DNA via intercalation47. Once this
process is initiated the progression of the enzyme topoisomerase, which is necessary to
allow DNA to undergo transcription. Through further stabilizing interactions with
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topoisomerase II complex, the DNA double helix can’t be resealed and thus replication is
halted48.
Paclitaxel belongs to the taxane family of drugs, along with Docetaxel and is
derived from the bark of the pacific yew tree49. A formulation of paclitaxel that is FDA
approved and readily available is known as Abraxane, which is an albumin bound
nanoparticle designed to overcome solubility issues with the free drug. Typically the drug
is used to treat breast, lung, ovarian and head and neck cancers. Due to solubility
concerns mentioned earlier, paclitaxel is an excellent choice for a therapeutic that would
benefit from being encapsulated in nanoparticle drug delivery systems. Paclitaxel targets
and stabilizes and protects cellular microtubules, which leads to prevention of the normal
breakdown of these during the cell division process. Specifically this prevents the
progression of mitosis and causes reversion back to the G-phase of the cell cycle50. Side
effects of administration of paclitaxel directly are related to the use of solubilization
agents and typically include nausea, vomiting, rashes and even female infertility9.

A

B

Figure 1.3. Chemical structures of doxorubicin (a) and paclitaxel (b).
Nucleic acid based therapies such as those utilizing small interfering RNA
(siRNA) and mircroRNAs (miRNA) have gained traction in treatment of various forms of
cancers. These are known as non-coding RNAs51, and can be used in theranostic systems.
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The miRNAs are conserved single stranded RNAs of 19-25 nucleotides that are
transcribed by RNA polymerase II52 and their abnormal expression is linked to various
tumors such as leukemia53 and lung cancer54. They can be used as therapeutic targets
since they have been shown to play a role in increasing chemo-resistance of both breast
cancer cells55 and prostate cancer cells56. To utilize miRNA as a therapeutic agent two
strategies have been employed the first is to block tumor suppressor miRNA and the
other is to target the genes involved in their transcription. For utilization in theranostic
systems the miRNA can be delivered to target cells by targeted nanoparticle systems,
such as using targeted liposomes for delivery of miR-34a into metastatic melanoma57 and
using gold nanoparticles loaded with miR-29b for delivery into HeLa cells58.
Small interfering RNA (siRNA) is a class of double stranded RNA that is also
being utilized in the treatment of cancers. These RNA are typically 20-25 nucleotides in
length and are known to interfere with the expression of a gene that shares a
complementary sequence with the double stranded DNA59. Liposomes decorated with
monoclonal antibodies were utilized to deliver siRNA specific to cyclin CD-1 in vivo and
were shown to silence the target in leukocytes60. Polymer nanoparticles decorated with
the integrin ligand RGD have been utilized to deliver siRNA to endothelial cells during
angiogenesis61.
1.2.2. FDA approved Nanoparticle drug carrier systems
One of the most common and important examples of a FDA approved and widely
available nanoparticle drug formulation is Doxil, approved for clinical use in 1995 and
made by Jansen biotech. This drug is a polyethylene glycosylated liposome drug carrier
loaded with the chemotherapeutic doxorubicin used to treat ovarian cancer and
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sarcoma62. Doxil, unlike the free drug, has been shown to be generally localized to the
blood pool, except for at site of increased vascular permeability like the liver, spleen and
within tumors. Due to these reasons Doxil has a circulation half-life that is reported to be
100 times longer than free doxorubicin while carrying a risk of cardio toxicity that is
seven fold lower63. DaunoXome is a formulation of liposomal danorubicin to treat
sarcoma that was approved in 199664. Another example of a successful FDA approved
formulations is Abraxane, which is albumin bound paclitaxel and used for the treatment
of metastatic breast cancer, lung cancer and pancreatic cancer65. A list of nanoparticle
based formulations that have been approved by the FDA are listed in Table 1.1.
Drug Name

Formulation

Usage

Year Approved

Abraxane

Albumin bound
paclitaxel

Breast cancer

2005

Cimzia

PEGylated fragment of
anti-TNF-α antibody

Chron’s disease and
arthritis

2008

Doxil

PEGylated liposomal
doxorubicin

Ovarian cancer and
sarcoma

1995

DaunoXome

Liposomal danorubicin

Sarcoma

1996

Eligard

PLGH-polymer and
leuoprolide formulation

Late-stage prostate
cancer

2002

Oncaspar

PEG-L-asparagine

Acute lymphoblastic
leukemia

2006

Genexol-PM

PLA-PEG micelle with
paclitaxel

Metastatic breast
cancer

2007

Table 1.1. Nanoparticle formulations that are FDA approved for clinical use.
For micelle-based system, numerous candidates are currently in clinical trials, and
these are listed in Table 1.2. Genexol-PM is a micelle based nanoparticle that was
approved by the FDA in 2007 and is polyethylene glycol poly-lactic acid micelle which
has indications for use in breast and lung cancer66. The micelles that compose the
formulation are a range of 20-50 nm in size. Genexol was designed to overcome one of
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the major limitations of using paclitaxel as a therapeutic, which is the need for
Cremophor-EL, a surfactant solubilization agent used to dissolve the paclitaxel in Taxol9.
This agent has been linked to hypersensitivity reactions and requires pre-medication for
administration. In the case of Genexol-PM, the paclitaxel is encapsulated and protected
within the hydrophobic core of the micelle and solubility is maintained through the
hydrophilic shell of the micelle. In a phase I study involving this formulation it was found
that hypersensitivity reactions were not observed and that the formulation had linear
pharmacokinetics66.
Name

Composition / diameter
(nm)

Therapeutic

NK105

PEG-P(aspartate) 85

Paclitaxel

Stomach Cancer

III

NK012

PEG-PGlu(SN-38) ~20

SN-38

Breast Cancer

II

NC-6004

PEG-PGlu(cisplatin) 30

Cisplatin

Solid Tumors

II

SPIO49C

Pluronic L61 and F127 ~25

Doxorubicin

Adenocarcinoma

III

PEG-pAsp ~40

Doxorubicin

Broad

I

NK9111

Usage

Stage

Table 1.2. Micelles currently in clinical trials.

1.3. Targeting Strategies
1.3.1. Passive Targeting
As of now, all clinically administered and approved nanoparticle formulations are
delivered to the site of interest in the body through passive targeting via the enhanced
permeability and retention (EPR) effect14. This phenomenon was developed by Maeda et
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al. after observing a higher concentration of colloidal particle drug conjugate in tumor
tissue as compared to free drug67 which was described as being due to irregularities in the
tumor tissues themselves. These irregularities include a highly leaky vasculature which
allows particles to enter into tumor from surrounding tissues68 and the lymphatic drainage
system is ineffective which leads to an entrapment of particles and prevents their
clearance. Various classes of nanoparticles, most effective when the size is between 10100 nm in diameter, have had their tumor interaction behavior described via the EPR
effect including, micelles21, liposomes69 and polymer nanoparticles70 and nanosized
materials up to 400 nm in diameter. Various studies in animal models have shown that
the EPR effect can lead to a 50 fold accumulation in tumors compared to healthy tissues4
and further the greater the circulation time of the particles the greater the accumulation.
However there are drawbacks to solely relying on the EPR effect for passive targeting,
such as the fact that many large tumors are known to be heterogeneous in nature, which
prevents the particles from accumulating throughout the tumor. Further the EPR effect is
negated in the central regions of the tumors which further reduces the accumulation of the
particles71. Also the negative pressure gradient that exists in the tumoral interstitial space
has the potential to limit the movement from the intravascular to extravascular space, thus
negating the advantages of the leaky tumor vasculature72. Another drawback is that not
every type of tumor will allow for accumulation via the EPR effect, including gastric and
pancreatic cancers73.
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Figure 1.4. Passive targeting via the EPR effect.
1.3.2. Active Targeting
As an alternative strategy to relying solely on passive targeting through the EPR
is to use active targeting strategies that rely on affinity ligands which will directly bind
nanoparticles to the over-expressed receptors on tumor surfaces74. This is achieved by
decorating the surface of the nanoparticles with these targeting elements. The origins of
active targeting are derived from modification of the surfaces of liposomes with
monoclonal antibodies that were designed to recognize antigens present on target cells75
and there are over 30 of these compounds approved to date. The most recognizable of
these is known as Herceptin (trastuzumab), which is used in the treatment of breast
cancer through the biding of the HER2/neu antigen76. Many types of targeting ligands
have been developed including antibodies, peptide fragments, nucleic acid ligands and
biomarkers. Short peptide fragments possess advantages over larger antibody fragments
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due to the fact they are inherently smaller, less immunogenic, possess more stability and
are far less complicated to manufacture77. Although peptide targeting tends to have lower
affinity for the target cells than antibodies, this issue is overcome by the fact that the
nanoparticle surface is entirely decorated with the peptide targeting fragments, which
leads to a situation where the peptides can achieve avidity. The development of a wide
library of peptides has been facilitated through the use of phage display78.

Figure 1.5. Internalization of nanoparticles via receptor-mediated endocytosis.
Despite the advantages of active targeting, there are only 6 known targeting
nanoparticles that have advanced to the state of reaching clinical trials, three of which are
polymers79 and three are liposomes80. Each of these compositions has demonstrated thus
far an enhancement in activity as compared to non-targeted versions. These are presented
in Table 1.3.
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Code

Usage

Therapeutic

Phase

Liposome

Gastric,
adenocarcinoma

Oxaliplatin

II

Antibody
tumor antigen
transferrin

Liposome

Tumors

P53

Ib

Antibody
fragment

Liposome

Stomach cancer

Doxorubicin

I

SEL-068

Antigen

Polymeric

Nicotine antigen,
TLR agonist

Bind-014

PSMA

Polymeric

Solid tumors

MBP-426
SGT-53

MCC-465

Targeting
fragment

Particle
Composition

Transferrin

Transferrin
Polymeric
Solid tumors
CALAA-01
Table 1.3. Active targeted nanoparticles in clinical trials

I
Docetaxel

I

siRNA

I

1.3.3. Types of targeting ligands
Antibody
This class of targeting ligand is the only that is currently clinically available and
has consistently demonstrated increased cellular uptake as compared to non-targeted
particles. This is most like due to the fact that antibodies have two epitope binding sites
on the same molecule, which offers high selectivity and affinity towards the target81.
Clinically available AB targeted nanoparticles include, Rituximab for lymphoma82,
Trastuzumab for breast cancer treatment76, Bevacizumab used to inhibit angiogenesis83
and Cetuximab for the treatment of advanced colorectal cancer84. These large monoclonal
antibodies however, have drawbacks that limit their desirable use in the laboratory. These
include their large size which can affect particle diameter, instability in solution making
self-assembly processes difficult, batch to batch variations and immunogenicity concerns.
To overcome these limitations, small fragments of antibodies have been utilized, known
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as affibodies that are used in combination with phage display to target specific cell
markers85.
Folate Receptor
The folic acid receptor (FR) is overexpressed in many kinds of cancer cells
including breast, bone, lung, head neck and brain and is one of the most studied receptors
in active targeting86. Folic acid is a vitamin that is necessary for cell function and
provides required components for the synthesis of DNA. Although the FR is present on
normal healthy cells, it presents low affinity for nanoparticles carrying folic acid
conjugates87. An example of the efficacy of the targeting is demonstrated by Lacroix et
al. who conjugated folate onto poly(L-lysine) polymers with encapsulated doxorubicin88
and showed enhanced toxicity compared to non-targeted nanoparticles. Using folate as
the targeting ligand has numerous advantages including the fact that it is easily
conjugated to particles and has high binding affinity for the folate receptor. Further it is
inexpensive, non-immunogenic, readily available and conjugation chemistry is simple.
Transferrin
Transferrin is an antibody that operates via transferrin receptor mediated
endocytosis, through the binding of iron and transportation into cells. Cancer cells, being
highly proliferative, have a need for tremendous amounts of iron during their growth
periods which leads to an overexpression of the transferrin receptor89. These receptors are
overexpressed on tumor and metastasizing cells by approximately 2 to 10 fold compared
to healthy cells90. Labhasetwar et al. used the transferrin receptor to decorate particles
with transferrin and loaded with paclitaxel to demonstrate an increase in an antiproliferative activity91. The advantages of using transferrin are that it is completely
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biocompatible due to non-immunogenicity, can be easily conjugated to many particles
and drugs and the acquisition is easy.
Peptides
Peptide targeting fragments are molecules that range in size from 2 to 50 amino
acids linked by peptide bonds92. There are numerous peptide receptors overexpressed in
tumor cells, which gives a large variation in the targets that are available and these
include luteinizing hormone-releasing hormone (LHRH), bombesin receptor, and
somatostatin. Peptides are also used as ligands to target integrins, which are
transmembrane receptors, whose role is vital in the adhesion between cells and
surrounding tissues. These are commonly overexpressed in tumor neo-vasculature93. The
most common of these integrin receptors that is targeted is αvβ3, which is overexpressed
on endothelium of cancerous tissues and is selectively targeted by the peptide RGD94.
Zhan et al. used PEG-PLA micelles conjugated with cyclic RGD and loaded with
paclitaxel to show an enhanced anti-glioblastoma effect by 2.5 times compared to nontargeted micelles95. Peptides as targeting ligands possess many desirable features
including the fact that they small in size, can be excreted through normal pathways, have
high binding affinity and their small size enhances the avidity effect on surface on
nanoparticles, they have high stability and are easy to reproduce.
1.3.4. Targeting ligands for Prostate Cancer
Prostate cancer is one of the most diagnosed cancers in males with an estimated
233000 new cases being estimated for 2014 or 27% of new cases with 29,480 deaths
resulting from it (~ 8%)1. Prostate cancer incident rates however have been declining, and
this is partly due to early detection improvement, but it is still the second leading cause of
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cancer death among males behind lung cancer1. When detected early there are a number
of treatment options which can include radiation therapy or removal of the tumor.
However, once the cancer has begun to metastasize it becomes resistant to removal and
becomes incurable96. Currently there is a need for treatment options that will enhance the
efficacy of care for late-stage prostate cancer. Unfortunately prostate cancer is a difficult
disease and no wide reaching strategies have proven successful, mostly due to the fact
that the tumors themselves display a high level of heterogeneity67. This however, presents
an opportunity for theranostic formulations to provide personalized treatment regimens to
enhance the chances for success.
Active targeting strategies
Two clinical trials have been performed in the last few years on actively targeted
nanoparticles for the treatment of prostate cancer, SGN-15 and ASG-5ME. SGN-15 is an
antibody conjugated nanoparticle loaded with doxorubicin and Docetaxel which was
completed in October 201197. ASG-5ME targets a transmembrane antigen and delivers an
anti-microtubulin drug known as MMAE. This study was completed in June 201398. As
of the publication of this thesis these are the only two targeted nanoparticle studies on
record, indicating that there is a pressing need for new strategies. What follows is a list of
possible targeting strategies to guide theranostic formulations in the future including a
table listing all the options (Table 1.4).
Prostate Specific Membrane Antigen
The prostate specific membrane antigen (PSMA) is a glycoprotein type II integral
membrane that is a common biomarker for prostate cancer multifunctional nanoparticle
studies99. The common usage of this target is due to it possessing highly elevated
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expression levels in a wide range of prostate cancer tumors as well as a high level of
internalization when targeted to100. When a PSMA antibody complex is formed it has
been shown that it will be internalized, eventually ending up in the lysosomes via the
clathrin coated pits route101. Xu et al. used unimolecular micelles conjugated with
aptamers targeting PSMA, composed of a PLA-PEG core and loaded with doxorubicin.
These micelles demonstrated a higher level of cytotoxicity than non-targeted
constructs102.
Six-Transmembrane Epithelial Antigen
Six-transmembrane epithelial antigen (STEAP) is a transmembrane protein that is
primarily expressed in the tissue of the prostate103. This antigen is also highly overexpressed in a variety of tissues including prostate cancer, lung, colon and bladder while
there is restricted expression in healthy tissues. Further the overexpression has been
shown to exist in metastases of prostate cancer in lymph nodes and in bone104. These
reasons make it an attractive target for prostate cancer treatments in the future. Currently
there is an ongoing clinical trial in phase I, using STEAP I as the targeting ligand to
measure the treatments effectiveness in dealing with metastatic castration resistant
prostate cancer105.
Gastrin-release peptide receptor
The gastrin-release peptide receptor (GRPR) is a glycosylated, 7-transmembrane
G-protein coupled receptor which belongs to the family of bombesin receptors106. It is
targeted to by the gastrin-release peptide, a bombesin analogue. This receptor has a broad
range of biological functions including exocrine secretion of gastro-intestinal organs and
stimulation of smooth muscle contraction. Also, once activated, the receptor stimulates
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cell growth and proliferation through activation of several protein and signaling
pathways. GRPR is overexpressed in prostate cancer as well as in a variety of other
tumors including breast and pancreas107. It has been shown that the rate of GRPR
expression varies from 63% to 100% in prostate cancer tumors106. A recent study was
conducted to determine the expression levels and profile of GRPR in the various stages of
prostate cancer, including healthy tissue, primary cancer following excision, castration
resistant prostate cancer (CRPC) and prostate cancer metastases108. This study was
conducted from a group of 530 patients and the findings were rather enlightening. GRPR
was strongly up-regulated in prostate cancers, especially of lower grade. Further
progressed prostate cancer tumors had a tendency to be closer to GRPR negative, while
metastases and CRPC displayed lower levels of GRPR expression. These findings are
rather important in demonstrating the potential to use GRPR for use in theranostic
applications, especially as an early detection and treatment method.
The gastrin release peptide (GRP) is the mammalian counterpart of bombesin and
was named for its first known activity of inducing gastrin secretion from G cells in the
gastrin antrum122. There is a strong similarity between the sequence of GRP and
bombesin including an amidated methionine at the C terminal. The 27 amino acid
sequence is represented as follows:
V-P-L-P-A-G-G-G-T-V-L-T-K-M-Y-P-R-G-N-H-W-A-V-G-H-L-M-NH2
The 10 amino acid C terminal fragment is identified as the most similar to bombesin and
is used as the targeting fragment for active targeted prostate cancer applications
G-N-H-W-A-V-G-H-L-M-NH2 (GRP)
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Glu-Gln-Arg-Leu-G-N-Q-W-A-V-G-H-L-M-NH2 (Bombesin)
Two examples of using the gastrin release peptide targeting fragment are
presented. Steinmetz et al. demonstrated active targeting utilizing the GRP peptide
fragment with viral nanoparticles of tobacco mosaic virus109. This system demonstrated
enhanced binding to GRPR positive pC3 cells compared to non-targeted nanoparticles.
Hosta-Rigau et al. used gold nanoparticles functionalized with GRP to demonstrate
enhanced binding and uptake in GRPR positive HeLa cells as compared to the nontargeted version110. These results lay the groundwork for the active targeting strategies
used in this work.
Type

Ligand

Receptor

Indications

Peptides

Gastrin release peptide

Gastrin release peptide
receptor

Prostate

NGR

APN / CD13

Angiogenic endothelial
cells

RGD

αvβ3 integrin

Melanoma, breast,
prostate, ovarian,
glioblastoma

VEGF

VEGF receptor

Endothelial cells

Mab A7

Antigen A7

Colorectal

Anti-HER2 scFv

ErbB2

Breast, ovarian, stomach,
uterine

Folate

Folate receptor

Ovarian, renal, lung,
breast, brain, pancreatic

Galactose

Asialoglycoprotein
receptor (ASGP-R)

liver

Transferrin

Transferrin receptor

Colon, breast, kidney,
lung, stomach ovary

PSMA

Solid

Prostate

EGF

EGFR

Lung, anal, glioblastoma,
NSCLC

Antibodies

Small Molecule

Protein

Table 1.4. Active targeting strategies for multifunctional nanoparticles.
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1.4. Imaging Techniques
In order to effectively utilize the theranostic nanoparticles for diagnostic purposes
molecular imaging is required to characterize biological processes at the cellular and
subcellular levels. Utilizing disease state specific targeting these modalities aided by
contrast agents or molecular probes can help to detect different disease states at various
stages of progression or be utilized to evaluate the efficacy of treatments. In order for the
imaging modalities to be utilized in theranostic systems they must not interfere with
nanoparticle self-assembly or alter the nanoparticle scale of existing particle systems
upon their inclusion. The successful utilization of these modalities requires there to be a
sufficient accumulation of the contrast agents, which is aided by both the nanoparticle
size and the disease state specific targeting.
1.4.1. Optical Imaging
Optical imaging utilizes photons emitted from bioluminescent or fluorescent probes to
detect disease states. It is considered to be an attractive option for imaging due to its high
sensitivity, lack of nonionizing radiation, ability to image the spectrum from visible to
near-infrared, ability to image in real time and it is inexpensive to detect the photons111.
Disadvantages of using optical imaging techniques are poor tissue penetration,
susceptibility to noise due to scattering, and potential auto-fluorescence112. Probes used
for this imaging include synthetic fluorophores, semiconductor fluorescent crystals, and
lanthanide based probes. Choi et al. utilized PEGylated hyaluronic acid nanoparticles
with a near-infrared fluorescent dye (Cy 5.5) loaded with irinotecan as a theranostic
agent113. This system was able to selectively target, treat, and image colon cancer tumors
in vivo.
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A common probe used in optical imaging is quantum dots which have the
advantage of being able to have their fluorescent properties tuned in any number of
ways114. Tan et al. used quantum dots as a contrast agent encapsulated in chitosan
nanoparticles that utilized HER2/neu siRNA for targeted delivery to HER2
overexpressing SKBR3 cancer cell lines and demonstrated the ability to specifically
target these cells as well as gene silencing behavior that was monitored via the quantum
dots115. Despite the advantages their utility may be hampered by cytotoxicity concerns116.
1.4.2. Computed Tomography
Computed tomography (CT) is used to primarily provide anatomical information which is
provided due to the differences in X-ray attenuation of different biological components
such as bone, muscle, fat, water, and air. CT scans can provide very good spatial
resolution while producing a 3-D image of an area of interest in great detail, with less
radiation present than other techniques117. When utilized in conjunction with a
nanoparticle platform clearance rates are reduced while allowing the system remain in the
blood for a longer period of time, without releasing high doses of the contrast agent prior
to clearance118. Materials used as the nanoparticle platform include core-shell, liposome,
gold, dendrimer, and bismuth. Zhu et al. recently synthesized multifunctional dendrimer
entrapped gold nanoparticles linked with alpha-tocopheryl succinate and folic acid as a
theranostic agent utilizing CT as the contrast agent119. Targeting CT imaging of cancer
cells was demonstrated both in vivo and in vitro while the system displayed therapeutic
efficacy. Rabin et al. demonstrated the use of long circulating bismuth nanoparticles as an
injectable CT contrast agent120. This system showed high stability at high concentrations,
a prolonged circulation time and the ability to image mice in vivo.
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1.4.3. Radionuclide Imaging (PET / SPECT)
For molecular imaging purposes radionuclide-based techniques are utilized, such
as positron emission tomography (PET) and single photon emission computed
tomography (SPECT). SPECT utilizes a camera to detect a dosage of γ radiation that is
emitted from the tissue of interest upon administration. Radionuclides such as Tc-99m, I131 and Ga-67 are typically administered and left to circulate in the blood121. Attaching
these radionuclides to a nanoparticle platform with both targeting ligands and drug for
use as a theranostic platform aids in directing it to appropriate tissue areas. After the
nanoparticle platform has accumulated gamma detectors are employed and rotated around
the body, which can aid in pin-pointing the location that is emitting the largest
concentration of γ rays. Further this can provide a 360 degree image and combinations of
these images can produce three-dimensional images of the area122. Advantages of using
SPECT include the fact that it is quantitative which allows for precise measurements,
little background interference, require no signal amplification, less expensive than PET,
long half-lifes of radionuclides, multiple radionuclides can be detected at once, and has
high sensitivity123. Disadvantages include a low spatial resolution in comparison to other
techniques, high costs, and use of radiation and relatively cumbersome size of detection
equipment122. Using SPECT as a contrast agent in theranostic nanoparticles has been
achieved by Kao et al.124. Gold nanoparticles were labeled with I-131, conjugated with
epidermal growth factor receptor to target specifically to A549 human lung cancer cells
and C225 monoclonal antibody. The specific binding and uptake of the particles was
confirmed as well as the therapeutic activity of the theranostic in mice models.
Significant accumulation of the contrast agent was also visible in the mouse model.
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Positron emission tomography (PET) also utilizes radionuclides and their emitted
γ rays to produce images. Radionuclides utilized include In-111, Cu-64, and F-18, which
are more expensive to produce and have a shorter half-life125. In contrast to SPECT, the
radionuclide emits a positron that travels a short distance to interact with an electron
before producing two γ rays which are then detected by two cameras in opposite
directions which are set to specific time intervals126. An advantage of using PET over
SPECT is that it directly produces a three-dimensional image, has higher sensitivity than
SPECT and requires low concentration of radionuclides to produce an image.
Disadvantages of using PET include spatial resolution limitations, cost of the equipment,
can only image one radionuclide at a time, and radiation concerns are present127. Chen et
al. synthesized biocompatible mesoporous silica nanoparticles for use a PET contrast
agent128. These PEGylated particles were 80 nm in diameter and targeted to breast cancer
tumors using a TRC105 antibody which effectively accumulated in the tumor in vivo.
This system also delivered doxorubicin effectively and was able to monitor the progress
of the system.
1.4.4. MRI Imaging
Magnetic resonance imaging is a prevalent diagnostic imaging technique that is
used primarily for acquiring high resolution anatomical images in the body while
providing excellent contrast with sub-millimeter resolution. It is also used for the
determination of physio-chemical states and functional MRI can give detailed
neurological information. MRI has many advantages over other imaging techniques such
as X-ray and computed tomography, including the fact that it is non-invasive and uses
non-ionizing radiation to acquire images. The image produced is 3 dimensional and
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acquired through differing relaxation times between physiological tissues. The
differences in these relaxation times can be either longitudinal (T1) or transverse (T2) and
are used primarily for the purposes of generating a large amount of image contrast.
MRI relies on the magnetic properties of the hydrogen atoms present in water
molecules, which have one proton and possess non-zero spin and is abundant in the body
with a large magnetic moment. Hydrogen atoms can then interact and be influenced by
external magnetic fields and radio waves. In a normal situation hydrogen atoms have no
net magnetization, due to the low energy state and exist in a completely random
orientation. Upon the application of a strong magnetic field, such as those present in MRI
systems, the hydrogen protons will obtain a new orientation and orientation that can be
parallel or anti-parallel. This magnetic field imposes torque on the magnetic moments of
the nuclei, which forces them to remain at these angles proportional to the magnetic field
B0. The magnetic moments of the nuclei wobble around the axis with a given frequency,
which is known as precessional motion and the frequency is called the Larmor frequency
(ω). This equation is represented by:
ω = B0γ
When a radiofrequency pulse is applied by the instrument perpendicular to the
magnetic field the water protons transition between high and low energy levels and this
causes the water protons will deviate from their orientation with B0. The radiofrequency
pulse is then removed and the aligned water protons will return to their original
orientation with the magnetic field, which is known as relaxation. This phenomenon is
the driving force behind MRI creating useful images and MRI signals are controlled by
the rates these protons return to equilibrium. After this process is completed protons relax
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through two simultaneous mechanisms, spin-lattice or longitudinal relaxation (r1) and
spin-spin or transverse relaxation (r2). Longitudinal relaxation, T1, time is the recovery
of net magnetization along the z-axis after the removal of the radiofrequency pulse. This
is a first order process and the T1 is the time required to recover ~63% of the net
magnetization of M0 and is represented in the following equation:
*

𝑀 = 𝑀$ (1 − 𝑒 )+, )
The transverse relaxation (T2) is the loss of transverse magnetization, measures
the time it takes for a nucleus to go from high to low energy state and is a much weaker
signal than T1. The T2 is the sum of the magnetic moments of many nuclei as they
precess, which eventually cancel each other out. The T2 is the time required for 37% of
the transverse magnetization to decay from its original value I0 and is represented by the
following equation:
*

𝐼 = 𝐼$ (1 − 𝑒 )+/ )
T1 weighted contrast is the primary mechanism of acquiring images with positive
contrast in MRI. Factors that control this are the repetition time (TR), which is the time
interval that exists between two successive excitation pulses. In order to generate T1
weighted contrast, a short TR is required, which allows tissues with short T1 to relax
quickly before the next radiofrequency pulse and give large signal intensities. Tissues
that have long T1 times will therefore undergo a small amount of relaxation during this
time and give little to no signal intensity.
Pulse sequences in MRI are a very important part of MRI and are typically
applied in specific order that are vital in generating an image. There are two main
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methods used to obtain MRI images known as gradient echo and spin echo. Gradient
echo sequence is the simplest type of MRI sequence available and consists of series of
excitation pulses, which are separated by a repetition time known as TR. The data is
acquired after the excitation pulses which is a time known as the echo time or TE, and is
the time between the mid-point of the pulse and the mid-point of the data acquisition. The
amount of contrast in the image can be altered through changing the TE and the TR times.
Advantages of the gradient echo sequence are fast image acquisition, a low flip angle and
requires less radiofrequency power. Disadvantages of using gradient echo are that it is
difficult to generate T2 contrast and is sensitive to susceptibility effects. The spin echo
sequence is very similar to the gradient echo, except for the fact that there is a 180 pulse
applied at TE / 2. The advantages of using spin echo are that it is useful for T2
weighting, has high signal to noise ratios and minimal susceptibility effects.
Disadvantages include ling scan times, which are costly and it requires more
radiofrequency power.
In order to actually determine the T1 pulse sequences are utilized, such as
inversion recovery, saturation recovery and the null method. The inversion recovery
pulse sequence is the most frequently used method to determine T1. For the purposes of
the work presented here, gradient echo sequences only were used due to the short scan
time and high contrast provided in T1 weighted imaging. Fat has a short T1 due to its
slow tumbling rate and gives very bright images in T1 weighted images. Water on the
other hand has a long T1 and appears dark on T1 weighted images. If a short TR is
applied there will be sufficient difference in contrast between the two, while in the case
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of a long TR they will both be recovered before the next pule and there will be no
differentiation in contrast.
Type

Magnetic Resonance
Imaging (MRI)

Nuclear Imaging
(PET / SPECT)

Probe

Gadolinium
(DTPA /
DOTA)

Radionuclides
F-18, In-111,
Cu-64

Sensitivity111

10-3-10-5

Nanoparticle Partner

Targeting Ligand1

Iron Oxide
Nanoparticles

GD2 Antibody

Lipid

Folic Acid

Dendrimer

Folic Acid

Micelle

LCP

Micelle (SPECT)

Folic Acid

Gold (SPECT)

RGD

Silica (SPECT)

RGD

Gold (PET)

CANF

10-10-10-12

Silica (PET)

Computed
Tomography (CT)

Optical TechniquesBiolumescence and
Fluorescence

Iodine

Fluorescent dyes
Quantum Dots

Unspecified

Fluorescence
10-15-10-17
Bioluminescence
10-9-10-12

RGD

Gold

GRP

Gold

Aptamer

Dendrimer

Folic Acid

Bismuth

Peptide

Quantum Dot

Aptamer

Quantum Dot

RGD

Polymer

Chlorotoxin Peptide

PEG

Hyaluronic Acid

Dendrimer

CPP

Table 1.5. Common imaging techniques with targeted nanoparticle platforms

1

RGD: Arginine-Gylcine-Aspartic Acid, LCP: lung cancer targeting peptide, CANF: natriuretic peptide
clearance recepetor, GRP: gastrin-release peptide, CPP: cell penetrating peptide
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1.5. Gadolinium based contrast agents
Due to the relatively low sensitivity offered by MRI, contrast agents are needed to aid
in distinguishing between healthy and diseased tissues. The water protons in the body
have a very high tumbling rate, which gives very poor relaxation rates and weak MRI
signals. MRI contrast agents catalytically reduce the rate of relaxation of surrounding
water molecules by altering the T1 and T2, both of which greatly affect the contrast of an
image, while reducing the signal to noise ratio. This effect is known as the relaxivity of
the contrast agent, or its ability to change the hydrogen proton relaxation, and is in
general the strongest indicator of how successful the contrast agent is. Typically contrast
agents are composed of paramagnetic substances, usually of the lanthanide series.
However, at the dosage amounts required to induce contrast in the tissues, these
paramagnetic ions are toxic to the body. Thus they must be chelated to form both
thermodynamically and kinetically stable complexes to ensure they remain intact in the
body. Therefore the design of any MRI contrast agents includes two parts 1) the actual
paramagnetic center (i.e. gadolinium) 2) chelating ligand. Of the various lanthanide
elements, gadolinium (or Gd3+) is the most commonly used as a paramagnetic center.
This is due to the following advantageous features:
1) 7 unpaired electrons in the 3+ state, which imparts a high magnetic moment
2) A longer electronic relaxation time than other lanthanides
3) Exerts the strongest effect on T1
The chelating ligand itself must have a few important characteristics to from a
successful contrast agent. The first is that it must be water soluble, for obvious reasons.
The second is that they form kinetically stable complexes with gadolinium that are not
35

susceptible to transmetellation via other metals present in the body. The final is that after
chelation occurs the ligand must have positions open for water exchange, which is one of
the crucial factors for relaxivity.
1.5.1. Factors affecting relaxivity
There are 4 main factors that affect the relaxivity of MRI contrast agents which
are based on the Solomon-Bloembergen-Morgan theory129 and are represented in Figure
1-4. They are
1) number of coordinated water molecules
2) radial distance
3) Rotational correlation time and molecular diffusion
4) Water exchange rate.

Figure 1.6. Solomon-Bloembergen-Morgan theory of relaxivity. Reprinted with
permission from130. Copyright 2010.
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Number of coordinated water molecules (q)
In the presence of gadolinium there are 3 types of water molecules are associated
with the paramagnetic center as represented in figure 1-. These are as follows: 1) inner
sphere water molecules that directly interact with the gadolinium. 2) second sphere
waters that are bound to the chelating ligand through weak interactions 3) outer sphere
water that interacts with the gadolinium due to the tumbling motion of both the water
molecules and the ligand / Gd complex. All 3 of these water molecules are necessary to
impart the relaxivity offered by the Gd magnetic moment to the surrounding water
protons in the environment. Therefore when we discuss the relaxivity of an MRI contrast
agent, it is really a combination of the inner sphere and outer sphere water effects.
Modification of the binding ligand itself can lead to direct changes in the inner sphere
water molecules, as it is directly related to the number of water molecules bound to the
gadolinium itself. This is achieved by increasing the hydration number, known as q,
which is most commonly a value of 1. Achieving multiple coordination sites on the
gadolinium to interact with inner sphere water is a difficult task, however it can greatly
increase relaxivity. This is possible because in aqueous form Gd3+ can have 8 water
molecules coordinated in its first sphere, and while chelated by a ligand those 8 sites are
coordinated leaving one free for water molecule binding. Altering the design of the
contrast agent allows for alteration of q.
Radial distance
The distance between the paramagnetic center and the bound water molecule
plays an important role in the relaxivity of a contrast agent. The relaxivity is proportional
to 1/r6 (with r being the distance) so any increase in distance between the two will
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decrease the relaxivity, while a decrease will increase the relaxivity. It has been found
that the distance between Gd and water is in the range of 2.5-3.3 Angstroms131. If the
distance between the
Rotational correlation time (τR) and Molecular Diffusion (τD)
The rotational correlation time is the time it takes for a molecule to rotate one
radian, which is a process that takes picoseconds. This parameter has important
implications in relaxivity because it affects the dipole-dipole interactions between the
gadolinium and water protons. Increasing the τR will have the effect of increasing
relaxivity, however at low magnetic field strengths decreased τR will affect relaxivity
more132. τR is also affected by the molecular tumbling rate with lower tumbling rates
leading to increased relaxivities. There are numerous ways to increase the τR but the most
important is through attaching the contrast agent to a protein or macromolecular based
carrier with high molecular weight. It was found that increasing that with increasing
generations of a dendrimers-Gd complex the relaxivity increased correspondingly133.
Water Exchange Rate
Water exchange between the chelated gadolinium in the ligand and the
surrounding water molecules needs to be a fast process due to the fact that the effect of
the relaxation is transferred from the gadolinium center to the surrounding water protons.
Water exchange that is too fast is actually a detriment to creating high relaxivity contrast
agents, because the water protons will experience a short residence lifetime in the
gadolinium bound to the ligand. This means that it does not actually get relaxed, which
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will mean no relaxivity occurs. Conversely if the water exchange is too slow, not enough
of the water protons will experience the effect of the gadolinium.
In summary for the design of a good contrast agent with high relaxivity, the
contrast agent should have fast water exchange, molecular correlation time must be
optimized depending on field strength and the hydration number should be as high as it
can be designed without sacrificing stability of the contrast agent.
1.5.2. Clinically approved MRI contrast agents
Currently all clinical gadolinium contrast agents used for T1 weighted imaging
are based on either of the two following organic ligands. The first is based on
diethylenetriamine derivatives, known as gadopentetic acid with the chemical formula
(C14H18N3O10). This was used to create the first MRI contrast agent in 1988134 and these
contrast agents form linear structures. Upon complexation with hydrated gadolinium ions,
the ligand is very flexible and rapidly wraps around the Gd3+ ion and leaves only a single
inner sphere water molecule. The complexation reaction is very quick and the stable
product is formed in seconds.
The others are based on 1,4,7,7-tetraazacyclododecane-1,4,7,10-tetraacetic acid,
which is commonly known as DOTA and has the formula (CH2CH2NCH2CO2H)4. This
compound is a twelve membered tetraazamacrocyclic derivative and contrast agents
formed from these are macrocyclic structures. When Gd3+ is complexed to the ligand
there is an intermediate formed first with 4 to 5 water molecules remaining in the inner
sphere, but this ligand is more rigid and thus takes much more time to form the final
complex.
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Another class of contrast agent are blood pool agents which are magnetic
resonance angiography contrast agents. These agents reversibly bind with circulating
albumin in the blood which affords them higher molecular weight and higher relaxivities
due to shorter T1 relaxation times. Their primary advantage is that they don’t diffuse
through the vascular system which allows them to stay in the blood for a longer period of
time and allow for longer imaging windows, which in turn can result in better signal to
noise ratio. One example of a FDA approved agent is known as Vasovist (or MS-325),
which binds to human serum albumin and has been shown to effectively enhance blood
vessels135.
Both of these ligands have several chelating arms and have an octadentate
orientation of the ligands as well as coordination numbers of 9 with Gd ions with the last
coordination site being occupied by a single water molecule (q=1), which is vital for
creating contrast. These contrast agents, although widespread in use and applications
have a number of drawbacks. One of the main ones is that upon intravenous injection
they tend to diffuse to the extravenous area due to their low molecular weight. Another
issue is that they are non-specific and are rapidly cleared via renal excretion. These
contrast agents also have maximized relaxivities around 5 mM-1s-1 and require high
dosages to have effective contrast. A list of FDA approved contrast agents is presented
in Table 1.6.
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Trademark
Name

Active
Component

Structure

R1 (mm-1s1)

USage

Dotarem

Gd-DOTA

Macrocyclic

4.2

Extracellular

ProHance

Gd-HP-DO3A

Macrocyclic

4.4

Extracellular

Gadavist

Gd-BT-DO3A

Macrocyclic

5.3

Extracellular

MultiHance

Gd-BOTPA

Linear

6.7

Extracellular

Optimark

Gd-DTPA-BMEA

Linear

5.2

Extracellular

Magnevist

Gd-DTPA

Linear

4.3

Extracellular

Omniscan

Gd-DTPA-BMA

Linear

4.6

Extracellular

Vasovist

MS-325

Linear

19

Blood-pool

Primovist

Gd-EOB-DTPA

Linear

7.3

Liver

Table 1.6. List of FDA approved MRI contrast agents. Also presented are their
relaxivities (mM-1s-1) and location of action.

41

Figure 1.7. Structures of FDA approved MRI contrast agents.
1.5.3. Protein Based MRI contrast agent CA1.CD2
Due to the limitations with FDA approved MRI contrast agents much focus has
been given to developing new and improved versions of contrast agents. Requirements
for a contrast agent design are to create ligands that have high relaxivity values, low
dosage requirements, display high affinity for gadolinium over physiological metals,
present no toxicity issues, long retention times in the body which reduces the need for
repeated dosage and finally the ability to be cleared through the bodies normal
mechanisms. In order to design new contrast typically the factors that affect relaxivity (as
discussed in section 1.) are altered with the most common being the number of hydrated
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waters and the τR. Strategies that alter the τR are most commonly to conjugate chelating
ligands to protein complexes, which has the effect of increasing molecular weight and
subsequently relaxivity. An alternative method of designing MRI contrast agents was
presented by Yang et al.136 which was to design a gadolinium binding domain directly
into a protein host. This protein based MRI contrast agent was known as CA1.CD2 or as
it is known now, ProCA1. The host protein scaffold was chosen to be domain 1 of rate
CD2, which is a cell adhesion protein found on the surface of T-cells, which is part of the
signal transduction pathway. Its structure is composed of 9 β-strands, which forms two
layers and has a common immunoglobin fold137. This host was chosen due to a variety of
features which include; wide range of stability across pH and salt concentrations, and is
very resistant to mutations. The chelating ligand was designed into CD2 by addition of a
group of carboxyl side chains from the differing β-sheets present as the following amino
acid changes from the host CD2 sequence: E15, E56, D58, D62, D64. Further one
position of the metal binding site was left open to allow for fast water exchange between
the gadolinium bound to the ligand and the bulk water, leading to high relaxivity values
(Figure 1-6).

Figure 1.8. Structure of CA1.CD2 protein based MRI contrast agent. Reprinted with
permission from 136. Copyright 2008 American Chemical Society.
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Also the designed binding site has very little internal flexibility due to the design
being from rigid stretches. The end result of this design is that the protein based MRI
contrast agent CA1.CD2 exhibited a per gadolinium relaxivity of 117 mM-1s-1 which is
20 fold greater than Gd-DTPA contrast agents. The τR was found to be ~10ns. Also this
domain displayed very strong selectivity for Gd3+ over physiologic metals as well as no
acute toxicity to cells with a Kd of 7.0 x 10-13 for Gd3+. Contrast was maintained in
animal models for a prolonged period of time, which has the effect of using this contrast
agent for long procedures without the need for repeated injections. Enhanced contrast to
noise ratio was also achieved at a 35 lower dosage than Gd-DTPA. Finally the contrast
agent was cleared through the kidneys.
This domain has been modified extensively for enhancing its functionality. A
HER-2 affibody138 was fused to the C-terminal of ProCA1 and the results showed that
this construct was able to impart significant contrast enhancement on SKOV-3 tumors at
a 100 fold lower dose. Also the targeted construct was able to cross the endothelial
boundary and had an even tissue distribution with problem retention time in tumor
models. Another modification showed that by adding various sizes of PEG chains to the
contrast agent the bio-distribution and blood retention times {157}}. These results taken
as a whole show that the protein based MRI contrast agent ProCA1 is amenable to
modification and maintains its excellent contrast agent properties through a variety of
changes.
1.6. Nanoparticle based MRI Contrast Agents
Using MRI for accurate diagnosis of disease and as a biomarker is often
challenging due to some of the limitations of the MRI modality. One of the first issues is
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that diseased tissues have similar T1 times to healthy tissues and thus the need for
contrast agents to enhance signal differentiation. The use of nanoparticles as platforms
for MRI contrast has opened up numerous avenues for future contrast agent design. Using
a nanoparticle base that is less than 150 nm in size will allow for many different things to
be loaded into the core or attached to the surface of the particles. Using Gd3+ loaded or
chelated nanoparticles combined with targeting motifs can help to ensure that disease
detection can be done in a quicker and more accurate manner, with a reduced dosage
requirement and be a vehicle to overcome any limitations that exist with MRI for
diagnostic applications. As discussed earlier a reduced molecular tumbling rate will result
in an increased relaxivity, and one of the best ways to achieve that is to attach or
conjugate the Gd chelating ligand to a nanoparticle host. When a nanoparticle is used as
the base platform for MRI the following advantages are found139:
1) Bio-distribution can be improved through surface modification or changing the
nanoparticle composition
2) Relaxivity is increased due to a reduction of the tumbling rate
3) The nanoparticles can be modified through the addition of targeting ligands or
peptides
4) The nanoparticles can have a large amount of gadolinium present in a small
volume which will lead to a reduced dose required for contrast as well as
reduction in possible toxic side effects due to free gadolinium
1.6.1. Examples of nanoparticle MRI contrast agents
There are a vast number of nanoparticle platforms available for the design of MRI
contrast agents. The overall goal is to enhance the positive properties of the imaging
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technique while not causing undue damage to the body. Factors that are important to
consider with each class of nanoparticle are biocompatibility, relaxivity values, targeting
properties and tenability of the response. What follows is some examples of nanoparticle
platforms used as MRI contrast agents.
Liposomal Contrast Agents
Liposomes are defined as spherical vesicles composed of a bilayer of
phospholipids that enclose a hydrophilic core and hydrophobic tails. Liposomes have
many advantageous properties including biocompatibility, ease of production, prolonged
stability, protection of cargo and their size can easily be controlled. However due to the
need for water exchange in contrast agents, Gd chelators in the core of liposomes have
limited success due to poor permeability140. To overcome this Gd chelators have been
linked to the surface of the liposomes by linking them to the hydrophobic chains, which
would put them on the outside after self-assembly. Kielar et al. synthesized liposomes
with a DOTA complex functionalized with two hydrophobic chains to allow for selfassembly141. The liposomes were prepared with PEGylation and their diameters were
between 45-60nm with r1 values were between 17 and 40 mM-1s-1 at 25°C.
Dendrimer Based Contrast Agents
Dendrimers are synthetic semi-biocompatible macromolecules that are well
defined, hyperbranched and mono-disperse. They possess multiple free amino acids on
their surface which leads to the ability to impart high surface functionality. Various
families of dendrimers are used including polylysines, polypropyleneimines and
polamidoamines (PAMAM). An easy way to characterize dendrimers is to count the
number of tree branches that extend from the central core, known as generations. With
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each increase of generation, molecular weight and particle diameter are increased,
however this number can’t be greater than 10 due to solubility concerns142. Also the size
of the dendrimer is directly related to the route of clearance, as increased size changes the
route from kidney to liver and spleen. Huang et al.143 developed PAMAM Gd conjugates
that were cross-linked to form clusters that contained biodegradable poly-disulfide
linkages. This construct had an extended half-life of ~1.5 hour in animal models and high
relaxivity of 11.7 mM-1s-1 per Gd3+.
Iron Oxide Nanoparticles
Superparamagnetic iron oxide nanoparticles (SPIONs) are contrast agents used in
MRI for T2 weighted imaging by providing high quantities of r2 relaxivity. Images
produced by SPIONs are negative contrast. SPIONs have an iron oxide core, which is
usually magnetitie Fe3O4 or mehemite γ-Fe2O3 and a polymer coating. One of the major
advantages that SPION have is that they have much larger magnetic moments compared
to Gd3+. Also they have many unique properties such as a large surface area, quantum
effects and ease of modification through surface chemistry144. There are generally two
main classes first is SPIO and the second is ultra-small SPIO (USPIO). Size of size of
SPION’s range from between 10-40 nm for USPIO and 40-150 nm for SPION, with
mono-dispersity. Various surface modifications of SPION enhance their ability to be
tailored at the nanoscale level while enhancing their bio-availability and limiting any
potential in vivo toxicity potential. Examples of coatings for SPIONs include dextran145,
chitosan146, PAMAM dendrimer147, PEG148 and PLGA149.
Smejkalova et al. prepared a hyaluronan acid polymeric micelles encapsulating
oleic acid coated SPIONs150. The micelles had a size of approximately 100 nm and were
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able to be loaded with 1-2 wt% SPION. These constructs were able to cluster inside the
core of the micelles with high r2 values at low concentrations. Further when injected into
tumor cells the micelles accumulated and displayed contrast enhancement. The
combination of micelles and SPION can provide powerful contrast agents, with the
potential for multi-functionality.
Micelle Based MRI Contrast nanoparticles
Micelles are amphiphillic spherical structures composed of hydrophobic chains
and hydrophilic head groups that form in a core-shell manner. They are widely used due
to the fact that they are easily prepared, can form uniform size structures, are easily
tunable using a variety of methods and are generally biocompatible151. Responsive
behavior is one of the most attractive features of using micelles as contrast agents, and
polymers such Poly(N-isopropylacrylamidee)152 or PNIPA and Elastin-like polypeptides
(ELPs) make attractive candidates for these carriers. The composition of the hydrophobic
tail, size and charge of the hydrophilic headgroups and the conditions used to promote
self-assembly determine the size, morphology and the surface properties of the micelles.
Typically micelles for nanoparticle contrast agents are synthesized by binding the Gd
chelating agent to the polymer prior to formation and designed in such a way that during
self-assembly the contrast agent is located on the hydrophilic heads of the micelle so it is
accessible. Due to this formation water exchange between the chelators and the bulk
water is not an issue. Another advantage of this formation process is the macromolecular
structure formed in this assembly is extremely rigid. The combination of the high
molecular weight which reduces molecular tumbling rate and the ridged structure
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increases rotational correlation time, both serve to help increase the relaxivity of the
constructs.
An example of a micelle based contrast agent used as a blood pool agent come
from Grogna et al.153. Micellar contrast agents were developed by forming
poly(ethyleneoxide)-b-poly(ε-caprolactone) (PEO-b-PCL) with PEG stealth and a GdDTPA contrast agent combination. This construct formed micelles between 14-40 nm
with relaxivities of 12 mM-1s-1 which is 3 times higher than Gd-DTPA alone. Further the
PEG allowed the construct to remain in circulation longer than free Gd-DTPA, which
makes it a good candidate for a blood pool agent. Jeong et al154 synthesized
Biocompatible poly-[N-(2-hydroxyethyl)-D, L-aspartamide]methoxypoly(ethyleneglycol)-hexadecylamine (PHEA-mPEG-C-16) conjugated with
1,4,7,10-tetraazacyclododecan- 1,4,7,10-tetraacetic acid-gadolinium (DOTA-Gd) for use
as micelle based contrast agents. These micelles had higher relaxivity values than
Omniscan and prolonged circulation time and contrast enhancement in rabbit liver
models demonstrating potential for use as a liver disease detection platform.
Shiraishi et al.155 synthesized macromolecular magnetic resonance imaging (MRI)
contrast agents that were composed of poly(ethylene glycol)-b-poly(L-lysine) block
copolymer (PEG-P(Lys)) chelated with 1,4,7,10-tetraazacyclododecane-1,4,7,10tetraacetic acid (DOTA) to create Gd-DOTA micelle contrast agents. These are an
example of using oppositely charged blocks that became neutral upon mixing. When the
charge changed in solution, there was a noticeable change in the relaxivity of the
constructs. Overall the constructs displayed high relaxivity values and enhanced tumor
contrast in animal models. Kim et al.156 recently developed a pH responsive micelle
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contrast agent that demonstrated enhanced activity upon a change of pH in solution.
Amphiphillic block co-polymers were synthesized out of methoxy poly(ethylene glycol)b-poly(L-histidine)(PEG-p(L-His)) and methoxy poly(ethylene glycol)b-poly(L-lactic
acid)-dietheylenetriaminopentaacetic acid dianhydrdide-gadolinium chelate (PEG-p(LLA)-DTPA-Gd). At physiological pH the micelles have a spherical shape of ~40nm and
r1 value of 8.56 mM-1s-1. When the pH drops to an acidic value of 6.5, which is
representative of the intertumoral environment, the micelles dissociate into positively
charge water soluble polymers with an increase of the r1 value to 12 mM-1s-1. These
results were confirmed through positive contrast enhancement in tumor bearing mice.
These two studies show the flexibility of using the micelle platform for contrast agents,
with both demonstrating multifold enhancement in relaxivity compared to free
gadolinium, as well as the ability to impart responsive behavior.
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Figure 1.9. Scheme of pH responsive micelle based MRI contrast agents. As the pH
drops the micelles dissociate leading to an enhancement of MRI signal. Reprinted with
permission from 156. Copyright 2014
1.7. Examples of micelle based theranostic systems
For the purposes of applicability to the system being presented in this work, this
section will focus on examples of micelle based theranostic multi-functional
nanoparticles. Liu et al. developed a novel micelle that was a pH sensitive β-cyclodextrin
star copolymer functionalized with folic acid for active targeting, DOTA for Gd imaging
and loaded with doxorubicin157(Figure 1.8). This system underwent a process of selfassembly into ~26 nm micelles at pH 7.4 and had an in vitro doxorubicin release profile
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that decreased with decreasing pH, accompanied by disintegration of the micelles. The
system displayed effective ability to undergo endocytosis and provide cytotoxicity to
HeLa cells and had a T1 relaxivity of 11.4 mM-1s-1. When incubated into tumor positive
rats, there was a large amount of accumulation of the particles into the liver and kidney of
the mice, and positive contrast enhancement in the organs. Overall, this system is a
powerful example of how powerful micelle based theranostics can be.

Figure 1.10. Self-assembling micelle for theranostic applications. Reprinted with
permission from reference157. Copyright 2012 Elsevier.
Another example of a micelle based theranostic formulation was developed by
Rowe et al.158. These micelles were composed of poly(N-isopropylacrylamide)-copoly(N-acryloxysuccinimide)-co-poly(fluorescein O-methacrylate), functionalized with
an RGD targeting peptide and loaded with methotrexate. These particles were shown to
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be biocompatible, provide active targeting, imaging capabilities with a T1 relaxivity of
33.4 mM-1s-1 and cytotoxic effects comparable to the free drug.
Yongjun at al. recently developed a system for combined MRI and treatment of
hecpatocellular carcinoma159. This system was composed of PLA-PEG-PLL-DTPA, with
the DTPA being used to bind gadolinium ions. Paclitaxel was encapsulated into the cores
of the micelles and biotinylated alpha-fetoprotein antibodies were linked to the micelle
surface. The particles demonstrated uniform size, positive zeta potential and high
encapsulation efficiency as well as a T1 relaxivity of 21.6 mM-1s-1 and superior cytoxicity
to controls. These examples show that using micelles for theranostic applications allows
for a level of superior control over size, shape, release properties and tunable properties.
1.8. Elastin-like Polypeptides as multifunctional nanoparticle systems
From the previous sections it is clear that the following properties are desirable in
choosing a material to use as the base for multifunctional nanoparticle design:
1) Biocompatibility and ability to be cleared by the body’s normal mechanisms
2) Control over size, charge, physical properties and assembly mechanism
3) Ability to store, protect and release cargo
4) Ease of modification to include targeting ligands, stealth properties or attachment
of functional groups
5) Ability to impart responsive behavior to tune response of the nanoparticle
One material that allows for all of these desirable properties to be met is a class of
responsive bio-polymers known as elastin-like polypeptides (ELPs). These responsive
biopolymers are derived from repetitive hydrophobic human tropo-elastin160. ELPs
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consist of a repeated sequence of amino acids (GVGXP)n, with the X position being
occupied by any of the 20 amino acids except proline161 and n being the number of
pentapeptide repeats. One of the most critical and important features of ELPs, especially
as it relates to developing multifunctional nanoparticle systems is the temperature
responsive behavior these systems are known to exhibit. This behavior is a
thermodynamic inverse phase transition in solution at a specific temperature known as
the transition temperature (Tt). Below this temperature ELPs exist as soluble protein
chains in solution while above this temperature ELPs are insoluble and eventually form a
protein rich phase known as a coacervate. The Tt can be described as a lower critical
solution temperature (LCST) and the process is rapid and entirely reversible. Besides
temperature, other stimuli can trigger the Tt including solutes162, pH163 and light164.
The use of ELPs has been rather wide spread mainly due to the fact that the
behavior of the proteins can be tuned to specific stimuli. In ELP design the Tt can be
specifically controlled through design of the system. The concentration of protein, length
of protein chains, molecular weight of the ELP and nature of the guest residue can all be
controlled to alter the Tt. Salt has a distinct effect on Tt and follows the Hoffmeister
series primarily to salt out or reduce the Tt165 and is also dependent on the concentration
of the salt. Molecular weight of the ELP, which is primarily a function of chain length, is
inversely proportional to the Tt, so when the molecular weight of the system is increased
the Tt will decrease166. Also the concentration of the protein follows the same pattern,
such that more highly concentrated ELP solutions will have a lower Tt {209}}. When
ELPs are designed with specific guest residues that are sensitive to pH, changes in the pH
can also alter the Tt167. Besides, pH guest residue substitution can alter the
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hydrophobicity and hydrophillicity of the system which have dramatic effects on Tt.
Substituting guest resides with side chains amiable to functionalization allows for
conjugation of various entities to ELPs. With the ease of synthesis due to molecular
biology techniques used and the 19 available substitution partners, the number of
combinations possible to design a system to meet a specific Tt or Tt stimulus is endless.
These combination of factors allow the ELP to be designed to meet specific needs of
design for any number of conditions. As mentioned earlier for the design of
multifunctional nanoparticle systems a number of requirements must be met. What
follows is a breakdown of how ELPs are a suitable candidate.
1) Biocompatiblity: The first requirement is biocompatibility and normal
clearance ability. ELPs are considered to be generally biocompatible while inducing
minimal inflammatory response and immune effects through numerous studies in animal
models168. Crosslinked ELP materials were implanted in 18 rabbits and their immune
response measured at various time points168. It was found that the implants were
completely biocompatible with no immune response or inflammation and was stable for a
6 week period. Studies on the degradation properties of ELPs have also been undertaken.
Due to the organic, entirely amino acid based composition of ELPs, it has been thought
that degradation should proceed without issue to break them down into individual amino
acids to be cleared through the body. Numerous studies have been performed to support
that assumption and show that ELPs are degraded by the body in a normal fashion169. It
was found that ELPs of 59.4 kDa degraded at a rate of 2.5 wt%/day after intravenous
administration, which means the ELP will not degrade too rapidly to deliver cargo, but
will eventually be degraded for full removal.
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2) Control over nanoparticle formation and properties: The second requirement
is to be able to control the size, shape, charge and other physical properties of the
nanoparticles. ELP nanoparticles are designed entirely at the gene level through the use
of molecular biology techniques. This gives a level of complete control over the factors
mentioned above. ELP nanoparticles are synthesized in many different fashions. The first
and most prevalent way to self-assemble ELP nanoparticles is through the use of block
co-polymers composed of alternating hydrophobic and hydrophilic blocks. Below the Tt
these structures exist as soluble monomers while above the Tt the hydrophobic segments
of the ELP become dehydrated and drives the structure into micelle self-assembly. These
self-assembled micelle are composed of this hydrophobic segment as the core, with the
hydrophilic segment staying hydrated and forms the micelle corona170. Variations in the
ratios of blocks, as well as altering the Tt of the individual blocks has been found to
influence the size and shape of the self-assembled micelles.
Another method to form ELP nanoparticles is to fuse a hydrophobic entity to one
end of the ELP. This was first displayed with a hydrophilic segment with attached
doxorubicin through a conjugation site at the C terminal171. This construct formed stable
40nm particles that were driven by the number of doxorubicin molecules attached and
proved to exhibit success as a drug carrier in mouse models. This method is driven by the
hydrophobicity of whatever is attached to the system. A study was undertaken to
determine how the LogD of the molecules attached affected nanoparticle self-assembly172
and it was found that a value of less than 1.5 did not induce formation and a value greater
than 1.5 does. Therefore the efficacy of the system can be pre-determined by the
hydrophobicity of the drug.
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Utilization of the protein rich coacervate phase can also form ELP nanoparticles
that serve as stable drug depots for large periods of time. The sequence GVGAP was
utilized to form a coacervate into slightly larger nanoparticles, however when loaded with
bone morphogenic proteins there was a delayed release lasting 14 days173. This shows
how changing the guest residue changes the nature and characteristics of the particle
formed.
Cross-linking of ELP nanoparticles is another way to control the nanoparticles,
through stabilization of the structure. Numerous methods have been used to achieve this
including chemical174, photo induced175 and enzyme induced176 are available to
demonstrate the wide ranges of options available. The degree of cross-linking and density
are related directly to ELP design, which can be controlled through amino acid
substitution either by the site of crosslinking or the number of crosslinking residues
present in the gene. One example of sequence specific crosslinking of ELP comes from
Chung et al.177 where tetrakis(hydroxymethyl) phosphonium chloride (THPC) as a
covalent crosslinking agent to react with primary and secondary amines. It was found that
lysine provided the best crosslink efficiency in the presence of THPC acid, and thus the
ELP was designed to have specific reaction sites. This study demonstrated this chemical
as a sequence specific enhancer of hydrogel properties and also showed cytocompatiblity.
Lim et al. demonstrated the same principle with THPP acid as well178. Glutaraldehyde
used as the crosslinking agent was also achieved in a sequence specific manner by
Benitez et al.179. This ELP was designed again with lysine reactive sites and it was found
that after crosslinking of the fibers the sequence specificity of the gene design preserved
the position of the targeting residues and provided stable native like mechanics. The
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process proceeded in a two-step manner, with the first being a vapor phase initiation in
glutaraldehyde followed by a quenching step in concentrated sodium chloride buffer
without any glutaraldehyde to complete the reaction.
3) Ability to store and release drug: ELPs are excellent materials to be used as
drug delivery vehicles. The first generation of ELP drug delivery vehicles centered on
exploiting the thermal behavior of the proteins as a triggering mechanism for release. The
idea is to use targeted hypothermia to heat a tumor (40-44°C) to cause the ELP to localize
and aggregate at the site of interest using techniques such as ultrasound. The ELP can be
designed to have a Tt between body temperature and the heating temperature180 which
will enhance this aggregation behavior. Dreher et al. demonstrated the efficacy of this
method through the use of temperature cycling the system181. When the ELP aggregates
in the tumor vasculature due to focused hypothermia, the local concentration of ELP is
increased, and when that temperature is removed the aggregates dissolve into the tumor.
This cycling caused the effect of creating a concentration gradient that drove the ELP into
the extravascular space of the tumor. Further this cycling cause an increase in the rate of
extravasation into the tumor space. This method provides an excellent way of using ELP
as delivery vehicles through the use of passive targeting. This method has been proven to
also enhance delivery of therapeutic loaded ELP nanoparticles. Doxorubicin loaded ELPs
through hypothermia enhanced methods have been shown to have in vivo efficacy against
tumor models, with prolonged circulation time, enhanced drug accumulation in the tumor
and dose reduction182.
ELPs are also capable of presenting a dual way of storing therapeutic cargo, with
both encapsulation in the micelle core and therapeutic bound to the surface functionalized
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corona of the micelles183. This sample demonstrated a dual mode drug release pattern
with a burst release stage with a half-life of 1.9 hours of the encapsulated drug while the
drug that was bound to the functionalized surface displayed a half-life of 57.8 hours. In
vivo efficacy was also shown through a reduction in size of tumor growth in animal
models as well as a reduction in toxicity as compared to the free drug.
4) Functionalization with targeting ligands: One advantage of the method of
constructing ELP multifunctional nanoparticle systems is the ease of which
functionalities can be added to the system. Through the use of molecular biology any
number of targeting ligands can be added in a seamless fashion. One peptide that was
used to demonstrate enhanced uptake of ELPs is known as cell penetrating peptides
(CPP), which are non-specific and promote endocytosis. The addition of the SYN-B1
penetrating peptide to an ELP-paclitaxel conjugate that contained an acid sensitive linker
was demonstrated by Moktan et al.184. This system was able to inhibit cell proliferation in
a paclitaxel resistant cell line.
Active targeting peptide mechanisms have also been investigated. Simick et al.
used the RGD peptide to target the αvβ3 integrin to demonstrate the combination of
focused thermal targeting and high-avidity of targeting ELP nanoparticles185. This system
showed a 14 fold increase cellular uptake compared to non-targeted ELPs as well as
greater uptake in the micelle form compared to unimer form. Self-assembling micelles
from block copolymers decorated with NGR tri-peptide ligand were developed as well to
further demonstrate active targeting of ELPs186. Self-assembly of the micelles enhanced
the availability of the NGR peptide to selectively targeted tumor vasculature in vivo
along with greater retention and extravascular accumulation. Hassouneh et al. showed
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multivalent effects of using fibronectin type III domain as a targeting mechanism to the
integrin187 in combination with thioredoxin. The fibronectin type III domain is a 10 kDa
100 amino acid long protein domain that after attachment to the C terminus of ELPs did
not disrupt the formation of micelles, which existed between 24 and 37 nm diameter.
This system again enhanced cellular uptake and binding in cells that over express the αvβ3
integrin when the temperature was above the critical micelle temperature.
5) Design the nanoparticle to have responsive behavior: One of the most
attractive feature of ELPs as a class of proteins is the responsive behavior that they are
known for. The stimuli responsive nature of the Tt mechanics can be driven by be
triggered by a number of stimuli other than temperature including light164, pH167 or
solution conditions. In order to change the nature of the stimulus usually, the most
common method is to change the guest residue in the GVGXP sequence. For instance a
model was developed to quantify the Tt as a function of pH, with one group being
stimulated in highly basic conditions and the other in highly acidic conditions188. Using
this knowledge a pH responsive ELP micelle system was developed by Callahan et al.189.
Another example of using the triggered response of ELP for in vivo drug delivery
applications comes from Hassouneh et al who developed a system that formed spherical
micelles in the range of 50 nm in the presence of calcium190. A calcium binding sequence
was inserted into ELP block copolymers that were calcium insensitive, such that when
calcium was present in the system in the range of 50-500 mM it drove assembly. This
study was motivated by the large difference in calcium concentrations between the
intracellular and extracellular spaces.
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Thus it is clear that ELPs offer numerous advantages that make them desirable
candidates for use as multifunctional nanoparticle systems. Further there are numerous
examples of ways to create these systems and how to exploit the advantages offered by
ELPs.
1.8.1. Alternative approaches to modify ELPs
Our labs approach to making new ELP constructs was not based on methods that
have been reported before. Stemming from the theory of ELP transition behavior new
constructs were designed. It is thought that as ELPs go through their thermal transition
behavior they move from a random coil state, to three associated chains that then take on
the form of type II β-turns. Once an appropriate concentration of β-turns exists in solution
they assembled into β-spirals that are stabilized by internal hydrophobic contacts. As
more water is removed from the system they take on the form of fibers, which are
composed of long triple stranded β-spirals. Eventually if held above Tt long enough these
triple stranded ELPs settle into an aggregated phase separated system. This process of
dehydration, folding and aggregation (Figure 1-10) is completely reversible and mediated
by chain length, concentration and solution properties.

Figure 1.11. Representation of the ELP Tt mechanism as the temperature is raised.

61

In an attempt to influence the rate at which this transition process occurred an
oligomerization domain known as foldon191, a 27 amino acid globular domain located on
the C terminus of T4 fibritin, was attached to the C terminus of ELPs of varying length.
This oligomerization domain is a natural trimerizing domain, that has been shown to
stabilize collagen triple helices as well as reduce their concentration dependence192.
When attached to ELPs foldon was found to reduce the Tt of ELP constructs over a range
of chain lengths, ELP concentration and solution conditions as compared to linear
structures, which was the basis of my thesis work.
Further investigation of the ELP-foldon construct showed that at low salt and high
pH conditions above the Tt, this system self-assembles into spherical micelles193. These
micelles ranged in size from 25 to 30 nm in salt conditions less than 15 mM. As the salt
concentration increased between 15 and 45 mM, the size of the particles increases to a
diameter of 60-65 nm. Beyond a salt concentration of 45 mM the constructs aggregate
and fall out of solution, the range of particle size is represented in Figure 1-11.

a

b

Figure 1.12. Schematic of ELP-foldon micelle formation b) representation of particle
size as a function of salt concentration. 3 distinct regions are found.
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The formation of these micelles can be described in the following ways. The
foldon domain carries a net negative charge and acts as a hydrophilic head group in this
system. When the Tt is passed the hydrophobic chains separate into the interior of the
micelle while the foldon domain forms the corona of the micelle. The effect of salt on the
micelles can be explained by the fact that as the salt increases the size of the foldon
domain becomes smaller while the length of the ELP chains in the core increases. This is
supported by a large increase in molecular weight as the salt increases to the second
regime194. The pH of the solution must be kept high to allow for micelle self-assembly
due to the fact that at pH above 9.6 it is above the pKa of N-terminal amines. At pH
values below the pKa there is a net charge on the ELP core, which prevents micelle
formation. Also below these pKa values there are end charges which prevent the arms
from folding together, thus extending the chains further and disrupting particle formation.
Further it was found that as the salt increased the micelles changed from a spherical
shape to a cylindrical shape. These studies have shown our labs ability to create selfassembling micelles, wherein the size and shape can be controlled by changing the
parameters of the environment.

1.9. Scope of the Project
The scope of this dissertation is to use elastin-like polypeptides as the basis for
creating a multifunctional theranostic nanoparticle system. To create a theranostic system
a step-wise approach was undertaken. The first step was to add a imaging modality to the
base (GVGVP)40-foldon nanoparticle system that we have fully designed, developed, and
characterized. The protein based MRI contrast agent CA1.CD2 was chosen as the fusion
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partner for a number of reasons. These include the fact that it is entirely protein based,
has a similar protein structure, has defined hydrophilic character, and is amenable to
alteration and resistant to change in solution. The first part of this work discusses the
process of fusion of this domain to ELP-foldon using molecular biology techniques,
followed by its expression and purification, as discussed in chapter II. After the
successful fusion of the protein, the activity of both components was investigated and
both domains retained their individual properties. This showed the fusion of these two
components created a successful nanoparticle based MRI contrast agent that displayed
higher relaxivity values on a per Gd3+ basis than clinical MRI contrast agents and
displayed temperature responsive behavior, as discussed in chapter III.
The next step in creating the theranostic system was to introduce targeting ligands for
site-specific localization of the contrast agent and particles, as discussed in chapter IV.
Gastrin release peptide was chosen as the targeting peptide for this part of the study.
Once this was incorporated the new ELP was characterized as well as its MRI activity to
compare to non-targeted versions. To demonstrate the efficacy of the targeting peptide,
three cancer cell lines were chosen with varying levels of receptor expression. After
incubation of the targeted protein with cancer cells specific targeting and cellular
localization was demonstrated using fluorescent microscopy and MRI. The final step was
to demonstrate the ability to load therapeutic into the core of the nanoparticles and
characterize the release properties as well as the cytotoxic effects of the constructs.
The final chapter discusses efforts made to modify the molecular architecture of the
construct through substitution of different chain lengths as well modification of the guest
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residues. Finally there are recommendations as to how to improve the construct for future
use to overcome some of the limitations present.
This system displays and demonstrates many of the desirable feature of ELPs
including 1) general biocompatibility 2) control over size shape and charge of particles 3)
ability to store and release a therapeutic cargo 4) simple method to modify the system to
include various functionalities 5) responsive behavior. Taken as a whole these steps
represent the construction of fully protein based responsive nanoparticle for use in
theranostic applications.

Figure: 1.13. ELP-foldon nanoparticle formation. Schematic showing how ELP-foldonCA1.CD2 undergoes nanoparticle formation.
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CHAPTER II
DESIGN, SYNTHESIS, EXPRESSION AND CHARACTERIZATION OF
PROTEINS
2.1. Introduction
The scope of this work is to use elastin-like polypeptides as the basis for creating
a multifunctional theranostic nanoparticle system (Figure 2.1). To create a theranostic
system a step-wise approach was undertaken with the first step being the design of the
system. Following this is a detailed explanation of the expression and purification
methods as well as their relative levels of success. After this, an explanation of the
characterization methods used to test protein purity and activity, gadolinium binding
levels, and therapeutic protein interactions. Finally detailed explanations of cell culture
protocols and images are presented. A summary of the constructs created and their
properties can be found in Table 2.1.
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Figure 2.1. Final theranostic nanoparticle form. Schematic of final nanoparticle product
produced from individual components used in this study.

67

Construct Name

Sequence

Molecular
Weight (kDa)

Tt 25 µM
PBS (°C)

ELP-IMG

MGH(GVGVP)40-foldon-CA1.CD2

31.2

31.7

ELP-SPACER-IMG MGH(GVGVP)40-SPACER-foldonCA1.CD2

33.4

31.5

E-ELP-SPACERIMG

MGHGVGVPGEVGVP(GVGVP)4
1-SPACER-foldon-CA1.CD2

34.2

30.8

10ELP-IMG

MGH(GVGVP)10-CA1.CD2

15.9

>70

20ELP-IMG

MGH(GVGVP)20-CA1.CD2

19.6

52.5

40ELP-IMG

MGH(GVGVP)40-CA1.CD2

28.3

40.5

40c20ELP-IMG

MGHGVGVP41GCGVP(GVGVP)2
1-CA1.CD2

36.4

28.3

ELP-NS-THO

MGH(GVGVP)40-foldonCA1.CD2-GRP

32.4

31.4

ELP-THO

MGH(GVGVP)40-foldonCA1.CD2-SPACER-GRP

35.3

30.7

Table 2.1. Summary of the constructs created in this study. Presented are their respective
molecular weights and transition temperatures (Tt).
2.2. Use of molecular biology to design new protein constructs
The design and synthesis of protein based polymers and other protein constructs
requires the use of various molecular biology techniques. Through years of research I
have acquired extensive experience making ELP genes of varying length, composition,
and with various fusion proteins present utilizing these techniques. What follows is a
brief explanation of some of the underlying principles used in the synthesis of the
constructs used in this study.
The basic process of DNA cloning is the primary mechanism used to synthesize
the constructs used in this study, wherein a large number of identical DNA molecules are
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prepared. The key to utilizing this process is to have the DNA fragment in a vector that
can replicate within a host cell. This recombinant DNA, which consists of the vector plus
inserted DNA fragment, is placed in the host cell (E.coli.) it can replicate and generate a
large number of copies.
In order to isolate specific sequences of DNA that constitute specific genes, the
sequence must be able to be cleaved at distinct locations in its genome. This is achieved
with the process of restriction enzyme digestion, which allows DNA molecules to be cut
into small fragments. Restriction enzymes recognize specific sequences of base pairs that
are typically 4 to 8 base pairs in length and called restriction sites. Upon recognition the
enzymes will cleave both strands of DNA at this site and can leave staggered cuts (Figure
2.2). These cuts generate single stranded fragments at both tails, which are
complimentary to those on fragments generated by the same restriction enzyme. These
single stranded regions are called sticky ends and will base pair with those on the other
DNA fragments with the same restriction enzyme site. These cut DNA fragments can
then be inserted into vector DNA with the aid of enzyme ligases that covalently link the
cut DNA fragment into a vector DNA with complimentary sticky ends. The process of
linkage comes via a 3’ to 5’ phospho-diester bond between the 3’ hydroxyl end of one
restriction enzyme fragment and the 5’ phosphate end of the other fragment. When DNA
ligase supplemented with ATP is added to a reaction containing restriction enzyme
digested fragments with compatible sticky ends, the pieces are covalently ligated
together.
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Figure 2.2. Restriction enzyme digestion producing sticky ends.
Now the fragment of interest is located within bacterial plasmid DNA. These
plasmids are used as cloning vectors and are closed circular molecules of double stranded
DNA that range in size from 1-200 kb and are capable of autonomous replication in a
cell195. The most commonly used plasmids in recombinant DNA techniques are able to
replicate in Escherichia coli (E. coli). One such vector is the one used in this study,
pET20b, a common expression vector that contains the following sections: a replication
origin, a drug resistant gene and a region where DNA fragments can be inserted (Figure
2.3).

Figure 2.3. pET20b vector map. Highlighted replication region, insertion region and
antibiotic resistant region.
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The replication origin is a specific DNA sequence of 50-100 base pairs present in
plasmids which replication of the DNA to be inserted is initiated. Once the DNA
replication is initiated it continues around the circular plasmid regardless of the DNA
sequence and thus any DNA inserted is replicated along with the plasmid DNA. The
antibiotic resistant region in the plasmid encodes the enzyme β-lactamase, which gives
antibiotic resistance, in this case ampicillin, to bacteria carrying them. The presences of
these antibiotic resistant genes on plasmids allow isolation of bacteria containing the
plasmid from those that do not by growing them on agar plates containing ampicillin
where they survive and form colonies.
The process of transformation allows foreign DNA to be inserted into a cell.
When E.coli cells are mixed with recombinant DNA a small fraction of the cells will take
up the plasmid DNA. In order to facilitate this process the cells must be made competent
through the use of “competent cells” containing Calcium chloride (CaCl2). The CaCl2
ions neutralize the repulsion between the cell membranes and the DNA. After heat
shocking the competent cells a thermal gradient is created that allows the DNA to enter
the cells. Placing the transformed mixture of cells on agar plates containing ampicillin,
only cells containing the drug resistant gene in the plasmid will survive while those that
do not take up the plasmid will die. Thus DNA fragments to be cloned can be inserted
into plasmid vectors containing an ampicillin resistant gene. When this mixture of
plasmid, E.coli and competent cells undergoes the transformation process the resulting
cells contain the same inserted sequence of DNA but multiplied into many copies (Figure
2.4).
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Figure 2.4. DNA cloning process.
2.3. Synthesis of ELP CA1.CD2 fusion protein
The base structure for these studies is (GVGVP)40-foldon (Figure 2.5) and the
gene encoding the ELP-foldon structure was synthesized as reported193. The amino acid
structure for the foldon domain is GYIPEAPRDGQAYVRKDGEWVLLSTFL191 and is 3
kDa in weight.
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Figure 2.5. GVGVP40-Foldon Micelle. Representation of three-armed star micelle
formed by GVGVP40-foldon.
To complete this work this all structures had to have an imaging domain fused to the
ELP-foldon, which in this case is the 99 amino acid CA1.CD2 protein based MRI
contrast agent136. This protein domain is encoded by the following amino acid sequence:
RDSGTVWGALGHGIELNIPNFQMTDDIDEVRWERGSTLVAEFKRKMKPFLKSGAFEIDANG
DLDIKNLTRDDSGTYNVTVYSTNGTRILDKALDLRILE

A schematic representation of the design of the design of ELP-foldon + imaging domain
structure is presented in Figure 2.6.
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Figure 2.6. GVGVP40-foldon CA1.CD2 micelle. Representation of three-armed star
micelle formed by the fusion of GVGVP40-foldon and the CA1.CD2 protein domain.
To utilize this domain with the base structure of ELP-foldon and to use the molecular
biology techniques compatible with my previous work there were three main
requirements:
1) Encode as a single domain that would be able to be ligated into a GVGVP40foldon vector
2) Contain recognition sites for NdeI, PflmI and BglI restriction enzymes with
correct sticky ends
3) Contain no internal recognition sites for these restriction enzymes ensuring no
digestion takes place internally
The first step was to create a series of overlapping oligonucleotides196(Figure 2.7), which
would encode the 99 amino acid CA1.CD2 domain and provide the necessary enzyme
digestion sites to fulfill the requirements.
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Figure 2.7. Alignment of designed oligonucleotides. Representation of the alignment of
the oligonucleotides used to encode the CA1.CD2 gene
DNA Sequence

Oligo Name

CGTGACTCTGGTACCGTTTGGGGTGCGCTGGGTCACGGTATCGAACTGAACAT

Gad1

CCCGAACTTCCAGATGACCG

Gad1b

ACGACATCGACGAAGTTCGTTGGGAACGTGGTTCTACTCTGGTTGCGGAATTT

Gad2

AAACGTAAAATGAAACCGTT

Gad2b

CCTGAAATCTGGTGCGTTCGAAATCGACGCGAACGGTGACCTGGACATCAAAAACC

Gad3

TGACCCGTGACGACTCTGGT

Gad3b

ACCTACAACGTTACCGTTTACTCTACCAACGGTACCCGTATCCTGGACAAAGCGCT

Gad4

GGACCTGCGTATCCTGGAA

Gad4b

TTCCAGGATACGCAGGTCCAGCGCTTTGTCCAGGATA

Gad5

CGGGTACCGTTGGTAGAGTA

Gad5b

AACGGTAACGTTGTAGGTACCAGAGTCGTCACGGGTCAGGTTTTTGATGTCCAGGT

Gad6

CACCGTTCGCGTCGATTTCG

Gad6b

AACGCACCAGATTTCAGGAACGGTTTCATTTTACGTTTAAATTCCGCAACCAGAGT

Gad7

AGAACCACGTTCCCAAC

Gad7b

GAACTTCGTCGATGTCGTCGGTCATCTGGAAGTTCGGGATGTTCAGTTCGATACCG

Gad8

TGACCCAGCGCACCCCAAACGGTACCAGAGTCACG

Gad8b

AATTTACATATGGGCCACGGCGTGGGTCGTGACTCTGGTACCGTTTGG

GadN Primer

ATTTATGGCCGGCCCGGCCTCATTATTCCAGGATACGCAGGTCCAG

GadC Primer

Table 2.2. Oligonucleotides used to encode the CA1.CD2 gene.
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When the oligonucleotides are assembled and the sequence checked, they encode
the correct amino acid sequence. Further inserting the sequence into the New England
BioLabs “cutter tool” allows for the visualization and location of the restriction enzyme
sites that are present. Assembly of these oligonucleotides to prepare them for insertion
into a compatible pET20b vector required five steps. The first step in the process is to
mix each of the 16 oligonucleotides, excluding the N-terminal and C-terminal primers,
together in equi-molar ratios of 10 pmol. This was followed by phosphorylation with T4
poly-nucleotide kinase (New England Biolabs). T4 PNK is used to catalyze the transfer
and exchange of the phosphate from ATP to the free hydroxyl end of the 5’ RNA. To
utilized T4 PNK combine 160 pmol of DNA (approximately 25µl) with 5µl 10x reaction
buffer, 5µl 1x T4 DNA ligase, 1µl T4 PNK and 14 µl nuclease free water. This mixture
was incubated at 37°C for 30 in a water bath. Following this the reaction was heat
inactivated at 65 °C for 20 minutes. Thermo-annealing then took place using a thermocycler (Thermo-Scientific PCRSprint). The annealing procedure was a process of heating
to 95 °C. This annealed product was then run on agarose gel, extracted, and purified
using a gel extraction kit (Qiagen). This product was annealed together after this using
E.coli DNA ligase (New England BioLabs), which is used to catalyze the formation of
phospho-diester bonds between 5’ phosphate and 3’ hydroxyl termini in DNA with
cohesive ends. The E. coli DNA ligase reaction was composed of 21 µl of DNA from
step 3, 21 µl of E. coli ligase buffer and 2 µl E. coli ligase. The mixture was held at 16 °C
for 30 minutes, followed by heat inactivation by incubating at 65 °C for 20 minutes.
Finally, the resulting annealed DNA is used as the template DNA in a 100 µl PCR
reaction involving the N-terminal and C-terminal primers shown in Table 1. The reaction

76

was composed of 5 µl of the ligated product from previous step, 5 µl forward primer
(Gad N primer), 5 µl reverse primer (Gad C primer), 50 µl of PCR master mix and 35 µl
nuclease free water. PCR reaction took place and the end product was the final gene.
At this point the CA1.CD2 gene was fully constructed and compatible with our
labs molecular biology methods. This DNA was digested with the two restriction
enzymes NdeI and BglI to allow it to be inserted into a pET20b vector (Novagen), which
contained complimentary sticky ends from an enzyme digestion with NdeI and SfiI
restriction enzymes. The procedures for these reactions are as follows. In a 40 µl reaction
I combined 15 µl of DNA template, 4 µl of buffer 4, .4 µl of BSA, 2 µl of NdeI, 2 µl of
SfiI and 16.6 µl of nuclease free water. The reaction was then incubated for 3 hours at
37°C and followed by agarose gel running and purification. For a NdeI and BglI
restriction enzyme digestion, I combined 15 µl of DNA template, 4 µl of buffer 3, 2 µl of
NdeI, 2 µl of BglI and 17 µl of nuclease free water, which was then incubated for 3 hours
at 37°C and followedd with agarose gel running and purification. Finally, a NdeI and
PflmI restriction enzyme digestion combines 15 µl of DNA template with 4 µl of buffer
2, .4 µl of BSA, 2 µl of NdeI, 2 µl of PflMI and 16.6 µl of nuclease free water. The
reaction was incubated for 3 hours at 37°C and proceed with agarose gel running,
extraction and purification.
After gel purification, the insert and vector were ligated together using a quick
ligation kit (New England BioLabs), which enables the ligation of cohesive or blunt ends
of DNA fragments. The protocol for a quick ligation reaction is to combine 1µl (amounts
can vary) of vector (pET20b DD with NdeI and SfiI), 4-9 µl of insert (CA1.CD2 PCR
product from step 5) with nuclease free water up to 10 µl, 10 µl quick ligase buffer and 1
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µl of quick ligase in a centrifuge tube. These components were combined, given a pulse
in a micro centrifuge and allowed to sit at room temperature for 5 minutes, then chilled
on ice before transforming.
To transform the plasmid the following protocol was utilized. First competent
cells are removed from the -80°C freezer and thawed on ice. Next, 10 µl of the reaction
mixture was chilled in a 1.5 ml microcentrifuge tube. A volume of 50 µl of competent
cells is added to the DNA and mixed by gentle pipetting up and down. This mixture is
placed on ice for 30 minutes, followed by a heat shock at 42 °C for 30 seconds. LB media
without ampicillin is then added in a volume of 950 µl. This mixture is then held at 37°C
for one hour. After one hour, 300 µl is spread onto pre-warmed agar plates and incubated
overnight. Resulting colonies are picked and grown overnight in LB media with
ampicillin at 37°C and 300 RPM shaking. Overnight cultures were mini-prepped
according to standard protocols and were screened using PCR techniques, with T7
forward and T7 reverse as the forward and reverse primers for a pET20b vector. To
perform a PCR 1 µl of template DNA, extracted from colonies on agarose plates, 2.5 µl
forward primer, 2.5 µl reverse primer, 12.5 µl PCR master mix and 6.5 µl of nuclease
free water are combined and placed in the thermo-cycler where a standard PCR protocol
is applied.
The resulting gene contained 105 amino acids (green highlight CA1.CD2, blue
highlight ELP overhang) and the sequence was verified by DNA sequencing (Cleveland
Clinic Genomics Core), and is:
MGHGVGRDSGTVWGALGHGIELNIPNFQMTDDIDEVRWERGSTLVAEFKRKMK
PFLKSGAFEIDANGDLDIKNLTRDDSGTYNVTVYSTNGTRILDKALDLRILE
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After checking the sequence on the NEB cutter tool the correct restriction enzyme
digestion sites were present.
The results of this confirmed that the pET20b-CA1.CD2 construct was now ready
to be modified in many ways, including through the addition of the GVGVP40-foldon
structure from Figure 2.5. To achieve the construct described in Figure 2.6, the pET20bCA1.CD2 construct was double digested with NdeI and PflMI restriction enzymes to
create a vector (3), while the GVGVP40-foldon construct was double digested with NdeI
and BglI (4). Ligation and transformation of 3 and 4 yielded the final construct for ELPIMG (Figure 2.8).

Figure 2.8. Design of ELP-IMG fusion protein. Schematic detailing the construction of
the ELP-CA1.CD2 fusion protein. The step-by-step nature of the construction is clear,
and the final construct retains the necessary cut-sites to use the system in a modular
fashion.
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This final construct, which is the base structure for this work, contains
GVGVP40foldon-CA1.CD2 (ELP-IMG), and the sequence was verified using DNA
sequencing and the final construct contained the following:
MGHGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVG
VPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVP
GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGV
GVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGYIPE
APRDGQAYVRKDGEWVLLSTFLGPGVGRDSGTVWGALGHGIELNIPNFQMTDDI
DEVRWERGSTLVAEFKRKMKPFLKSGAFEIDANGDLDIKNLTRDDSGTYNVTVY
STNGTRILDKALDLRILE
Blue regions represent ELP, green represents the foldon domain, and the yellow
represents the CA1.CD2 domain.
2.4. Synthesis of ELP-CA1.CD2 fusion protein variations
One of the main objectives of this work was to create a flexible system that would
be able to undergo modification in a simple manner utilizing only molecular biology.
After the successful synthesis of ELP-IMG, variations were synthesized to determine the
effects. The first variation was to create a spacing element between the foldon
headgroups and the CA1.CD2 domain. Also, it has been theorized that in ELP-fusion
proteins, a peptide spacer element may help retain the functional activity of the targeting
protein197. The design of the spacing element was chosen so that it would be expected to
have little effect on ELP properties due to neutral charge and balance of hydrophobic /
hydrophilic amino acids. It is represented by the sequence:
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WTSTGPQSSNTGNPSTSGQNNVPGVG
This sequence was inserted into a pET20b (previous work) vector and can be double
digested digested with NdeI and BglI to allow it be inserted into another compatible
vector. After digesting the pET20b-CA1.CD2 vector with NdeI and PflmI restriction
enzymes, the two components were compatible and after ligation, transformation, and
screening the new construct was sequenced as follows with the red highlights being the
spacer element, and the yellow highlights being the CA1.CD2 domain.
MGHGVGWTSTGPQSSNTGNPSTSGQNNVPGVGRDSGTVWGALGHGIELNIPN
FQMTDDIDEVRWERGSTLVAEFKRKMKPFLKSGAFEIDANGDLDIKNLTRDDSG
TYNVTVYSTNGTRILDKALDLRILE

This construct was then digested with NdeI and PflMI to allow a GVGVP40-foldon insert
double digested with NdeI and BglI to be ligated into it. After completion DNA
sequencing confirmed the construct, which we call ELP-SPACER-IMG: Blue highlights
are ELP portions, green highlights are the foldon domain, red is the spacer element, and
yellow is the CA1.CD2 domain.
MGHGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVG
VPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVP
GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGV
GVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGYIPE
APRDGQAYVRKDGEWVLLSTFLWTSTGPQSSNTGNPSTSGQNNVPGVGRDSG
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TVWGALGHGIELNIPNFQMTDDIDEVRWERGSTLVAEFKRKMKPFLKSGAFEID
ANGDLDIKNLTRDDSGTYNVTVYSTNGTRILDKALDLRILE

The next variation that was created was to add a glutamic acid to the N-terminus
in order to eliminate the pH dependence of the micelle formation. A construct was
created separately with the sequence: MGHGVGVPGEGVP (VEV), inserted into a
pET20b vector. This was accomplished in the same manner as described earlier with the
ELP-SPACER-IMG construct being digested with NdeI and pflMI and the VEV digested
with NdeI and BglI. The same process as described earlier was applied for ligation,
transformation and screening and after DNA sequencing this construct was obtained. This
construct is known as E-ELP-SPACER-IMG and the grey region is the glutamic acid
containing portion, blue highlight regions represent ELP, green is the foldon domain, red
is the spacer and yellow is the CA1.CD2 domain.
MGHGVGVPGEGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVG
VPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVP
GVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGV
GVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGVPGVGV
PGVGVPGVGVPGYIPEAPRDGQAYVRKDGEWVLLSTFLWTSTGPQSSNTGNPS
TSGQNNVPGVGRDSGTVWGALGHGIELNIPNFQMTDDIDEVRWERGSTLVAEF
KRKMKPFLKSGAFEIDANGDLDIKNLTRDDSGTYNVTVYSTNGTRILDKALDLRI
LE
Constructs were also made that did not contain the foldon domain, in order to compare
the behavior of the CA1.CD2 attached to monomeric ELP to the behavior of the
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CA1.CD2 domain to the trimeric ELP. The process was the same as described previously
however, instead of a GVGP40-foldon used as the insert varying lengths of GVGVP were
inserted into the vector. Lengths chosen were based on number repeats of GVGVP and
were 10, 20 and 40 repeats, as well as a construct of the form 41-C-21GVGVP.
2-5. Construction of ELP-THO targeted construct
The genes that encode the ELP-THO structure (GVGVP40-foldon-CA1.CD2Spacer-GRP) were synthesized as discussed in previous sections. The C terminal
fragment of the gastrin release peptide is represented by the amino acid sequence:
GNHWAVGHLM. To modify the structure of ELP-IMG to allow for addition of gastrin
release peptide a new set of oligonucleotides were created as well as a new primer (Table
2-3). There were two variations, one that included a flexible spacer between the headgroups and targeting element and one that did not. Also, the CA1.CD2 domain needed to
be modified to remove the stop codon that was present in it, in order to add these
elements after the CA1.CD2 to make a new C terminus.
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DNA Sequence

TATGGGCCACGGCGTGGGTGGGAATCACTGGGCAGTGGGACACTTGATGTGAGCC

Primer Name

GRP Forward

CGGTGGGC

CACCGGGCTCACATCAAGTGTCCCACTGCCCAGTGATTCCCACCCACGCCGTGGCC

GRP Reverse

CA

TATGGGCCACGGCGTGGGTTGGACCTCTACTGGCCCGCAATCCTCTAACACTGGCA

Spacer Forward

ATCCGTCTACCTCTGGTCAAAATAACGTGCCGGGC

CGGCACGTTATTTTGACCAGAGGTAGACGGATTGCCAGTGTTAGAGGATTGCGGGC

Spacer Reverse

CAGTAGAGGTCCAACCCACGCCGTGGCCCA
CGTATCCTGGAAGAGCCCGGCTGGCCATTTTTT

Gad No stop
Forward

AAAAAATGGCCAGCCGGGCTCTTCCAGGATACG

Gad No stop
Reverse

Table 2.3. Oligonucleotides used to encode GRP and spacer element.
Upon receipt of the GRP forward and reverse oligonucleotides they were
annealed in the thermo cycler as described previously. The annealed GRP primers were
inserted into a pET20b vector that had been double digested with NdeI and PflMI. These
constructs were ligated together and transformed to give a new vector pET20b-GRP,
which had the amino acid sequence: MGHGVGGNHWAVGHLM. The second variation
of the construct that was created included the spacer element before the gastrin release
peptide fragment. To achieve this the pET20-GRP vector was modified through the
addition of the spacer element. The pET20b-GRP vector was double digested with NdeI
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and PflMI, run on agarose gel and purified and the annealed spacer was ligated into this
vector. The resulting construct had the amino acid sequence
MGHGVGWTSTGPQSSNTGNPSTSGQNNVPGVGGNHWAVGHLM. This
sequence contains ELP overhangs as highlighted in yellow, spacer element highlighted in
red and the gastrin release peptide fragment highlighted in pink. These constructs both
contain the appropriate restriction enzyme digestion sites for further modification with
ELP’s and also contain stop codons.
In order to incorporate the CA1.CD2 domain into these vectors a set of primers
were created that would remove the stop codon from the domain, so the expression would
end at the GRP fragment and not after the CA1.CD2 domain. The primers were annealed
together using the thermo cycler, then used in a PCR reaction with T7 forward primer and
run on an agarose gel followed by extraction and purification. The purified product was
double digested with NdeI and BglI, run on agarose gel, and purified. This was used as
the insert in a ligation with both of the vectors described above that had been digested
with NdeI and PflMI (Figure 2.9).
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Figure 2.9. Design of ELP-THO protein. Schematic detailing the construction of the
ELP-THO targeted protein. The step-by-step nature of the construction is clear, and the
final construct retains the necessary cut-sites to use the system in a modular fashion.

After PCR screening the DNA sequences were confirmed (Cleveland Clinic Genomics
Core) and resulted in the following amino acid sequence:
GVGVP40-foldon-CA1.CD2-GRP (ELP-NS-THO):
MGH(GVGVP)40GYIPEAPRDGQAYVRKDGEWVLLSTFLGPGVGRDSGTVWGAL
GHGIELNIPNFQMTDDIDEVRWERGSTLVAEFKRKMKPFLKSGAFEIDANGDLDI
KNLTRDDSGTYNVTVYSTNGTRILDKALDLRILEGNHWAVGHLM
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GVGVP40-foldon-CA1.CD2-Spacer-GRP (ELP-THO):
MGH(GVGVP)40GYIPEAPRDGQAYVRKDGEWVLLSTFLGPGVGRDSGTVWGAL
GHGIELNIPNFQMTDDIDEVRWERGSTLVAEFKRKMKPFLKSGAFEIDANGDLDI
KNLTRDDSGTYNVTVYSTNGTRILDKALDLRILE
GPGVGWTSTGPQSSNTGNPSTSGQNNVPGNHWAVGHLM
2.6. Expression and Purification of ELPs
Typically elastin-like polypeptides (ELPs) are purified using a process known as
inverse transition cycling (ITC)198, which takes advantage of the inverse transition
temperature (Tt) displayed by the proteins. ELP’s are highly soluble below their Tt, but
will aggregate and come out of solution rapidly when the temperature is raised above Tt
due to hydrophobic collapse and aggregation. This creates a separate ELP-rich phase.
This entire process is reversible and the ELP-rich phase can be solubilized when the
temperature is dropped below the Tt. Regardlesss of composition the Tt of ELPs is
dependent upon the concentration of protein, in an inverse-log fashion199.
The stimuli that drive the Tt of the solution, as mentioned previously, can be
easily tuned to a desired temperature through many different methods. Two most
common ways include changing the nature of the guest residue200 and changing the
length of ELP chains through addition of pentapeptide repeats199. When different guest
residues are introduced the balance of hydrophobic and hydrophilic components is
altered. Hydrophobic guest residues have the effect of lowering the Tt and polar or
charged residues raise the Tt. Longer ELP chains will have a lower Tt regardless of
composition. The effect of salt on ELP Tt has been investigated thoroughly over the
years. The type and concentration of salts are known to follow the Hofmeister series165
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such that kosmotropes or Cl- and higher salts of the series will lower the Tt as well as an
increase in the salt concentration will have a salting out effect. Salts that are lower on the
series or chaotropes will have a salting in effect. NaCl is used extensively in ELP
purification to drive the Tt and ease the purification process. Buffers used to re-suspend
the ELP solution can vary depending upon the application and any specific characteristics
of the fusion protein that are required. Proteins that are more hydrophobic tend to resuspend better in pure water, while PBS is widely used to investigate suitability in vivo.
When a fusion protein is attached to an ELP construct, the ability to control the
purification of the ELP through either gene design or addition of additives generally
makes the purification of the target protein a simple process162. The thermal properties of
the ELP are retained after the fusion201, although there can be a difference between the Tt
of the pure ELP and the Tt of the ELP-fusion protein. The fact that ELP can be
genetically appended to its protein or peptide partner with precise control over the gene
design of ELP fusion, such as the position of the fusion and that the thermal properties of
the ELP tag can be easily tuned are considerations for the desirable use of ELPs for
recombinant protein purification. If the ELP is used as a vehicle to purify protein targets
that are otherwise difficult or require special methods, a protease site can be engineered
between the target protein and the ELP gene. Some examples of successful ELP fusion
proteins include ELP-Thioredoxin202 purification, which was investigated as a function of
ELP chain length. ELP was used to purify β-galactosidase, which is highly acidic and
hydrophilic203. ELP-intein systems were used also to purify target proteins in conjunction
with investigation of Hofmeister series to purify GFP and β-lactamase204.
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Expression of proteins is carried out in growth media, either Luria-Bertani (LB)
or terrific broth (TB) supplemented with ampicillin. Various additives have been
investigated to enhance the expression levels of ELP due to depletion, and there are many
options to create hyper-expressions205. Starter cultures are prepared by either picking a
fresh colony from an agar plate or taking a piece from glycerol frozen stocks in anywhere
between 10-50 ml of volume and growing overnight at 37°C and 300 RPM shaking. After
overnight growth, starter cultures were centrifuged at 3000 RCF (Dynac) to separate the
soluble and insoluble part of the protein. The pellet was then re-suspended in fresh
expression media from the flask for expression, and transferred to a 2 liter flask. Growth
then took place until the optical density at 600 nm (OD600) of the solution was between
0.-9-1 as measured on a UV-vis spectrophotometer (Thermo-Scientific Biomate 3). When
this level was reached the protein was induced using 1 mM Isopropyl β-D-1thiogalactopyranoside (IPTG), which is used to trigger the transcription of the lac operon,
which induces expression of genes that are under control of the lac operon. After
induction, the protein grew for another 5 to 5.5 hours. At the end of the growth period the
media was centrifuged at 9000xg and 4°C, the supernatant was discarded and the pellets
frozen for purification at a later time (Figure 2.10).
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Figure 2.10. ELP expression process.
To determine which expression media and amount of starter culture required, as
well as to ensure that ELP-IMG did not have significant deviation from the typical
expression rates of GVGVP constructs used in our lab, growth curves were constructed
by monitoring OD600 at regular time intervals. The results are shown in Figure 2.11 and
show the expression growth rate does not deviate from other constructs grown in the lab.
It was also shown that the fastest growth rate was achieved using TB media and a 50 ml
starter culture, which was then used as the standard for expression of ELP-IMG.
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Fig 2.11. Growth rate curves for ELP-IMG. Growth rates of ELP-IMG in different media
and varying volumes of starter culture compared to ELP-foldon.
Purification of ELP’s using the ITC process, typically proceeds as follows. The
cells contained in the frozen pellet are re-suspended in 10 ml of PBS per tube and
combined into one. Sonication then took place with the tube an ice cold water bath and
stored on ice for 1 hour after this to ensure complete cooling of the mixture. The protein
is then centrifuged at 27,000xg at 4°C for 20 minutes to separate the soluble and
insoluble fractions. The supernatant from this spin is kept due to the protein residing in
the soluble fraction. The soluble portion is then heated above Tt in a centrifuge tube for at
least 4 hours to allow the protein to aggregate out of solution. The aggregated proteins
were centrifuged at 27,000xg at 40°C for 20 minutes. At the end of the centrifugation, the
soluble and insoluble portions need to be separated immediately, with the protein now
residing in the insoluble pellet. The process of hot and cold spins gets repeated 2.5 times
total per purification and after the final cold spin, the purified protein resides in the
soluble fraction (Figure 2.12).
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Figure 2.12. ELP purification process. Process of purifying ELP proteins to reach the
desired pure target protein at the end.
2.6.1. Determination of soluble vs. insoluble content of ELP-IMG and ELP-THO
Purifed elastin-like polypeptides typically reside in the soluble fraction and can be
purified using only inverse transition cycling (ITC). However, occasionally the insoluble
nature fusion protein drives the polypeptide into the insoluble fraction limiting
purification through simple ITC. The purification of the CA1.CD2 protein domain206 was
carried out using Glutathione Sepharose 4B beads207, on a size exclusion column, which
indicated that the protein was insoluble.
To determine the soluble or insoluble nature of the ELP-IMG / ELP-THO protein
Bacterial Protein Extraction Reagent II was utilized (BPER II Pierce). BPER was
designed to facilitate the extraction of soluble proteins from bacterial cells without the
need for harsh chemicals, while being in a mild buffer of 20 mM Tris-HCL at pH 7.5.
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Starting at the expression of the protein, every hour pre and post induction a 1ml sample
was taken from the expression flask and centrifuged at 14,000xg on a micro-centrifuge
(Eppendorf 5415C). The supernatant was removed and the pellet was frozen and stored
for analysis (Figure 2.13).

Figure 2.13. Determining soluble vs. insoluble content. Process of using BPER II to
determine insoluble vs. soluble protein content.
To analyze the frozen pellets the following protocol was applied. Thaw the pellets for 10
minutes at room temperature and then re-suspend the cells in 150 µl of BPER II reagent
by vigorous vortexing of the mixture until the cell suspension is homogeneous, then
continue for one more minute. Following this centrifuge at 14,000 RPM for 5 minutes to
separate the soluble proteins from the insoluble proteins. At the completion of this step
separate the supernatant from the pellet. The supernatant contains the soluble fraction and
will be used in SDS-PAGE analysis. Re-suspend the pellet in 150 µl of BPER II reagent,
which contains the insoluble fraction for SDS-PAGE analysis. After the separation of the
components run SDS-PAGE gel with 15 µl of each fraction to determine the solubility
content.
SDS-PAGE gels were run with 15 well 4-20% gradient Tris-HEPES-SDS gel (Pierce)
and samples were prepared in 4X loading buffer containing 1% SDS and DTT and run in
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Tris-HEPES loading buffer on a mini protean gel system (Bio-Rad). Sample volumes of
15 µl were prepared and combined with 5 µl loading buffer and a full range rainbow
molecular weight marker was used (GE healthcare). This is a representation of how the

15

5hr post

Figure 2.14. SDS-PAGE to determine soluble vs. insoluble protein content. The ELPIMG protein was only visible in lanes 13 and 15, which are insoluble fractions 4 and 5
hours post induction with IPTG.
The results from this SDS-gel showed that the protein was in the insoluble fraction and
thus standard ITC purification would most likely not be successful in purifying the
protein.
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2-6-2. Insoluble protein purification methods used to purify ELP-IMG and ELPTHO
There were five methods attempted to purify the fusion proteins. All methods
require the purification to occur using the pellet from the first cold spin, which is where
the insoluble protein is located. This is opposite to the regular purification procedure
where the protein is purified from the supernatant. The first method was to follow the
insoluble protein purification methods that are laid out with the BPER protocol, which is
used for general inclusion body purification. The method was as follows:
Method 1: BPER Purification
After spinning the culture media down, the next step was to re-suspend the 1st cold
pellet in 10 ml of BPER and vortex until the solution was homogeneous. This was
followed by centrifugation for 25 minutes at 4°C and 27,000xg after which the
supernatant was poured off and discarded. Then 200 µl of 10 mg/ml lysozyme stock
solution was added to to the pellet followed by 19.8 ml of 1:20 diluted BPER II reagent.
Once the pellet was re-suspended it was centrifuged for 25 minutes at 4°C and 27,000xg
and the supernatant from this step was poured out. This process was repeated 2 more
times then the final pellet was re-suspended in 2 ml of 6M Guanidine HCL. This solution
gets diluted 20 fold using refolding buffer (50 mM K2PO4, 100 mM NaCl) and left to
chill at 4°C for 48 hours. At the completion of the 48 hours the solution was centrifuged
for 25 minutes at 4°C and 27,000xg and the resulting supernatant from this spin
contained the final protein.
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This protocol produced extremely poor yields of no more than 20 mg / L of culture,
even after attempts at concentrating the solution using various methods. Particle
formation was also non-existent. This can be explained, however, by the fact that the
yield was never sufficient enough to keep the salt content low enough to be in the proper
salt regime. It is believed that the extra steps in the BPER protocol were not necessary,
and the excess centrifugation caused loss of protein.
Method 2: Purification using pure GVGVP40-foldon
The first step was to re-suspend the first cold pellet of both GVGVP40-foldon and
ELP-IMG in 10 ml of 6M guanidine hydrochloride and combine the two. The solution
was then vortexed until it was homogeneous followed by a dilution of the the solution 20
fold through addition of 380 ml refolding buffer and finally left to sit for 72 hours at 4°C.
Centrifugation followed for 25 minutes at 4°C and 14,000xg, after which the supernatant
was poured into another tube as it contained the fusion protein in the soluble fraction. It
was then incubated at 45°C and the purification proceeded with these 380 ml as the first
hot spin in regular ELP purification
This method produced yields between 30-40 mg / L of culture, which is far less than
would be expected for GVGVP40-foldon alone (typically 80-100 mg /L). This yield is
sufficient, however SDS-PAGE analysis showed an anomaly with the protein (Figure
2.15). The multiple trimer domains that are present in this form of the construct caused
issues with the self-assembly of nanoparticles leading to bi-modal distributions as the
only particle populations that could be achieved. This is not optimal for use of the
construct, so this method was not used. The next method skipped BPER and GVGVP40-
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foldon co-purification entirely and went directly to incubation in 6M guanidine
hydrochloride.

Figure 2.15. SDS-PAGE gel method 2. SDS-PAGE gel for purification using method 2,
showing the multiple trimer domains as a result of the combination of proteins.
Method 3: Purification using pure 6M Guanidine HCL
The first cold pellet was re-suspended after sonication and centrifugation of ELPIMG in 10 ml of 6M guanidine hydrochloride. The solution was vortexed until
homogeneous and let sit for at least 6 hours. Then it was diluted 20-fold through addition
of 180 ml refolding buffer and let sit for 72 hours at 4°C. Followed by centrifuging for 25
minutes at 4°C and 14,000xg and pouring off of the supernatant from this step. The
supernatant was incubated at 45°C for 4 hours and centrifuged for 25 minutes at 40°C
and 27,000xg. The supernatant from this spin was discarded and purification proceeded
with the pellets. This yields 6 pellets in 6 tubes, which need to get purified individually.
250 µl of 6M guanidine HCL was added to each pellet and stirred gently until
homogeneous, then re-suspended 1:20 with 4.75 ml of refolding buffer, with the eventual
combination of all 6 pellets. This solution was then centrifuged for 25 minutes at 4°C and
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27,000xg. The supernatant was then used to proceed with hot spin and was incubated at
45°C for 4 hours, followed by centrifuging for 25 minutes at 40°C and 27,000xg. At the
conclusion of centrifuging the supernatant was discarded and purification proceeded with
the pellet. The final pellet was re-suspended in 5 ml of appropriate solution and the
concentration was measured.
This method successfully purified the protein with yields of 20-25 mg / L of culture.
Self-assembly of nanoparticles took place as expected, however, the yield was less than
optimal and the solution tended to have a very slight cloudy appearance and would
precipitate if stored for more than 30 days.

Figure 2.16. SDS-PAGE gel method 3. SDS-PAGE gel resulting from the method 3
purification schematic. Lanes with the + symbol indicate samples that were heated to
100°C to denature the foldon domain, while lanes with the – symbol indicate samples that
are at room temperature, which we expect to trimerize due to the activity of the foldon
domain. Lanes 1 shows the monomer form as expected while lane 2 shows trimer
formation.
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Method 4: Purification using pure 8M Urea and ITC:

Figure 2.17. 8M urea + ITC purification method.
The first step was to re-suspend the first cold pellet in 5 ml of 8 M Urea and vortex
until the solution is homogeneous, followed by sitting for 6 hours at room temperature.
Then it was dialyzed against 4 M urea for 24 hours using 3000 MWCO dialysis tubing
(Spectra-Por), followed by dialysis against 2 M urea for 24 hours using 3000 MWCO
dialysis tubing (Spectra-Por). This was then dialyzed again using 3000 MWCO dialysis
tubing (Spectra-Por) against RO H2O for 2 hours with 3 changes of the water. Following
this the solution was purified using the ITC method described earlier.
This method has been used to successfully purify the protein with high purity (Figure
2.18) and yields that are between 25 and 30 mg/L of culture. Self-assembly of
nanoparticles took place as expected, however, a higher yield was desired. This method
also eliminated the cloudiness as well as the precipitation problem.
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Figure 2.18. SDS-PAGE gel method 4. Lanes with the + symbol indicate samples that
were heated to 100°C to denature the foldon domain, while lanes with the – symbol
indicate samples that are at room temperature, which we expect to trimerize due to the
activity of the foldon domain. Lanes 1 and 2 are completely purified samples, while 3-4
and 5-6 are samples that are no 100% purified and require another round of ITC.
Method 5: Purification using pure 8M Urea Only:

Figure 2.19. 8M urea only purification method.
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The steps used in this method mirror the steps in method 4 up to the point of ITC
purification. Instead of the usual 2.5 rounds of ITC, there was only one round of
centrifugation at 27,000xg at 4° C. This was then followed by another round of dialysis in
pure H20 for 24 hours. At the conclusion of this the purified protein was present and
ready for use.
This method has been used to successfully purify the protein with high purity (Figure
2.20) and yields that are between 70-90 mg/L of culture. Self-assembly of nanoparticles
took place as expected and the yield was 2-3 times more than the other methods (Table
2.4), which makes this process ideal for sample preparation. This method also eliminated
any cloudiness as well as the precipitation problem. Purification of the protein is
performed using this method.

Figure 2.20. SDS-PAGE gel method 5. Lanes with the + symbol indicate samples that
were heated to 100°C to denature the foldon domain, while lanes with the – symbol
indicate samples that are at room temperature, which we expect to trimerize due to the
activity of the foldon domain. High purity and yield are demonstrated in this gel.
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Method Additive

Nanoparticle

Yields (mg /L of

formation

culture)

1

BPER / lysozyme / GuHCL 6M

No

< 10

2

GVGVP40-foldon

Bi-modal

30-40

3

6M GuHCL + ITC

Yes

20-25

4

8M UREA + ITC

Yes

25-30

5

8M UREA No ITC

Yes

70-90

Table 2.4. Summary of purification methods and their associated yields.
2.7. ELP-fusion protein characterization methods
ELPs after purification are characterized by a number of general methods to
ensure molecular weight, folding behavior, purity, transition temperature profiles and
nanoparticle formation of samples.
2.7.1. SDS-PAGE Gel
Polyacrylamide gel electrophoresis (PAGE) using sodium dodecyl suflate (SDS)
anionic detergent to impart negative charge to the proteins is used to separate proteins
according to their electrophoretic mobility. This is primarily a function of their molecular
weight, such that larger proteins will take a longer time to migrate through the gel, while
smaller proteins will migrate faster. Thus the technique is used to ensure that the purified
protein is of the proper molecular weight. Further depending on the conformation of the
protein and buffer or temperature used proper folding can be visualized (i.e. dimer or
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trimer formation). A generalized procedure for running SDS-PAGE follows. ELP
samples were prepared for analysis in 15 µl aliquots (highly concentrated samples should
be diluted with H2O, typically 5 µl sample + 10 µl H2O). Into these 5 µl of 4X DTT was
added containing sample buffer dye. The sample was then heated to 100° C in a dry bath
for at least 5 minutes and briefly pulsed in a micro centrifuge to collect condensation.
Samples that need to visualize the trimer activity of foldon domain were not heated to
ensure that the thermal stability limit of foldon is not passed. The gel box was then
assembled and filled with running buffer and securing the gel in place. Samples were
then loaded into gels using gel loading pipette tips and run at 100 V until the dye reached
the bottom of the gel. At the conclusion of this the voltage was stopped and the gel
cassette was removed, transferred to a plastic holder and washed 3X with RO H2O.
Comassie blue solution was added to the gel, covered and set on the shaker for at least 2
hours followed by de-staining with H20 or de-staining solution (methanol/glacial acetic
acid/H2O).
2.7.2. UV-Vis Spectrophotometry
A spectrophotometer is used to measure the amount of light that passes through a
sample in relation to the initial amount of light. In the case of our ELP fusion proteins,
this is used to measure the onset of turbidity of the solutions by measuring at a constant
wavelength, with a computer controlled temperature ramp. A brief procedure follows for
the use of the Shimadzu UV-1800 series. ELP solutions were prepared in desired buffers
and checked to ensure that they were free of turbidity or precipitation. The software was
initiated and the method in the TM-Analysis software was set to read at 350nm with a
sweep from 20-60°C at 1°C/min (can change if desired). If no turbidity is observed at the
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completion, the Tt can either be above the range measured or the sample may be forming
nanoparticles. At the conclusion of the run the Tt was determined by plotting the
absorbance @350 versus temperature and find the steepest part of the turbidity curve.
The point of intersection was found and this corresponds to the Tt.
2.7.3. Dynamic Light Scattering
Fixed angle dynamic light scattering is used to investigate the formation of
nanoparticles of ELP fusion protein samples. The hydrodynamic radii of nanoparticles
can be studied through the use of dynamic light scattering (DLS) in which a beam of light
passes through the aqueous sample. As it passes through the sample the light is scattered
by the particles in different directions and parts of the light then pass through a detector.
The Brownian motion of the particles results in constantly changing measured intensity
that fluctuates with time giving distribution intensity. The intensity-time correlation
functions are then analyzed by software using algorithms to calculate the hydrodynamic
radius of the nanoparticles. To accomplish this a Brookhaven 90 plus particle size
instrument is used. Samples were measured at 350 nm, typically at a temperature below
Tt (~20°C) and above Tt (~45-50°C). A brief procedure follows. Samples were prepared
in appropriate concentrations of protein and salt for nanoparticle formation (<150 µM
protein and <50 µM salt). The samples were filtered directly into cuvettes using .22µM
filters (Millipore) and placed into the cuvette holder. BPIC software was opened and
analysis was performed in triplicate (3 runs of 3 x 1minute each = 9 total).
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2.8. Characterization of gadolinium loaded fusion protein samples
The ELP-IMG, ELP-IMG variations and ELP-THO proteins are defined by their
fusion with the protein based MRI contrast agent CA1.CD2 domain. A critical
component in determining the success of the fusion protein, and the construct as a whole
is the successful binding and retention of gadolinium.
2.8.1. Inductively coupled plasma optical emission spectroscopy
Inductively couple plasma optical emission spectroscopy (ICP-OES) is an
analytical technique used for the detection of relatively low amounts of metals in
samples. This instrument uses argon gas to ignite a plasma torch that excites atoms and
ions that will emit electromagnetic radiation at wavelengths that match those of the
element of interest. Intensity of the emission recorded corresponds to the concentration of
the element within the sample, based upon creation of calibration curves. The plasma
reaches a temperature of ~ 7000 K, while a peristaltic pump delivers the sample into a
nebulizer to be analyzed by turning the sample into mist inside the plasma flame. This
process will break the sample down into only charge ions, which undergo a rapid
collision process inside the chamber and give off radiation that corresponds to the
characteristic wavelength.
In designing the experiments to determine the Gd3+ content bound to the ELP fusion
proteins there were some important considerations that took place. These were as
follows:
A. Samples must be clear: no turbid, precipitated or non-filtered protein samples
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B. Choice of wavelength: For Gd3+ use multiple as there is confusion as to which
would be the best, these include 342 and 376 nm
C. Make sure 3 replicates are performed
D. Use an internal standard to ensure that the protein is not interfering with the
atomizing of the gadolinium à typical between 80-120% internal standard
recovery is acceptable
E. Add 2 ppm of rhenium to each sample as the internal standard
F. After construction of calibration curve ensure that it has an R2 value of at least
.999
G. Measure blank sample of pure 2% nitric acid in h20 + internal standard and the
lowest standard has to have an intensity of at least three times the blank for the
measurement to be accurate
When using the instrument the following steps took place. The argon flow was turned on
from the wall, followed by switching on of the instrument. The computer was then turned
on and the WinLab32 program was initiated followed by the opening of the “JCgd3+IS”
method. When using the instrument, it was imperative to construct a new calibration
curve each time to gauge instrument response (Figure 2.23). The inlet tubing was placed
into the blank sample, held for 20 seconds then analyzed. After this, the inlet tubing was
placed in a solution of 2% nitric acid for washing (after each run as well). For the running
of each protein sample the same steps took place. Results were generated and the
instrument was cleaned and shut down.
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Figure 2.21. Calibration curves generated from ICP-OES analysis.
2.8.2. Free gadolinium detection assays
For any gadolinium chelating nanoparticle system there exists the possibility that
unchelated gadolinium can exist in the formulation either due to instability of the soltion,
excess gadolinium due to lack of available binding sites or precipitation. Free gadolinium
is a known toxicant, which has been linked to nephrogenic systemic fibrosis in FDA
approved MRI contrast agents208. For these reasons it is critical to have assays available
to be able to detect whether or not there is free gadolinium present in the solution.
Arsenazo III (C22H16As2Na2N4O14S2) is a bis-azo derivative of chromotropic acid
(Figure 2.22) and is capable of forming stable complexes with a large number of ions209.
Specifically it binds to metal ions forming a metal-ion complex but does not bind to
complexed metal ions. This method allows for both a visual and numerical detection of
this interaction. Visually there is a colorimetric interaction that occurs with a solution of
pure aresenazo III appearing pinkish in color, as well as in solutions with little to no free
gadolinium present. As the amount of free gadolinium increases the color shifts from
pink to purple to finally green when there is an excess of free gadolonium in
solution210(Figure 2.23). These color shifts are also represented in a shift of the
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abosrbance spectrum. When the dye is free in solution there is a strong absorption peak at
548 nm and when complexed with metals there is a peak absorption at 652 nm (Figure
2.24).

Figure 2.22. Chemical structure of Arsenazo III

Figure 2.23. Examples of ELP-Gd3+ arsenzao III complexes. Sample 1: Free Arsenazo III
(pink), sample 2: 40foldon-CA1.CD2 with 5 µM Gd3+ added drop-wise (all bound
purple) sample 3: 40foldon-CA1.CD2 with 20 µM Gd3+ added drop-wise (all bound
purple) Sample 4: 40foldon-CA1.CD2 with 250 µM Gd3+ added drop-wise (excess
present as an intermediate orange) Sample 5: 40foldon with 5 µM Gd3+ added drop-wise
(excess present green).
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Figure 2.24. Absorption spectrum of Arsenazo III calibration standards.

The first step undertaken to perform the assay used in this study is to make a
series of standards, which leads to the creation of a calibration curve, which is then used
to determine the concentration of free gadolinium. The presence and amount of free
gadolinium in protein samples can then be quantified using Arsenazo III. To construct the
calibration curve gadolinium chloride (MW 263.61, Acros) is dissolved in water at
concentrations spanning 0-48 µg / ml or 0-182 µM. A 20 mg/ml solution (21.8 mg
dissolved in 1 ml RO H2O) is made which is used a stock solution and then diluted to 2
mg/ml in 1 ml which is used to make the calibration stocks (Table 2.5).
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Sample

Volume of stock

Volume h20

GdCl H20

Gd (µg/ml)

Concentration (µM)

Absorbance

1
2
3
4
5
6
7
8

0
1.55
3.1
6.22
12.43
18.66
27.98
37.32

1000
998.45
996.9
993.78
987.57
981.34
972.02
962.68

0
3.39
6.78
13.56
27.12
40.68
61.02
81.36

0
2
4
8
16
24
36
48

0
7.59
15.17
30.35
60.70
91.04
136.57
182.09

0
0.026
0.06
0.135
0.306
0.48
0.728
0.93

Table 2.5. . Calibration Standards for Arsenazo III. Calibration standard preparation table
and their resulting absorbance measurements.
To measure the calibration standards, which were made into 1 ml volumes, 100 µl
of 0.2 mM Arsenazo III, 50 µl of calibration standard (represented as sample 1-8) and
850 µl of water are mixed together. A blank is created composed of just 950 µl water and
50 µl Arsenazo III. A UV-vis spectrophotometer (Thermo Scientific Bio-mate 3) was
used to get the absorbance readings at 652 nm, using the Arsenazo III and water standard
as the blank. A Beer’s law plot is constructed by plotting the absorbance at 652 nm
versus Gd3+ concentration.

Figure 2.25. Calibration curve of arsenazo III. Arsenazo III calibration curve constructed
from a series of standards. The slope of the line represents the extinction coefficient used
in this study.
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To determine the amount of free gadolinium present in a sample the same
procedure is applied but instead of 50 µl calibration standard 50 µl of nanoparticle / Gd3+
conjugate is added. The mixture is composed of 850 µl water, 50 µl sample and 100 µl of
Arsenazo III. The absorbance of the sample is then divided by the extinction coefficient
as represented in equation
𝑭𝒓𝒆𝒆 𝑮𝒅 (µ𝐠 /𝐦𝐥) =

𝐴𝑏𝑠 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 + 0.01
∗ 1000
0.02

This assay covers a range of 0-182 µM of free gadolinium that may be present in
the sample. As most of the samples presented in this study have a working range of 10150 µM gd3+ present, this represents an easy way to determine the amount free. For
simplicity purposes and ease of facilitating a large number of samples, a microplate
reader can be substituted for the UV reader. A Synergy H1 microplate reader (Biotek)
with a 96 well plate was also used to process a series of samples (Figure 2.26).

Figure 2.26. ELP samples in 96 well plate for microplate analysis. ELP-Gd3+ samples in
96 well plate to test for amount of gadolinium present. Sample preparation also gives a
visual representation of gadolinium present in excess.
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Xylenol Orange Assay
Another common indicator for presence of lanthanide ions is xylenol orange211,
whose chemical structure is represented in Figure 2.27. The color of the solution of
xylenol orange is largely dependent upon the pH; at acidic pH the solution is yellow,
while at basic pH the solution is purple. The change in color is due to the de-protonation
of the phenolic hydroxyl group, which in turn leads to an extended electronic delocalization which then shifts the absorption wavelength to higher values212. This effect is
the same in the presence of metal coordination. When a stable Gd chelate is present such
as the one presented in this study or any of the many clinically available (Gd-DTPA, GdDOTA and derivatives) the xylenol orange is not able to extract the metal ion from the
chelate, thus any change in color or absorbance is only due to free metal ions.

Figure 2.27. Chemical structure of xylenol orange
Xylenol orange, like Arsenazo III, is able to provide both a visual and numerical
representation of the free Gd3+ in a solution. Xylenol orange has two absorption maxima,
at 433 and 573 nm, with the 433 being more intense. As free Gd3+ increases in the
sample, the second band increases while the first one decreases (Figure 2.28).
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Figure 2.28. Xylenol orange chemical shift determined spectrophotometrically a) Gd3+
content as determined spectro-photometrically. Increasing Gd3+ content causes the band
at 573 nm to increase while the band at 433 nm decreases. Spectra was taken in acetic
buffer solution pH 5.8 across a range of gadolinium from 0-50 µM. b) Samples of Gd3+ +
xylenol orange with the visible shift in color upon addition of excess free gd3+.
In order to obtain this spectrum a working sample of xylenol orange was first
prepared by dissolving 3 mg of xylenol orange (Acros) in 250 ml acetate buffer at pH 5.8.
This working stock was frozen in 50 ml aliquots and protected from air, to prevent any
issues with the pH of the solution. When the curve was ready to be prepared this solution
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was thawed and 2 ml transferred to a quartz cuvette. Each gadolinium standard was
prepared from a 1 mM stock (made from dissolving 3.72 mg of GdCl3 (Acros) in RO
H2O) and made in 10- 80 µM concentrations. A 200 µl of each standard was added to the
quartz cuvette and vigorously shaken to ensure complete mixture. A wavelength scan was
performed using UV probe software on a UV-vis spectrophotometer (Shimadzu UV1800) from 700 to 300 nm. The free Gd3+ content is proportional to the ratios of the 573
and 433 nm wavelength absorbance and across a concentration range of free Gd3+ a linear
relationship is observed (Figure 2.29).

Figure 2.29. Calibration curve for xylenol orange. Calibration curve for xylenol orange /
Gd3+ determined spectrophotometrically, as the ratio of two absorbance maxima.
To measure the amount of free Gd3+ in an ELP nanoparticle / Gd chelate, we use
the slope of this line as an extinction coefficient and divide the absorbance of the solution
by it, represented in equation;

𝑓𝑟𝑒𝑒 𝐺𝑑3 + µ𝑀

=

573
− 0.325
433
0.016

𝑅𝑎𝑡𝑖𝑜 𝐴𝑏𝑠
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Examples of solutions of ELP nanoparticle / Gd3+ chelate are presented with the
color shift being rather visible (Figure 2.30). The orange to light purple solutions
correspond to < 10% free gadolinium while the brighter purple solution on the left is 27%
free gadolinium.

Figure 2.30. ELP-Gd3+ xylenol orange complexes. Examples of ELP / Gd3+ chelates in
presence of xylenol orange solution used to determine free Gd3+ content.
Xylenol orange was also used to determine the saturation point at which addition
of Gd3+ to ELP nanoparticle solutions exceeded the > 10% free Gd3+ limit (Figure 2.31).

Figure 2.31. Using xylenol orange to determine excess amounts. Usage of xylenol
orange to find point of gadolinium addition saturation.
A cross-linked protein of 50 µM concentration is placed in a 5ml round bottom
flask and gadolinium in citrate buffer is added in a step-wise manner of 10µM drops with
constant stirring. Thirty-minute time points are taken between additions of more
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gadolinium. Before the addition of the next amount of gadolinium 200 µl of sample is
removed and added to 2ml of xylenol orange solution and absorbance spectrum is
recorded. Using the equation and the spectrum recorded it was found that as long as the
addition of gadolinium was in 1:1 molar ratio with the protein, there was less than 10%
free gadolinium in the solution. As the 1:1 ratio was exceeded the amount of excess
increased significantly (Figure 2.32).

Figure 2.32. Gadolinium addition saturation point.
2.8.3. ELP-IMG metal binding complexes
Terbium III (Fisher Scientific) was used as a probe to determine metal binding
affinities of ELP-IMG fusion proteins as compared to ELP-foldon. A Hitachi
fluourescent spectrophotomer was used with an excitation wavelength of 283 nm and
emission wavelength of 545 nm. Constant protein concentration of 50 µM was used for
both ELP-IMG and ELP-foldon and these solutions were loaded into a quartz cuvette.
Terbium III was titrated into the cuvette and measurements were recorded as a function
of absorbance. From figure 2.33 it is clear that ELP-IMG has a dramatic increase in
absorbance as higher concentration of terbium III is added to the cuvette, while ELPfoldon is virtually unaffected by the addition of the terbium.
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Figure 2.33. Terbium III + ELP-IMG vs Terbium III + ELP-Foldon. Comparison of
ELP-IMG + Terbium III and ELP-Foldon + Terbium III showing that an increase in
metal binding complex is seen for ELP-IMG, while ELP-Foldon has little to no effect on
the terbium solution.
2.9. Detailed Cell Culture Protocols
To investigate the active targeting properties of ELP-THO constructs cancer cell
lines were obtained, cultured and passaged. Cells were cultured from storage in vapor
phase of liquid nitrogen in the following manner:
Culture protocol
Vial obtained from ATCC was thawed in a heat bath at 37°C while keeping the O-ring
and cap out of water to avoid contamination. Once this was completed, the tube was
removed from water and sprayed with 70% ethanol to decontaminate the surface. The
tube was then spun at 125xg for five to 7 minutes in a micro centrifuge. At the conclusion
of centrifuging the media was aspirated and the pellet was re-suspended in an appropriate
amount of pre-warmed fresh growth media and incubated at 37°C and 5% CO2.
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Cell passage protocol
Cells were checked at appropriate intervals under a microscope and when they reached
approximately 75% confluence and are fully attached to flask surface they were ready for
passage. The first step was to remove and discard the cell culture medium into a separate
flask. Then between 2 and 10 ml of Trypsin-EDTA solution was added to the flask and
incubated at 37°C and 5% CO2 for between 5 and 15 minutes. It is important to visually
inspect the cells to ensure that they are detaching from the surface. At this point add 6 to
8 ml of fresh media to flask and transfer all of the contents to a 15 ml centrifuge tube
followed by centrifuging at 125xg for 10 minutes to remove any excess trypsin present.
The media was the aspirated and the pellet re-suspended in 10 ml of fresh growth media.
Finally an appropriate amount of growth media was added to the flask and incubated at
37°C and 5% CO2.
Well Seeding protocol
To seed the wells, for further study, from passaged cells 100 µl of the re-suspended cells
were first transferred to a hemocytometer in order to count the total amount of cells. Once
cell count was determined the amount needed per well was calculated and the appropriate
amount of cell pellet suspension was added to the well, followed by filling to volume
with fresh growth media. Once wells were seeded and filled they were incubated at 37°C
and 5% CO2. After 16 hours of seeding wells were checked to ensure that attachment was
taking place and 24 hours after experiments were able to begin.
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Protein incubation study protocol
To visualize proteins in cells they needed to be dyed with the use fluorescein
isothiocyanate (FITC), which was dissolved in DMF at 10 mg/ml and mixed completely.
Once the solution was mixed a 15-20 fold molar excess of FITC solution was added to
the protein and immediately mixed. The solution was then incubated for 1 hour at room
temperature, and wrapped in aluminum foil to protect from light. Before use, the
solutions need excess FITC to be removed either through dialysis or use of the dye
removal columns. Finally, once they are ready, they can be incubated with cells in
appropriate molar concentrations for desired time periods.
Protein and cell interaction analysis—Cell fixation protocol
After the desired incubation time of protein and cells is reached the first step is to aspirate
the media from flask and then wash the cells with sterile ice-cold PBS 2 times, followed
by removal of media and PBS. The cells were then washed with ice cold 4%
paraformaldehyde (PFA) solution for 5 to 8 minutes, followed by removal of the PFA
solution and a wash step with ice cold PBS for 5 more minutes. At this point DAPI
solution is added to the well to stain the nuclei and let to sit for 5 minutes, after which
inverted field microscopy was started.
Antibody Detection protocol
Level of gastrin-release pepetide receptor content was visualized using the following
antibodies; Anti-gastrin release peptide primary antibody (Ab22623) and goat polyclonal
secondary antibody to Rabbit IgG (compatible with primary) conjugated to Alexa flour
488 (Ab 96883) were ordered from Abcam. U87 RFP and PC3 cells both overexpress
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GRP in a high level and thus we expected positive results from the antibody test, while
H441 expresses at an extremely low level (figure 2.34). To perform these experiments
the same fixation protocol was applied as discussed in step 5. After fixation with PFA, a
solution composed of PBS containing 5% goat serum and .1% triton X-100 was added to
the wells then allowed to sit for 20 minutes. The well was aspirated, then a solution
containing 5% serum, .1% triton X-100 and 1% primary antibody and left to sit overnight
at 4°C. Once this solution was removed the wells were washed 3 times with warm PBS
for 5 minutes each time, to remove any unattached material. Next, while in the dark, the
seconday antibody, which was contained in a solution composed PBS, 5% serum, .1%
triton X-100 and .1% seconday antibody, was added to the well and left to sit 20 minutes
in the dark. Finally DAPI is added to the well and imaged on the inverted field
microscope.

120

A

B

C

Figure 2.34. Antibody staining test. A) PC3 cells B) U87 C) H441. The positive
indication of GRPR is displayed by the large amounts of green staining in A and B, while
no green staining is present in C, indicating GRPR negative.

Live / Dead Assay Protocol
To determine the overall vitality of the cell population a Live / Dead assay can be used
(Life technologies). The first step is to take a fresh passage of cells and seed them in
wells at appropriate concentrations for 24 hours for at least 24 hours. After ensuring
attachment and health of the cells, the media is changed and left to incubate at 37°C and
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5% CO2 for one hour. Protein samples at varying concentrations and for varying time
points, are then incubated with the cells to determine the level of effect that they may be
having on the cell population. Once incubation time has been completed, the media from
the well is removed and 100-150 µl of live/dead media to the well, or enough to ensure
complete coverage of the cells. All of these steps must be performed in the dark to ensure
that the reagents are not activated by light. The combination of cells + proteins + live /
dead assay mixtures is then incubated for at least 30 minutes at 37 °C 5% CO2. At the end
of this period the cells can then be imaged with an inverted fluorescent microscope or
covered with D-PBS and stored for later viewing.
Imaging of Live/Dead results with ImageJ Software
During imaging take at least one image at each point in the well of interest using the
green wavelength channel, one at red wavelength channel then save the images, and label
appropriately. Make sure to take 4 images per well, representing each corner of the well
and getting a good representation of the population as a whole (figure 2.35). It is also a
good idea to take images using only the brightfield channel as a reference in case there is
any auto-fluorescence. A second control that should be performed is to have one well that
is left without any protein to represent an entirely alive population and to have a second
well that is combined with a toxicant like 70% ethanol to represent an all dead population
(figure 2.36). The next step is to open the ImageJ program and use the plugin called
Shapelogic, which allows for counting of particles. Choose a region of interest and using
the plugin count number of green and number of red particles. Using these numbers you
can then make a ration of live to dead and find a survival percentage.
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Figure 2.35. Live / Dead staining images with mixed populations.

Figure 2.36. Live / Dead staining images with a) all live b) all dead. Live / Dead assay
applied, to a sample as a positive control (all alive) A, and a negative control B (all dead).

2.9.1. Examples of Cell images
PC3 cells: The shape, spacing and homogeneity of the cells is a good indication they are
healthy and growing well. As they grow more confluent than this they begin to cluster
and will grow very rapidly. It is a good idea to keep the flask seeding density low if they
are not planning on being used frequently (figure 2.37 A).
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H441 cells: These cells tend to grow in a segregated and clustered manner. During
growth it may appear that large quantities of the cells are not attaching, thus necessitating
media changes that are not part of passaging. Also they may take longer time than the
other two cell lines between passages and grow in lower number, so that must be planned
accordingly when attempting to match up cell based experiments (figure 2.37 B).
U-87 RFP: These cells have been spliced with red fluorescent protein and thus they can
be imaged in fluorescent microscope without the addition of dyes using the red
wavelength channel. These cells are a nueroglioblastoma and grow in a branching
manner out from a central area (figure 2.37 C).

Figure 2.37. Images of healthy growth of cell lines. Bright field image of A) U-87RFP
B) H441 C) PC3 cells taken as an example of healthy cell growth.
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CHAPTER III
MRI ACTIVITY OF SELF-ASSEMBLING NANOPARTICLES OF ELASTINLIKE POLYPEPTIDES

3.1. Abstract
Presented is a fully protein based self-assembling nanoparticle system for use as
an MRI contrast agent. These particles are formed using the thermally responsive
behavior of elastin-like polypeptides (ELP’s), which comprise the core of the particle.
We have previously reported thermo reversible micelle formation of ELP’s and have
modified the system by fusing the protein based MRI contrast agent, CA1.CD2 to the C
terminus of ELP-foldon to create a new system (ELP-IMG). Micelles formed by ELPIMG are cross-linked to form stable nanoparticles. These nanoparticles are
environmentally responsive, effectively bind and retain gadolinium while effectively
providing contrast in T1 weighted imaging with higher relaxivity than clinical contrast
agents. This fusion protein is entirely protein based and was designed using molecular
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biology techniques that allow for effortless expansion and modification of the construct.
Due to these reasons this fusion protein serves as an excellent platform for the creation of
a class of protein based theranostic nanoparticles. Here we detail the design, synthesis,
expression, purification and characterization of the system.
3.2. Introduction
Soft material nanoparticles formed by self-assembly of polymer macromolecules
is an area of great interest in cancer diagnostics and imaging111. Nanoparticles less than
150 nm in diameter generally avoid rapid clearance by the body213, possess the ability to
extravasate into the tumor vasculature and be retained there due to the enhanced
permeability and retention effect (EPR)67. They can also utilize targeting ligands to allow
them to be targeted to specific disease states14. The base platform for theranostic systems
is a nanoparticle structure often composed of inorganic materials such as gold
nanoparticles214, magnetic iron oxide144 or organic materials such as liposomes215,
polymer macromolecules216 and polymeric micelles217. Multifunctional theranostic
(therapeutics + diagnostics) nanoparticles are gaining traction in nano-materials research
and can be described as materials that aim to combine these features into a single
package218. These agents are capable of delivering a therapeutic dose to a molecular
target and providing diagnostic imaging at the same time5.
Magnetic resonance imaging (MRI) is a technique used to acquire images of the
body that are of high resolution and depict the anatomy clearly. In order to use MRI for
disease detection however, there needs to be a significant enhancement of signal due to
diseased tissues and healthy tissues having similar signal intensity139. An approach to
enhance the signal is to use paramagnetic lanthanide ions such as gadolinium as contrast
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agents, which interact with water protons and lead to a decrease in T1 relaxation time219.
The most common MRI contrast agent clinically approved for use are gadolinium-DTPA
(diethylene triamine pentaacetic acid) or gadolinium-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). These contrast agents are limited by their relatively
low relaxivities (~ 4-5 mM-1s-1), low rotational correlation time, limited number of
coordinated water molecules and short tissues retention times137. A protein based MRI
contrast agent, CA1.CD2136 is a novel gadolinium chelating protein that was rationally
designed to overcome these limitations and was chosen as the diagnostic imaging
component of this nanoparticle based MRI contrast agent. CA1.CD2 is derived from
domain 1 of rat CD2 and was rationally designed to contain a high coordination Gd3+
binding site. This domain displays large r1 relaxivity values (~120 mM-1s-1), excellent
contrast in T1 weighted imaging, a hydration number q of 2, strong selectivity for Gd3+
over physiologic metals and enhanced tissue retention time3-136. Other features that made
this a desirable fusion partner is that it is entirely protein based which is encoded using
only oligonucleotides, is composed of β sheet architecture and has strong stability against
pH changes. Further the domain displays no acute toxicity in vivo and was shown to be
cleared through the kidneys14.
We have previously reported the self-assembly of ELP micelles through the
addition of a negatively charged trimer forming oligomerization domain193 known as
foldon191. These particles are temperature, pH and salt dependent and are some of the
smallest ELP particles reported in literature41. Elastin-like polypeptides are part of a class
of environmentally responsive biopolymers found in nature that are based on a repetitive
peptide sequence of GαGβP161. The α position can consist of any amino acid and β

127

position can be any amino acid except for proline161. A distinct feature of ELP’s is that
they undergo a sharp phase transition above a specific transition temperature (Tt), known
as a lower critical solution temperature (LCST)220. Transition from above and below the
Tt is a reversible process which is dependent on the length, concentration and amino acid
composition of the polypeptides, and can be triggered by many different stimuli
including pH189, light221 and ionic strength222. Due to their responsive nature,
biocompatibility and specific control potential of Tt, ELP’s have been used as the
platform for many ideas including drug delivery223, tissue engineering224, microfluidics225
and hydrogels226. Using molecular biology techniques we were able to synthesize this
system in a manner that allows for seamless integration of other domains227.
ELP’s used as the platform for protein based nanoparticle MRI contrast agents
possess many distinct advantages. These include the ability to control the size of the
particles, precise tuning of the transition temperature and mechanism of stimulus.
Modification of the amino acid sequence using modular molecular biology techniques
allows for any number of targeting ligands or motifs to be included in the system which
will allow result in an accumulation of contrast agent at a site of interest and
subsequently increasing local concentration139, reducing dosage requirements228 and
avoiding potential side effects related to excess gadolinium208.
This paper will detail the process of incorporating the protein based MRI contrast
agent CA1.CD2 with the three armed star elastin like polypeptide micelles to form a new
MRI active multifunctional nanoparticle system (ELP-IMG). We show that the fusion
protein of CA1.CD2 and ELP micelles maintain their individual properties. The ability to
combine multiple functional properties in a single peptide provides a simpler approach to
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form theranostic nanoparticles, compared to other multi-step synthetic methods. In
addition, it provides a modular approach for designing particles with different properties
without the need for post-translational modification. Thus this new fusion protein can
serve as a modular platform for use in environmentally responsive organic theranostic
systems.
3.3 Materials and methods
3.3.1. Gene Design and Preparation
The gene encoding the ELP-foldon structure was synthesized as reported
previously193,229. The base structure for the formation of particles has the amino acid
sequence MGH(GVGVP)40-GYIPEAPRDGQAYVRKDGEWVLLSTFL. The use of
directional ligation makes the process modular, allowing for simple incorporation of
other domains.
To synthesize the DNA that encoded the 99 amino acid CA1.CD2 gene, 18
oligonucleotides were synthetically assembled including an N-terminal and C-terminal
primer196. A detailed explanation of the process can be found in the materials and
methods section.
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Figure 3.1. Schematic detailing the construction of the ELP-IMG fusion protein. Any
variation of ELP can be used as the base component at the N terminal and peptide
targeting sequences as well as spacing elements can be implemented at the C terminal.
3.3.2. Expression and Purification of Fusion Proteins
Starter cultures were prepared from frozen stocks in 10ml LB media supplement
with 100 mg/L ampicillin at 37°C. The starter cultures were then added to 1 L of LB
medium and shaken at 300 rpm and 37°C. OD600 readings were taken until the mixture
reached a level between 0.9-1.0 at which time 240 mg of IPTG was added for induction.
After 5 hours of shaking the cells were collected by centrifuging at 7000xg for 30
minutes. The cells were then lysed after being re-suspended in 30 ml of PBS using a
sonic dismembrator. The soluble and insoluble fractions were separated by centrifugation
at 4°C and 19000xg. ELP-IMG was determined to be in the insoluble fraction through
SDS-PAGE analysis and thus the cold pellet contained the protein. It was then resuspended in 10 ml of denaturing agent for 1 hour after which 190 ml of PBS was added
and left to sit overnight. Centrifugation at 4°C and 7000xg followed and the protein was
then present in the soluble fraction. Supernatant was collected and heated to 40°C at
which point ELP-IMG precipitated out of solution followed by centrifugation at 17000xg
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and 40°C. Two more rounds of the thermal cycling process were the performed and the
final pellet was re-suspended in PBS.
3.3.3. Characterization of Proteins
Protein purity, trimer formation and molecular weight confirmation was
performed using SDS-PAGE with 4-20% gradient Tris-HEPES-SDS gel. Samples were
prepared in loading buffer containing 1% SDS and either heated above the denaturing
temperature of the foldon domain230 (>70°C) for 5 minutes or left at room temperature to
confirm the association of foldon. Molar concentrations of the purified proteins were
determined based on calculated extinction coefficients231 and absorbance at 280 nm
measured on a Biomate 3 (Thermo Scientific).
The transition temperature of the fusion protein was determined by measuring the
UV-absorbance of solutions at 350 nm on a Shimadzu 1800 UV-vis spectrophotometer
with an attached temperature control cell. 25 µM protein samples were made in PBS at
neutral pH. Temperature ramp was done at 1°C / min across a range of 20-55°
Particle sizing was performed on a 90 plus Brookhaven particle size analyzer
(Brookhaven Instruments). This unit is a fixed angle dynamic light scattering system with
a Peltier temperature control system. Samples were made as 25 µM solutions in 1X PBS
at varying pH conditions. The solutions were filtered using a .22 µM filter (Millipore)
and loaded into quartz cuvettes. The pH was adjusted through the addition of filtered 1N
NaOH.
Measurements were performed in triplicate and made in 2-minute long runs. The
results were analyzed by the BIC software, which utilized a non-negatively constrained
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least squares algorithm (Brookhaven Instruments) and were reported as mean diameter of
multimodal size distribution (MSD).
3.3.4. Crosslinking of Nanoparticles
Protein samples of varying concentrations were diluted in filtered H2O and had
the pH adjusted to 10.2-10.4 using 1N NaOH. Stir bars were added to the sample and
they were heated to 55°C with constant stirring for 1 hour. After 1 hour 10%
glutaraldehyde was added to the solution to facilitate cross-linking of the micelles.
Samples were kept in this state for at least 18 hours after which they were filtered using a
.22 µM filter (Millipore). Samples were then dialyzed using 1000 Da MWCO 7 dialysis
membranes (Spectra-Por) against PBS overnight. To test stability a sample of crosslinked
particles was analyzed over a course of 44 days both above and below the Tt. Particle size
measurements of the cross-linked micelles were then analyzed as described.
3.3.5. Gadolinium Binding and Characterization
Gadolinium chloride in citrate buffer at pH 4 was added to protein samples in
appropriate molar concentrations with constant stirring overnight. Samples were then
dialyzed at 4°C against PBS for at least 6 hours. After the addition of Gd3+ to protein
solutions the samples were dialyzed to remove any potential excess Gd3+ and tested using
the xylenol orange232 and Arsenazo III233 assays to ensure there was no free gadolinium
present. Confirmation of the amount of gadolinium bound to fusion protein samples was
determined by inductively coupled plasma optical emission spectroscopy (ICP-OES)
[Perkins-Elmer] after the samples were diluted 300 times in 2% nitric acid.
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T1 Relaxivity Measurements
Aliquots of varying concentrations of Gd3+ loaded fusion proteins were loaded
into NMR tubes. The T1 values of the proteins were measured using a minispec Mq60
1.4 T 60 mHz analyzer (Bruker). Runs were performed at 40°C and 10 points of
measurement were taken. Relaxivity was calculated using the following equation: 𝑅1 =
,
+,ST

−

,
+,UVW

/𝐶, where C is the concentration of gadolinium bound to the protein.

In vitro MRI Imaging
MRI images were obtained on an Espree 1.5T clinical scanner (Siemens).
Samples were contained in NMR tubes containing at least 200 µl of sample and arranged
asymmetrically in a plastic rack holder. Control samples consisted of H20, PBS, and free
Gd3+ free in solution. Images were produced using a gradient echo sequence (TE = 5.12
ms, TR =150 ms, resolution matrix 512x336, 111 slices, slice thickness= 2mm). Sample
images were collected and analyzed using OpenDicom viewer software.
3.4 Results
Protein Synthesis and Expression
The fusion protein was successfully synthesized and purified with a yield between
70 and 90 mg per liter of culture. SDS-PAGE (Figure 3-2) showed that when the foldon
domain is heated above its thermal stability limit (lane 1 + symbol) we expect the trimer
to dissociate into a monomer structure which is visible as the single band on the gel at 32
kDa. By keeping the sample at room temperature (lane 2 – symbol) we demonstrate the
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proper folding of the foldon domain by showing trimer structures that are 3 times the
molecular weight of the monomer at 96 kDa.

Figure 3.2. SDS-PAGE gel of ELP-IMG fusion protein structures. Samples were kept at
room temperature (24°C) or heated above the thermal stability limit of foldon domain
(100°C).
Transition Temperature Measurements
The transition temperature of the construct with bound Gd3+ and without bound
Gd3+ was determined using a UV-vis spectrophotometer at 25 µM protein concentrations
in PBS. The fusion protein at neutral pH and physiologic salt conditions has a Tt of
31.7°C. The addition of Gd3+ to the fusion protein has no effect on the Tt value of the
system.
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Figure 3.3. Transition temperature panel of ELP-IMG fusion proteins. A) ELP-IMG Tt
as a function of protein concentration in PBS. B) ELP-IMG Tt as a function of salt
concentration C) Determination of ELP-Fusion protein Transition temperature (Tt) as a
comparison of linear and trimer structures. Tt is characterized for gd3+ bound proteins
(solid) and proteins with no gd3+ present (dashes).ELP-IMG Tt as a function of
concentration in PBS.
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Construct

Sequence

Weight
kDa

Tt
(°C)

ELP40

MGH(GVGVP)40

17

41.5

GVGVP40foldon

MGH(GVGVP)40- GYIPEAPRDG

20

34.5

29

40.1

31.2

31.7

QAYVRKDGEWVLLSTFL
MGH(GVGVP)40- GPGVGRDSGTV

GVGVP40CA1.CD2

WGALGHGIELNIPNFQMTDDID
EVRWERGSTLVAEFKRKMKPFLKS
GAFEIDANGDLDIKNLTRDDSGTY
NVTVYSTNGTRILDKALDLRILE
MGH(GVGVP)40-GYIPEAPRDGQ
AYVRKDGEWVLLSTFL GPGVG

GVGVP40foldonCA1.CD2
(ELP-IMG)

RDSGTVWGALGHGIELNIPNFQ
MTDDIDEVRWERGSTLVAEFKR
KMKPFLKSGAFEIDANGDLDIKN
LTRDDSGTYNVTVYSTNGTRILD
KALDLRILE

Table 3.1. Transition temperature comparison (25 µM in PBS).

Dynamic Light Scattering

Dynamic light scattering (DLS) was then used to confirm that micelle formation
was occurring at low salt and high pH conditions as depicted in Figure 3.4. At neutral pH
and high salt conditions aggregation occurs into particles above 700 nm in size. However,
at salt concentrations below 20 mM and pH between 10.2-10.4 the construct forms
particles ~ 32 nm in diameter. This is comparable to ELP-foldon16 without the CA1.CD2
domain.
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Figure 3.4. Dynamic light scattering of ELP-IMG compared to ELP-foldon. Tests were
performed on samples of 25µM concentration at 42°C. A narrow distribution between 26
and 34 nm is observed. After crosslinking the size increased to ~40 nm with a broader
distribution.
In order to prevent the samples from aggregating in physiologic conditions
polypeptide micelles were cross-linked with glutaraldehyde. This cross-linking allows the
system to exist as particles above or below the Tt in and dialysis in PBS prevents particle
aggregation. The DLS results of the cross-linking experiment are shown in Figure 3.5. As
the temperature is raised above the Tt (42°C), the constructs collapse and have an average
size of 82.2 ± 5.7 nm and is not significantly affected by bound Gd3+ being present. To
show the diameter changes that occur from crosslinking conditions to PBS, heated 4M
NaCl was added in a drop-wise manner to crosslinked samples while continuously
monitoring the particle size (Figure 3.7). In order to successfully complete this test the
salt had to be added in time points of at least 15 minutes and had to be held at the same
temperature as the protein in the DLS cell. The results are analogous to the dialysis
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process, as the slow addition of salt results in particles that are approximately the same
size as when the dialysis process is applied.

Figure 3.5. DLS of cross-linked ELP-IMG. Dynamic light scattering results of crosslinked solutions of 25 µM GVGP40-foldon-CA1.CD2 fusion protein. Samples were crosslinked with 10% glutaraldehyde for 24 hours at 55°C filtered with a .22 uM filter, cooled
and dialyzed against PBS. Samples were then transferred to quartz cuvettes Samples were
run for in triplicate for 2 minutes each. After cross-linking the samples gadolinium
solution was added in a drop wise manner then they were analyzed to determine if there
was any change in particle size.
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Figure 3.6. Shrinking and swelling behavior of crosslinked ELP-IMG samples in PBS.

Figure 3.7. Particle size change in relation to amount of NaCl added.
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Figure 3.8. Crosslink stability of ELP-IMG samples in H2O reaction conditions (A) and
after dialysis in PBS (B)
When the crosslinked constructs are cycled from below to above their Tt, the
strength of the crosslinks is confirmed and there is no longer dissociation of the particles
into monomer form below the Tt (Figure 3.6). This shrinking and swelling behavior is
carried over from crosslinking reaction conditions when dialysis in PBS occurs. Further
these particles display strong stability over time, as they were tested over a course of 44
days. Each time they were tested particle size was measured above and below Tt, to
ensure the stability of the crosslinks. Between tests samples were stored at 4°C.
Transmission electron microscopy on a FEI tecna G2 Twin instrument was
performed on dehydrated cross-linked fusion protein samples. A 5 µL sample was placed
on the TEM grid at room temperature and left to dry and any excess sample was wiped
off the grid. The samples were then imaged at 160Kv as shown in Figure 3.9.
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Figure 3.9. TEM results of crosslinked ELP-IMG in PBS. TEM results of dehydrated
cross-linked 10 µM protein sample ELP-IMG constructs in 1xPBS and neutral pH.
Relaxometry
Gd3+ loaded fusion proteins were used to determine the T1 relaxivity of the
construct at 1.4T field strength. To ensure that no free Gd was present in samples the
methods of section 2.7 were applied. Relaxivity values were plotted according to the
following equation. Varying gadolinium concentrations and the slope of the resulting line
gives the values for T1 relaxivity (Figure 3.10).
1
1
−
𝑇1Z[
𝑇1\]^

= 𝑅1[𝐺𝑑 `a ]

The results of the relaxivity experiments show that the fusion protein is capable of
providing T1 relaxivity of 21.7 mM-1s-1for cross-linked nanoparticle samples, 31.7 mM1 -1

s for soluble constructs samples and 34.8 mM-1s-1 for soluble monomers. These values

are significantly higher than clinical MRI contrast agents (~4 mM-1s-1).
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Figure 3.10. Relaxivity plots for ELP-IMG in various conditions. Relaxivity plots for
cross-linked fusion protein samples, soluble trimer protein samples and soluble
monomers. The results show a linear relationship between Gd3+ concentration and 1/T1
values. The slope of the lines is the value of the relaxivity r1 of the constructs

In vitro MRI Imaging
The results of the MRI experiments confirmed the relaxometry findings. Fusion
protein samples with bound gadolinium were used to determine the contrast provided in
T1 weighted images using a 1.5 T scanner (Siemens Espree). The results of the imaging
show that the fusion protein is capable of producing contrast in T1 weighting (Figure
3.11) and that the intensity of the contrast increases slightly with increasing Gd3+
concentration. These results correlate with what is found for the CA1.CD2 domain
alone136
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Figure 3.11. T1 weighted MR images of ELP-IMG. T1 weighted MR image of fusion
protein samples using GRE sequence (TE = 5.12 ms, TR =150 ms, resolution matrix
512x336, 111 slices, slice thickness= 2mm). Samples 1-4 are soluble protein samples at
varying concentrations in 1xPBS and neutral pH. Samples 5-8 are cross-linked nanoparticles and are in 1xPBS at neutral pH. The images are arranged in the following order
1) 0.025 mM Gd3+- ELP-IMG 2) 0.050 mM Gd3+-ELP-IMG 3) 0.1 mM Gd3+ ELP-IMG
4) 0.15 mM Gd3+ ELP-IMG 5) 0.01 mM Gd3+ ELP-IMG 6) 0.025 mM Gd3+ ELP-IMG 7)
0.05 mM Gd3+ ELP-IMG 8) 0.1 mM Gd3+ ELP-IMG
3.5 Discussion
The addition of an imaging domain to self-assembling ELP nanoparticles to create
a new nanoparticle based MRI contrast agent opens up numerous possibilities for its use
as a potential biomarker system or as a theranostic platform. A distinct advantage of this
system is the ability to seamlessly integrate any ELP-foldon construct as the base using
molecular biology. The Tt or any other condition used to drive the stimuli can be
optimized for potential use in vivo through amino acid substitution. Further addition of
any peptide based targeting moiety can be accomplished in the same manner. This allows
for the creation of any number of systems composed of entirely organic components,
without the need for any post-translational modification. This eliminates the need for any
excess conjugation steps or further chemistry being performed on the system in order to
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add functionality. To our knowledge this is the first MRI active elastin-like polypeptide
nanoparticle system reported in literature.
The first and most important part of this fusion was to ensure that both proteins
retained their positive properties after the fusion takes place. The ELP retains its
responsive behavior while the imaging domain retains the ability to effectively bind
gadolinium. ELP constructs are defined by their transition temperature (Tt), which is a
measure of the temperature at which the protein transitions from a soluble state below the
Tt to an insoluble state above the Tt. The Tt of ELP-IMG is 31.7°C with or without bound
gadolinium ions, compared to 34.5°C for ELP-foldon. Similarly when the construct was
created without the foldon domain, the Tt was 40.8°C compared to 41.5°C for ELP40.
This is a good indication that the CA1.CD2 domain binding gadolinium does not interfere
with ELP properties nor does the trimerizing foldon domain cause a loss of CA1.CD2
domain properties.
When Dynamic light scattering was performed on these samples it was shown that
the ELP-IMG constructs forms stable micellar nanoparticles in non-physiologic
conditions (low salt, high pH), which is indicative of previously seen activity from ELPfoldon constructs. The foldon domain at the C terminal of ELP carries a net negative
charge and will act as a hydrophilic head group creating micelle structures with 3
hydrophobic ELP chains and a charged head group. We anticipated that the CA1.CD2
domain would not interfere with the activity of the ELP-foldon structure due to its similar
architecture; stability across a range of pH’s and net negative charge. In essence the
CA1.CD2 positioned after the foldon domain acts an extension of the head group to
encourage micelle formation. The results of dynamic light scattering showed that this was
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the case as in conditions of low salt and high pH the fusion protein formed micelles with
an average diameter of 31.65 ± 1.45 nm. In low salt conditions the charge on the head
groups is sufficiently shielded in order to prevent aggregation and allow micelle
formation to take place.
To use the micelles as a theranostic platform the micelles need to be stable in
physiologic conditions i.e. high salt and neutral pH. A method to stabilize micelles into a
single nancoparticle shape regardless of temperature, salt or solution conditions is
through the use of crosslinking42. Various methods have proven to be effective for crosslinking micelles including dimethyl 3,3-dithiobispropionimidate (DTBP)234, disulfide
based cross-linkers235 and glutaraldehyde236. Glutaraldehyde was chosen as the crosslinking agent since it is considered most effective at high pH values, in which the
micelles form. After the crosslinking reaction took place the size of the micelles
increased to 39.7 ± 4.8 nm with a broader distribution than non-crosslinked micelles. To
be utilized in physiologic conditions dialysis into PBS dynamic took place after which
light scattering revealed that the constructs had increased in size to about 82.5 ± 5.7 nm at
42°C which is approximately 2.5 times the size of non-cross-linked ELP-IMG constructs.
The increased salt content may cause the construct to swell as the shielding on the
headgroup decreases and the headgroup decreases in size. This was further confirmed by
the addition of salt to crosslinked samples and monitoring particle size changes (Figure
3.7). The strength and stability of the crosslink reaction was also shown through the
shrinking and swelling behavior of the particles as well as monitoring their stability over
the course of 44 days. It is possible that due to the nature of glutaraldehyde cross-linking
being non-specific head-groups are being cross-linked together creating nanoscale
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aggregates of micelles rather than individual micelle structures. Further the crosslinking
reaction causes a slight increase in diameter, indicating that multiple micelles may be
being crosslinked together. This is consistent with the TEM image of the constructs in
Figure 3.9. However, the strength and nature of the glutaraldehyde cross-linking is
sufficient enough to prevent the structures from losing their nanoparticle structure and
becoming completely soluble again.
Relaxometry measurements show that the ELP-IMG constructs display a r1
relaxivity value of 35.4 mM-1s-1 for soluble monomers, 31.7 mM-1s-1 for soluble trimer
constructs and 21.7 mM-1s-1 for cross-linked samples. These results are less than what is
reported for the CA1.CD2 domain on its own, which is 117 mM-1s-1 however, they are
still 5 times larger than that of Gd-DTPA and comparable to other micelle based contrast
agents with Gd3+ chelators237. One possible explanation for the drop in relaxivity of the
constructs is that the CA1.CD2 domains become crowded when they form after the
foldon headgroups in micelle structures. When Gd3+ ions are closely packed together as
they would be in this situation it brings two paramagnetic centers into close proximity238,
which in turn causes, a reduction of proton relaxivity (r1) by increasing the transverse
electronic relaxivity12. To understand this further, on a per volume basis the number of
trimers per micelle can be calculated using the molecular weight of trimer as 93,600
g/mol, a density of 1.2*103 g/L and the radius of an ELP-IMG micelle as 16nm. The
volume of an ELP-IMG trimer is 363.15nm3. The volume of ELP-IMG micelle can be
calculated using 4//3πr3, giving a value of 17,157 nm3. The number of trimers per micelle
can then be calculated as 47 and with 3 gadolinium binding sites per headgroup, it is a
total of 141 gadolinium binding sites per micelle.
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In the cross-linked constructs the relaxivity decreases further. This can most likely
be explained by the non-specific nature of using glutaraldehyde cross-linking for this
process. The crosslinking process brings multiple headgroups closer together. Thus if
multiple CA1.CD2 domains are being cross-linked together or packed on top of each
other in the cross-linked structure the proximity of paramagnetic centers would be even
closer. Compounding this would be a possible loss of availability to bulk water in the
particle, which would reduce the ability of water exchange to take place for the CA1.CD2
domain as compared to the water available in the soluble constructs. When these are
crosslinked the number of gadolinium binding sites per headgroup most likely increases
even further potentially explaining the crowding condition. In order to optimize the
relaxivity properties of the construct different ELP architectures, including mixtures of
linear and trimer structures need to be investigated to attempt to reduce headgroup
crowding
3.6 Conclusion
Taken as a whole, this fusion protein represents a promising wholly peptide based
MRI contrast agent with potential for use in in vivo applications and as a future platform
for theranostic systems. The system exists as a nano scaled structure in physiologic
conditions that is dependent only on the temperature of solution to drive the transition.
Diagnostic imaging in MRI is provided by the fusion of the CA1.CD2 domain, which
provides positive contrast in T1 weighted imaging at low gadolinium concentrations.
Further expansion or modification of the construct is made possible through simple
molecular biology procedures eliminating the need for post-translational modification.
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CHAPTER IV
ACTIVE TARGETING EFFECTS OF THERANOSTIC NANOPARTICLES OF
ELASTIN-LIKE POLYPEPTIDES
4.1. Abstract
The addition of active targeting to a theranostic protein system based nanoparticle
system, which is capable of MRI contrast and disease state targeting specificity is
described. This theranostic system is composed of nanoparticles of the protein-based
polymer elastin-like polypeptide. We previously described the development of
nanoparticle contrast agents based on the fusion of these particles with a MRI binding
domain. The system has been further enhanced to provide specific targeting through the
addition of the gastrin-release peptide decorated on the outside of the nanoparticles. The
construct displays relaxivity that is approximately four times higher than current clinical
contrast agents and the contrast agent provides enhancement in cell lines in a short time
frame. Being entirely protein based and highly amenable to alteration, this platform
serves as an excellent candidate for soft matter theranostic systems.
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4.2. Introduction
Theranostics is a revolutionary new field of research that aims to combine both
therapeutic and diagnostic imaging components into a single nanoparticle formulation218.
Eventually formulations of this nature will help to create a future of personalized
medicine, where treatments are designed to meet the specific needs and can be tailored to
the specific response of individual patients6. Due to the variability in response for each
patient to a therapeutic formulation, this concept may help to increase the efficacy of
cancer treatment. The use of theranostic nanoparticles decorated with targeting elements
and molecular imaging can lead to site specific treatments and positive recognition of the
interactions111. This approach has multi-fold benefits, which include individualized dose
response recognition, real-time monitoring of the response to combinatorial treatments
and the possible creation of a new class of biomarkers for recognition of phenotypes.
Nanoparticles are vital to the success of creating theranostic systems and can be
composed of inorganic or organic components including polymers239, lipids39,
dendrimers41 and magnetic iron oxide144. In the case of cancer cells, the size and shape of
nanoparticles offer great advantages in their ability to localize to these cells more so than
to normal cells through the enhanced permeability and retention effect (EPR)67 and a
general method known as passive targeting. This strategy has been shown to be
successful in demonstrating a level of accumulation of nanoparticles at the target site.
The EPR effect is limited by the poor vascularization of large tumors as well an
insufficient accumulation of nanoparticles to achieve diagnostic imaging240.
These limitations can be overcome through the use of active targeting, which
involves the attachment of targeting ligands or peptides to the surface of the
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nanoparticles77. The targeting ligands have high affinity for various receptors or antigens
present on the cell surface. When the targeted particles interact with these receptors,
binding occurs through ligand-receptor interactions that can lead to receptor-mediated
endocytosis and localization of the nanoparticle inside the tumor81. In order for active
targeting to be successful the receptors must be over-expressed on the cell surface and
should be evenly distributed to ensure the whole surface has a chance to experience the
targeted nanoparticle241. The gastrin release peptide targeting ligand is a bombesin
analogue used for prostate cancer specific targeting. This peptide targets to the gastrinrelease peptide receptor (GRPR) which is a G-protein coupled receptor106 and is overexpressed on many types of cancers including pancreas106, breast107, and prostate108. A
recent study found that GRPR was highly over-expressed in lower grade prostate cancer
tumors, indicating that the GRPR is a potential target for early detection using theranostic
nanoparticles81. Prostate cancer is the second most highly diagnosed cancer in men and
the second leading cause of cancer related death1. If prostate cancer becomes too
advanced, it will reach a state where it is not treatable known as prostate resistant cancer
(PRC), thus early detection is critical96.
The use of magnetic resonance imaging (MRI) as the imaging modality for this
theranostic system is desirable due to the fact that it is a non-invasive technique, high
anatomical contrast and high spatial resolution242. When utilized for the purpose of
disease detection and diagnosis of cancer states, however, there is a lack of sufficient
contrast between the cancerous state and the surrounding healthy tissue219. MRI contrast
agents are used to overcome this limitation, with the majority being based on the
lanthanide, gadolinium243, which produces positive contrast images. Although contrast
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agents are widespread in use, both in clinical and diagnostic practice, they have several
drawbacks. These include a relatively low relaxivity on the order of 3-8 mM-1s-1, which
leads to a large amount of contrast agent required to generate sufficient contrast137.
Second, typical contrast agents are cleared rapidly from the vasculature through renal
mechanisms, which lead to poor tissue retention and the need for repeated dosages. Using
nanoparticle based contrast agents has shown the ability to overcome these limitations
mainly through an increase in rotational correlation time which increases the molecular
tumbling rate and increases with increasing molecular weight132. Further combing
nanoparticle based MRI with active targeting strategies allows for specific targeting and
imaging of a disease state with enhanced contrast accumulation244.
We have previously reported the design and characterization of elastin-like
polypeptide (ELP) based micelles193. These nanoparticles are environmentally responsive
and form with the aid of a negatively charged head group. ELPs are a genetically encoded
responsive biopolymer based on the repetitive pentapeptide sequence VPGXG161. The X
position is typically valine, but is substitutable for any of the amino acids except for
proline, which makes for a limitless number of combinations. The most desirable feature
of ELPs is their transition temperature (Tt) behavior where in an increase in the
temperature of solution causes the ELP to change from a soluble state to an insoluble
state where they aggregate into coacervates245. This behavior is rapid, reversible and able
to altered in many ways including chain length and weight of the ELP199, the composition
of the guest residue200 and solute conditions246, giving a wide range of options for tuning
the response of the protein to different conditions. As the basis for a theranostic system,
the combination of tunable responsive behavior, control over composition, size, and
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charge along with generally biocompatible behavior make ELPs an excellent material
choice.
Fusion with the protein based MRI contrast agent CA1.CD2 was successfully
achieved, and described in previous chapters. This cross-linked nanoparticle system
displayed a relaxivity approximately five times that of clinical contrast agents, and
displayed tolerance to being incubated with human serum as well as with zinc indicating
stability of gadolinium binding. New modifications to the system include the addition of
active targeting elements, through use of the gastrin release peptide c terminal fragment.
This peptide was added to the system using common molecular biology techniques, and
included a flexible spacer element between the headgroups and the targeting peptide.
After expression and purification of the protein the contrast agent properties were
examined, and the targeting efficacy of the modified ELP nanoparticles was investigated
in three cancer cell lines. This system is the first ELP based theranostic nanoparticle
reported in literature and is a promising candidate for use in many applications.
4.3. Materials and Methods
4.3.1. Gene Design and preparation
The genes that encode the ELP-THO structure (GVGVP40-foldon-CA1.CD2Spacer-GRP) were synthesized as previously reported. To modify the structure of ELPfoldon-CA1.CD2 to allow for addition of gastrin release peptide receptor a new set of
oligonucleotides were created, as represented in Table 1, which includes a flexible spacer
between the head-groups and targeting elements. The amino acid sequence, which
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contains the spacer and the targeting element, is represented by:
GPGVGWTSTGPQSSNTGNPSTSGQNNVPGNHWAVGHLM
DNA Sequence

Primer Name

TATGGGCCACGGCGTGGGTGGGAATCACTGGGCAGTGGGACACTTG

GRP Forward

ATGTGAGCCCGGTGGGC

CACCGGGCTCACATCAAGTGTCCCACTGCCCAGTGATTCCCACCCAC

GRP Reverse

GCCGTGGCCCA

TATGGGCCACGGCGTGGGTTGGACCTCTACTGGCCCGCAATCCTCTA

Spacer Forward

ACACTGGCAATCCGTCTACCTCTGGTCAAAATAACGTGCCGGGC

CGGCACGTTATTTTGACCAGAGGTAGACGGATTGCCAGTGTTAGAG

Spacer Reverse

GATTGCGGGCCAGTAGAGGTCCAACCCACGCCGTGGCCCA

Table 4.1. Oligonucleotides used to create ELP-THO construct. Representation of
oligonucleotides used to encode the spacer and gastrin release peptide receptor fragment.
4.3.2. Protein expression, purification, and characterization
Starter cultures were prepared from frozen stocks in 50 ml TB media supplement
with 100 mg/L ampicillin at 37°C. The starter cultures were then added to 1 L of TB
medium and shaken at 300 rpm and 37°C. OD600 readings were taken until the mixture
reached a level between 0.9 and 1.0 at which time 240 mg of IPTG was added for
induction. After shaking for a time of 5 hours the cells were collected by centrifugation at
9000xg for 30 minutes at 4°C. The cells were then lysed after being re-suspended in 30
ml of PBS using a sonicator. The soluble and insoluble fractions were separated by

153

centrifugation at 4°C and 27000xg. The protein was determined to be in the insoluble
fraction in our previous study, which required the need for denaturation. The insoluble
fraction from the first cold spin was re-suspended in 8M urea and sat at 4°C for at least 6
hours and subsequently dialyzed against 4 M urea at 4°C overnight, followed by dialysis
against 2 M urea at 4°C overnight. Dialysis then took place against water three times for
at least 2 hours followed by centrifugation at 4°C and 27000xg. The soluble portion from
this centrifugation contained the final protein, which then was dialyzed against water at
4°C for at least 24 hours to remove any residual salts from the denaturation process.
Protein purity, trimer formation and molecular weight confirmation was
performed using SDS-PAGE with 4-20% gradient Tris-HEPES-SDS gel. Molar
concentrations of the purified proteins were determined based on calculated extinction
coefficients231 and absorbance at 280 nm measured on a Biomate 3 (Thermo Scientific).
The transition temperature of the fusion protein was determined by measuring the
UV-absorbance of solutions at 350 nm on a Shimadzu 1800 UV-vis spectrophotometer
with an attached temperature control cell. Particle sizing was performed on a 90 plus
Brookhaven particle size analyzer (Brookhaven Instruments). This unit is a fixed angle
dynamic light scattering system with a Peltier temperature control system. Samples were
made as 25 µM solutions in PBS at varying pH conditions. The solutions were filtered
using a 0.22 µm filter (Millipore) and loaded into quartz cuvettes and the pH was
adjusted through the addition of filtered 10 N NaOH. Measurements were performed in
triplicate and made in 2-minute long runs. The results were analyzed by the BIC
software, which utilized a non-negatively constrained least squares algorithm
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(Brookhaven Instruments) and were reported as mean diameter of multimodal size
distribution (MSD).
For crosslinking reactions protein samples of varying concentrations were diluted
in filtered water with the pH adjusted to 10.2-10.4 using 10 N NaOH. Stir bars were
added to the sample and they were heated to 55°C with constant stirring for 1 hour. After
1 hour pre-warmed 10% glutaraldehyde (~2 µl) was added to the solution to facilitate
cross-linking of the micelles. Samples were kept in this state for at least 18 hours after
which they were filtered using a .22 µM filter (Millipore). Samples were then dialyzed
using 1000 Da MWCO float-a-lyzer dialysis tubes (Spectra-Por) against PBS overnight.
Particle size measurements of the cross-linked micelles were then analyzed as described.
Transmission electron microscopy (TEM) took place on FEI tecna G2 twin instrument on
crosslinked protein samples in PBS at room temperature.
4.3.3. MRI imaging properties and characterization
Gadolinium chloride in citrate buffer was added to cross-linked protein samples in
appropriate molar concentrations with constant stirring overnight. Samples were then
dialyzed at 4°C against PBS for at least 6 hours to remove any potential excess Gd3+ and
tested using the xylenol orange212 and Arsenazo III210 assays to ensure there was no free
gadolinium present. Confirmation of the amount of gadolinium bound to fusion protein
samples was determined by inductively coupled plasma optical emission spectroscopy
(ICP-OES) [Perkins-Elmer]. The samples were diluted 300 times in 2% nitric acid using
rhenium as an internal standard and compared to calibration plots. Aliquots of varying
concentrations of Gd3+ loaded fusion proteins were loaded into NMR tubes. The T1
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values of the proteins were measured using a mini-spec Mq60 1.4 T 60 mHz analyzer
(Bruker). Runs were performed at 40°C and 10 points of measurement were taken. MRI
images were obtained on an Espree 1.5 T clinical scanner (Siemens). Samples were
contained in NMR tubes containing at least 200 µl of sample and arranged
asymmetrically in a plastic rack holder. Images were produced using a gradient echo
sequence (TE = 5.12 ms, TR =150 ms, resolution matrix 512x336, 111 slices, slice
thickness = 2 mm), and these images were collected and analyzed using OpenDicom
viewer software.
4.3.4. Cell Culture and Passaging
Cancer cell lines were chosen based on their expression levels of gastrin release
peptide receptor108. The three lines chosen were pC3 prostate cancer cells247, U87 RFP
glioblastoma248, and H441 lung cancer249. The pC3 and H441 lines were ordered from
ATCC and the U87 RFP glioblastoma cells were a gift from Dr. Joanne Belovich. All
cells were grown in a sealed incubator at 37°C and 5% CO2. U87 cells were grown in
Eagle’s minimum medium 10% FBS supplemented with 5 ml L glutamine (0.292 gm/L),
5 ml 100 x non-essential amino acids (10 mM concentration of each within the solution),
10 ml 1x HEPES buffer, 5 ml pen strep (100 I.U. /ml penicillin and 100 ug/ml
streptomycin) and 0.5 ml of 250 mg/ml amphotericia-B. Prostate cancer cell line, pC3
(ATCC CRL-1435) was ordered from ATCC and grown in F-12K media with 10% FBS.
H441 (ATCC HTB-174) lung cancer cells were ordered from ATCC and grown in
RPMI-1640 media with 10% FBS. Cells were passaged when they reached 75-80%
confluence. Standard passage protocols were applied and passage number was kept less
than 8 before using a fresh culture of cells.
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4.3.5. ELP Targeting Properties and Fluorescent Imaging
From a fresh passage of cells, total number of cells was counted. Once seeding
density was determined for each well per plate to transfer into, an appropriate amount of
cell suspension was added to each well and diluted with an appropriate amount of fresh
media. Cells were left to grow on the plates and were checked after 24 hours to ensure
that attachment took place. Once that was determined the media was aspirated and
replaced with fresh media and left to sit for 1 hour after which, protein samples at
appropriate concentrations were incubated with the cells. ELP’s were labeled with
Flourescein isothioctanate (FITC), using a labeling kit (Pierce) and following standard
protocols. After incubation times were completed the media was aspirated from the wells
and cells were washed 2 times with ice cold sterile PBS and removed. Following this
cells were washed with ice cold 4% paraformaldehyde for 5 to 8 minutes, followed by
washing one more times in ice cold PBS for minutes. Solution was removed and DAPI
was added and allowed to sit for 5 minutes before filling well with PBS and beginning
microscopy studies. An inverted fluorescent microscope (Zeiss Axiovert) was used for
imaging localization of ELP’s within the cells at wavelengths corresponding to FITC
(588 nm) and DAPI (461 nm) or red for RFP proteins (615 nm). Images were collected
and processed in ImageJ.
4.3.6. MR Imaging of cells
ELP-THO-Gd3+ at 4 different protein concentrations was incubated with PC3
cells for 4 hours. As controls both ELP-IMG-Gd3+ and Gd3+Cl in citrate buffer were
incubated with the cells for the same time period. At the completion of incubation period,
the cells were washed three times with ice-cold PBS and removed from their wells with
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trypsin. After trypsinization of the cells, volumes of 500 µl were then transferred into
micro-centrifuge tubes and spun down. The resulting pellets in solution were kept on ice
and taken immediately for MR imaging.
4.4. Results
Protein Synthesis, Expression and Characterization
Expression of the protein was successful and produced yields between 80 and100
mg/ml per liter of culture. Results of SDS-PAGE gel show that the trimer structures were
folding correctly and are represented in Figure 4.1.

Figure 4.1. SDS-PAGE results of protein expression. Lane 2 represents the sample at
room temperature with the trimer form present slightly above the 102 kDa marker and the
monomeric form is represented by Lane 1 at 100°C with a molecular weight between the
31 and 38 kDa marker.
The amino acid sequence of the construct was confirmed by DNA sequencing (Cleveland
Clinic genomics core) and was found to be MGH-(GVGVP)40GYIPEAPRDGQAYVRKDGEWVLLSTFL

158

GPGVGRDSGTVWGALGHGIELNIPNFQMTDDIDEVRWERGSTLVAEFKRKMKPF
LKSGAFEIDANGDLDIKNLTRDDSGTYNVTVYSTNGTRILDKALDLRILE
GPGVGWTSTGPQSSNTGNPSTSGQNNVPGNHWAVGHLM. The molecular weight
of this construct in monomer form is calculated to be 35,267 daltons.
Transition temperatures (Tt) of protein samples were measured at a range of 25
protein concentrations in PBS, as well as a 25 µM protein concentration sample in
varying salt conditions. At neutral pH and in PBS the transition temperature of the
protein at a concentration of 25 µM is 32.4 °C. When gadolinium is added to the system
the Tt is unchanged. Figure 4.2 represents a collection of Tt measurements taken as a
function of concentration and salt in comparison to the same construct without targeting
elements.

Figure 4.2. Transition temperature measurements as compared to ELP-IMG. Comparison
of Tt values between ELP-THO and ELP-IMG: A) As a function of protein concentration
B) As a function of NaCl concentration. Values of the two constructs are comparable
indicating insignificant change in protein character after addition of targeting elements.
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When dynamic light scattering was performed on the samples the self-assembly
of micelles was confirmed. In micelle forming conditions (salt <30 mM pH 10.2-10.4),
the constructs self-assemble into micelles above Tt with an average diameter of 37.7 ±
2.9 nm, and is comparable to previous iterations of the constructs (Figure 4.3c). After
cross-linking the nanoparticles have an average diameter of 44 ± 3.8 nm with a slightly
broader distribution. After dialysis in PBS overnight, the construct’s particle diameter
above the Tt increases to 70.8 ±1.8 nm, while below the Tt the particle diameter swells to
a size of 94.8 ±5.8 nm and the constructs do not dissociate. These particle diameters are
visible in Figure 4.3.
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Figure 4.3. Particle size characterization of ELP-THO construct. A) Particle diameter in
H2O particle forming conditions and in reaction conditions. B) Cross-linked particle
behavior above and below the Tt. C) Comparison of 3 ELP nanoparticle constructs
Using methods described previously, TEM images were acquired and further confirmed
the nanoparticle scale of the crosslinked constructs as shown in figure 4.4.
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Figure 4.4. TEM images of ELP-THO. TEM images of crosslinked ELP-THO samples at
room temperature in PBS.
Gadolinium addition, characterization, and imaging properties
Gadolinium chloride in citrate buffer (Acros) was added to cross-linked ELPTHO proteins in a drop-wise manner and allowed to stir overnight. It was found that a
protein to gadolinium ratio of 1:1 was required to ensure the level of excess gadolinium
present in the solution was minimal (<10%). ICP-OES analysis with the presence of the
internal standard showed 95-100% recovery of internal standard, which indicates that the
protein was not interfering with the detection of gadolinium. Xylenol orange and
Arsenazo III assays were used to show that the amount of excess gadolinium present was
< 10%. After addition and determination of bound gadolinium, relaxivity values were
determined using a series of ELP-THO Gd3+ chelates at varying concentrations and 37°C.
The results showed that the crosslinked constructs had a r1 relaxivity of 15.17 mM-1s-1,
which is slightly less than ELP-IMG (21.7 mM-1s-1).
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Figure 4.5. Relaxivity plot for ELP-THO construct compared to ELP-IMG. A linear
relationship is observed between the Gd3+ concentration and 1/T1 values, and when
plotted as a line the slope gives the r1 value of the construct as a whole.
MR Imaging
The results of the phantom experiment showed that the construct was displaying contrast
in T1 weighted imaging. Samples of increasing Gd3+ content (as measured by ICP-OES)
displayed increasing contrast (Figure 4.6).
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Figure 4.6. T1 weighted MR image of ELP-THO constructs. Phantom MR images of
cross-linked ELP-THO-Gd3+ samples in PBS. Gd content was present in the samples as
follows A) 0.01 mM B) 0.05 mM C) 0.1 mM D) 0.15 mM and T1 weighted MR images
were obtained using GRE sequence (TE = 5.12 ms, TR =150 ms, resolution matrix
512x336, 111 slices, slice thickness= 2 mm)
Active targeting properties of ELP-THO
Incubation of ELP-THO with gastrin release positive and negative cell lines and
subsequent fluorescent microscopy imaging confirmed that the attachment of the gastrin
release peptide targeting fragment allowed for active targeting of ELP constructs. As a
negative control ELP without the targeting fragment also underwent the same procedure
and was shown to have no interaction with the cell lines (Figures 4.7 and 4.8).
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Figure 4.7. Immunohistochemistry panel of ELP-THO for 3 cell lines. Panel of three cell
lines with either positive or negative GRPR content incubated with ELP-THO labeled
with FITC. Images are taken at three wavelengths and merged to determine the nature of
the targeting.

Figure 4.8. Immunohistochemistry panel of ELP-IMG as negative control. 3 cell lines
negative control using ELP-IMG labeled with FITC incubated with PC3 cells.

Specific uptake and targeting of PC3 cells was investigated with different time points of
incubation for 25 µM ELP-THO constructs labeled with FITC. Time points chosen were
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30 minutes, 1.5 hour, 4 hours. Fluorescence microscopy indicated that the nanoparticles
were targeting PC3 cells and were able to undergo interaction with cells in 30 minutes
(Figure 4.9). MR Imaging of cells was performed to show that Gd3+ loaded targeted
constructs would display MRI contrast even after interaction with cells (Figure 4.10).

Figure 4.9. Uptake of ELP-THO-FITC in PC3 cells at 3 time points. PC3 cells (25,000
cells/well) incubated with 25µM ELP-THO at three time points a) 30 minutes b) 90
minutes c) 4 hours. The images were taken at three wavelengths and merged.
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Figure 4.10. MR imaging of incubated cell pellets. PC3 cells at a density of 80,000
cells/well were cultured. ELP-THO Gd3+ was incubated at four concentrations (1-4) with
the cells for 4 hours, followed by harvesting and imaging. As controls Gd3+ only at a
concentration of 100 µM was incubated with cells (7) as well as the protein construct
without targeting elements (5-6).

Cytoxicity assays
The results of the live/dead assay showed that ELP constructs displayed minimal toxic
effects on PC3 cells while constructs with excess GTA and Gd3+ provided a higher level
of toxicity. DMSO was used as a control to provide a majority of cells as dead while one
well was left completely alive.
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Figure 4.11. Live / Dead controls cytotoxicity %. Results of a series of controls to
determine cell viability using a live / dead assay, which shows that ELP constructs
inherently display minimal toxic effects on cells.

..
Figure 4.12. Live / Dead control A) ELP-THO with Gd3+ B) DMSO control.
The live / dead assay were performed as function of ELP concentration in samples of
both PC3 cells, and U87 cells. The results showed that as ELP concentration increased
the toxic effects remained minimal (Figure 4.13).
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Figure 4.13. Live / Dead as a function of protein concentration. A) ELP-THO at protein
concentrations from 25-150 µM incubated with PC3 cells. B) ELP-THO at protein
concentrations from 25-150 µM incubated with U87 cells.
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4.5. Discussion
The addition of targeting elements to MRI active nanoparticles of elastin-like
polypeptides (ELP-IMG) is the first step to transforming the previously described system
into a theranostic nanoparticle. These targeting peptides allow for disease state specific
interaction between ELP nanoparticles and receptor positive cell lines.
After the addition of the targeting domains, it was important to determine the
changes on the ELP properties. Transition temperature (Tt) behavior was characterized
and compared to ELP-IMG. The Tt was found to be 32.4°C at 25 µM in PBS which is
comparable to previous results. Further over a series of protein concentrations and salt
concentrations the construct behaved in an expected manner. Also, with the addition of
gadolinium, there was not an appreciable change in the Tt. This is a strong indication the
addition of the spacing element and targeting peptide has no adverse effect on the ELP
properties. When samples were prepared in micelle forming conditions (low salt, high
pH) micelle self-assembly took place as expected and is comparable to both ELPfoldon193 and ELP-IMG with an average diameter of 37.7 ± 2.8 nm. Cross-linking of the
micelles was undertaken to stabilize the particles and prevent dissociation of the micelles
in physiologic conditions. Another benefit of crosslinking the ELP-THO with
glutaraldehyde (GTA) is that GTA has been shown to reduce drug burst release levels,
reduce release rates and increase the time it takes for total drug release to occur174. After
crosslinking took place in GTA the diameter of the constructs increased slightly, which
can be explained by the non-specific nature of glutaraldehyde, which utilizes free amines
for crosslinking250. Free amines are located on the N-terminal amines inside the core of
the micelles; however, others exist on the headgroups, which may lead to the crosslinking
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of individual micelles together to form aggregates. This behavior is clear from the TEM
image in Figure 4.4. After dialysis into PBS, the diameter of the constructs increased
approximately 200%. This can be explained by extra salt content that causes a decrease in
the shielding on the headgroups. This decreased shielding causes the headgroups to
become smaller while the length of the chains in the ELP core become extended194. The
extent of the crosslinking through glutaraldehyde interacting with amines prevents the
construct from dissociating as the temperature is dropped below the Tt. Instead the
nanoparticles swell, to allow for the influx of water into the core that would typically be
associated with soluble ELP. This swollen state, which only exists with the crosslinked
proteins, has a diameter of 94.8 ±5.9 nm with a relatively broad distribution. When the
temperature is raised above the Tt the diameter of the crosslinked nanoparticles collapses
to a diameter of 70.8 ±1.8 nm. This can be described as the water leaving the core of the
micelles as the ELP goes from a soluble to an insoluble state, but in this case the
nanoparticle shape remains, with less water located in the core. This shrinking and
swelling behavior can potentially be exploited in many ways for theranostic applications,
with the transition being only dependent upon temperature change.
The next step of characterizing the ELP-THO crosslinked nanoparticle was to
determine its properties as a contrast agent. Relaxometry was used to determine the value
of the relaxivity at various Gd3+ concentrations and compared to ELP-IMG. The
measurements showed that the constructs had a relaxivity of 15.1 mM-1s-1, which is 75%
of the value achieved for the ELP-IMG constructs without the targeting and spacing
elements. The spacer and targeting elements can be preventing water access to the
CA1.CD2 domain in order to allow for optimal interaction between the Gd3+ and the bulk
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water. Further, due to the non-specific crosslinking from the glutaraldehyde multiple
headgroups may be being crosslinked together and held in close proximity, which can
reduce relaxivity. The TEM may lend credence to this idea, as the headgroups appear to
be stacked on top of each other (Figure 4.4). Water exchange rates, however are still high
due to the soluble nature of the ELP construct in solution. Gradient echo MRI images
show that the construct does provide positive contrast in T1 weighted imaging which is
dependent on the concentration of gadolinium bound to the construct.
Incubation of the ELP-THO constructs with cancer cell lines with varying levels
of gastrin release peptide receptor expression confirmed the specificity of the targeting
mechanism. After an incubation periods of 30 minutes crosslinked ELP-THO samples
appear to be interacting with the PC3 cells, while after a period of 1.5 hours non targeted
ELP-IMG show no uptake into cells. Similar behavior was observed in the GRPR
positive cell line U87, while GRPR negative cell line H441, showed no interaction with
ELP-THO. These results are strong indicators of the efficacy of the targeting peptides, as
well as the ability of the targeted protein to interact with the cell. When MR imaging was
applied to collected cell pellets, there was an enhancement of contrast observed with an
increase in protein and Gd3+ concentration. Cytotoxicity analysis showed that the ELP
based protein constructs without therapeutic displayed minimal toxicity. A 10 fold molar
excess of Gd3+ with ELP-THO showed an increase in cytotoxic effects as well as a larger
increase in cytotoxic effects for the sample with 300 fold excess GTA. However, samples
that contained no excess amounts of either component had minimal toxicity. This is to be
expected as Gd3+ is only toxic to cells in very large doses251, and both ELP168 and
CA1.CD2 domain137 are considered biocompatible. Further when ELP-THO was
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incubated without bound Gd3+ in varying concentrations, minimal cytotoxicity was
observed.
4.6. Conclusion
The advantages of this system are numerous and clearly display that the ELPTHO construct has potential as a theranostic system. The system exists as a crosslinked
nanoparticle that is responsive to changes in the temperature of the environment. The
combination of self-assembly, imaging properties, and targeting specificity are presented
and represent the basis of using this system for numerous applications. A further
advantage of the system is that it is fully protein based which allows for easy
modification of the construct dependent only upon utilization of molecular biology.
Modifications that are possible include adding any peptide based targeting element,
changing the ELP composition to change the mechanism of response or to be more
sensitive to various therapeutic interactions.
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CHAPTER V
MODIFICATION OF THE ARCHITECTURE OF ELP-IMG CONSTRUCTS:
EFFECTS OF CHAIN LENGTH AND MIXTURES WITH ELP-FOLDON

5.1. Introduction
Through the use of molecular biology, modification of the previously described
ELP-IMG gene is a relatively straightforward process. The idea of this brief study was to
determine two things; the first being the effects of linear chain length without the foldon
domain on the properties of ELP-IMG and the second being making mixtures of ELPIMG and ELP-Foldon. The linear constructs were conceived to see if the foldon and
subsequent micelle formation had any adverse effects on properties and effectiveness of
CA1.CD2 domain. The mixtures were thought of as a solution to reduce headgroup
crowding that has been observed in ELP-IMG and ELP-THO. This chapter will detail
their development and characterization.
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Figure 5.1. Schematic of mixtures of ELP-IMG and ELP-foldon.

5.2. Materials and Methods
The molecular biology method to create the linear constructs follows the methods
previously described in other sections. The only difference was (GVGVP)10,
(GVGVP)20, (GVGVP)40 were double digested with NdeI and BglI and inserted into a
pET20b-IMG vector that had been double digested with NdeI and PflMI. Mixtures were
made based on a molar ratio which is what the percentages indicate, with only
(GVGVP)40-foldon and ELP-IMG being used. For example a 100 µM total protein
concentration sample will have the following composition for different mixtures:
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Composition: 2 ml
100

ELP-IMG (430 µM

ELP-Foldon (950 µM

µM protein

stock)

stock)

10 µM

90 µM

46.5 µl stock

189.5 µl stock

30 µM

70 µM

139.5 µl stock

147.4 µl stock

50 µM

50 µM

232.5 µl stock

99.25 µl stock

concentration
10/90

30/70

50/50
Table 5.1. Ratios of protein stocks used to make mixtures.
Expression and purification of the linear constructs followed the same methods as
described before, except for (GVGVP)20-IMG and (GVGVP)10-IMG, where NaCl was
added to aid in the warm purification steps. At the conclusion of purification samples
were dialyzed against H2O for 24 hours to remove residual salts. Characterization
including Tt measurements, dynamic light scattering and r1 time measurement proceeded
as described earlier. T1 weighted imaging was performed on a 1.5 T scanner (Siemens
Espree) using Spin echo imaging with a TR of 500 ms, a TE of 12 ms. Slice thickness
was 5 mm or 7 mM and the resolution matrix was 256x100.
5-3. Results
Mixture formation was successful in creating single entity constructs with mixed
headgroups. The transition temperature (Tt) of the mixtures decreased with increasing
ELP-IMG content with values for a 25 µM sample in PBS of: 10% ELP-IMG / 90%
176

ELP-Foldon having a value of 41.6°C, 30% ELP-IMG / 70% ELP-Foldon having a value
of 38.7 °C and 50% ELP-IMG / 50% ELP-Foldon having a value of 36.2°C (Figure 5-2.).

Figure 5.2. Transition Temperatures of mixtures. Transition temperature measurements
for ELP-IMG / ELP-Foldon mixtures. Samples were made at 25 µM concentration in
PBS.
Dynamic light scattering was applied to samples in particle forming conditions
(low salt, high pH), post crosslinking in water and post crosslinking in PBS. The diameter
of the particles in all conditions compares favorably to both ELP-foldon and ELP-IMG.
A broadened distribution in crosslinked samples is observed however (Figure 5.3).
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Figure 5.3. Dynamic light scattering of mixtures. Dynamic light scattering results for 3
mixtures, 10% 90%, 30% 70% and 50% 50% ratios. Single populations are observed
across all conditions.
Upon measurement of the relaxivity values for crosslinked samples it was found
that in mixtures with increasing ELP-IMG content, the relaxivity increased
(50%>30%>10%) as would be expected. These values range from 16.6 mM-1s-1 to 12.9
mM-1s-1 (Figure 5-4), which are still at least 2.5 times more than Gd-DTPA in clinical
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use. The advantage of the headgroup mixing however was as anticipated with a reduction
in headgroup crowding leading to an enhancement of relaxivity values.

Figure 5.4. Relaxivity plots for mixtures of ELP-IMG and ELP-Foldon.
When the linear samples were measured as soluble constructs below their
respective Tt GVGVP40-IMG and GVGVP20-IMG display relaxivities of 34.1 mM-1s-1 and
14.5 mM-1s-1, both of which are relatively high values in relation to clinical contrast
agents (Figure 5-5). GVGVP10-IMG was unable to be measured due to difficulty
purifying the sample.
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Figure 5-5: Relaxivity plots for linear ELP-IMG constructs.

Construct

Relaxivity (mM-1s-1)

Tt (°C)

GVGVP40-IMG

34.13

40.1

GVGVP20-IMG

14.5

55.5

10% ELP-IMG 90%ELP-Foldon

12.87

41.7

30% ELP-IMG 70%ELP-Foldon

14.95

38.6

50% ELP-IMG 50%ELP-Foldon

16.6

36.2

Table 5.2. Summary of relaxivity and Tt measured for modified constructs.
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Figure 5.6. In vitro MRI imaging of mixtures. T1 weighted MR image of linear ELPIMG samples. The images are arranged in the following order (1) 0.01 mM Gd3+GVGVP20-IMG (2) 0.025 mM Gd3+- GVGVP20-IMG (3) 0.05 mM Gd3+ GVGVP20-IMG
(4) 0.75 mM Gd3+ GVGVP20-IMG (5) 0.01 mM Gd3+ GVGVP40-IMG (6) 0.025 mM Gd3+
GVGVP40-IMG (7) 0.05 mM Gd3+ GVGVP40-IMG (8) 0.75 mM Gd3+ GVGVP40-IMG
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Figure 5.7. In vitro MRI imaging of linear constructs. T1 weighted MR image of
Mixtures of ELP-IMG and ELP-foldon samples. Samples 1-4 are 10% ELP-IMG / 90%
ELP-foldon, samples 5-8 are 30% ELP-IMG / 70% ELP-foldon and samples 9-12 are
50% ELP-IMG / 50% ELP-foldon. The images are arranged in the following order (1)
0.01 mM Gd3+, (2) 0.025 mM Gd3+, (3) 0.05 mM Gd3+, (4) 0.75 mM Gd3+, (5) 0.01 mM
Gd3+, (6) 0.025 mM Gd3+, (7) 0.05 mM Gd3+, 8) 0.75 mM Gd3+, 9) 0.01 mM Gd3+, 10)
0.025 mM Gd3+, (11) 0.05 mM Gd3+, and (12) 0.75 mM Gd3+
5.4 Discussion
Modification of the architecture of ELP-IMG constructs resulted in a series of
new contrast agent constructs. There were a few important results from this experiment
that may be able to shed light on the effects of ELP on contrast agent properties. The first
motivation for the experiment was to attempt to solve what is believed to be headgroup
crowding in crosslinked ELP-IMG nanoparticles. The strategy chosen was to attempt to
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make mixtures of ELP-foldon and ELP-IMG to create a reduction in CA1.CD2 domain
headgroups that would be present in each nanoparticle. On a positive note, these mixtures
behaved in exactly the same manner as individual constructs, with Tt and particle
formation that did not deviate from normal behavior. All mixture constructs however
displayed relaxivity values that were less than ELP-IMG on its own, however the 50% /
50% mixture was higher than ELP-THO. The expected gains in relaxivity were not
achieved through this mixture. Possible reasons include a drop in molecular weight of the
mixtures, or a gain in mobility due to the headgroups no longer being cross-linked
together. If multiple headgroups aren’t being cross-linked together along with a reduction
in molecular weight, there may be an increase in the molecular tumbling rate, which
decreases relaxivity. Alternatively as theorized earlier headgroup crowding could still be
occurring in the mixtures due to the choice of a non-specific crosslinking agent. These
ideas would need to be investigated further if the mixtures were to continue as a viable
project.
Linear constructs were synthesized to ensure that the foldon domain was not
radically interfering with the activity of the fused CA1.CD2 domain. The results showed
that the foldon domain does cause a loss of relaxivity (r1 GVGVP40-IMG > r1
GVGVP40-foldon-IMG) at the same chain length of ELP. This is most likely due to
reasons mentioned previously. The linear ELP-IMG construct would be the version most
similar to the CA1.CD2 domain alone, but in this case with a random coil polymer tail.
Interesting when the tail length is cut in half (GVGVP20) the relaxivity drops by 20 mM1 -1

s , which is most likely explained by the drop in molecular weight and increase in

rotational motion. The GVGVP20-IMG construct is well below its Tt during the T1
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measurement, which would mean it, exists as a random coil in solution, possibly
explaining the drop in relaxivity. The GVGVP40-IMG however construct has a Tt of 40.1
°C, which at the temperature of measurement for T1 puts the construct right at its Tt,
which could imply that the construct is going through the transition process during
measurement and may be measured during the onset of turbidity. During this period there
would be less random behavior of the ELP and a more ordered environment. T1 weighted
images confirmed that the constructs were displaying positive contrast in T1 imaging and
that the contrast increased in a linear fashion with increasing Gd3+ content (Figure 5.6
and Figure 5.7). This is important as the patterns are similar what was found for ELPIMG and ELP-THO alone.
5.5 Conclusion
Being able to modify the construct in this manner allows for a number of
possibilities to create mixed architectures that will still retain the positive properties of
the designed protein. Although the mixtures did not enhance relaxivity due to perceived
reduction of headgroup crowding, the mixtures still provide a positive route to attempt
new ELP-IMG based constructs without having to completely redesign the architecture.
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CHAPTER VI
CONCLUSION AND FUTURE DIRECTIONS
Utilizing elastin-like polypeptides as the base material for multifunctional
theranostic nanoparticle systems has many distinct advantages. Starting with an entirely
amino acid based composition has dual positive properties as the system is organic in
nature and can then be modified and designed at the gene level through the use of
molecular biology techniques in any applicable way. The responsive behavior can be
exploited to drive the transitional behavior in response to various stimuli, which opens
endless possibilities in the field of theranostics. The approach of this work was to utilize
these properties to design a new theranostic nanoparticle system, composed entirely of
organic components and needing no complex post-translational chemical modification.
Micelles of three-armed star elastin-like polypeptides were fused to a protein
based MRI contrast agent in the first part of this study. The aim was to create a stable
nanoparticle contrast agent composed of organic components that retained flexibility for
modification. This aim was successful as the fusion of the two components produced a
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stable crosslinked nanoparticle that was effective as a T1 weighted MRI contrast agent in
both particle and non-particle form that had relaxivity values 5 times that of clinical
contrast agents. To demonstrate the flexibility of the system the architecture was
modified and it was established that the system could undergo changes without loss of
effectiveness of the positive properties.
This system was then modified through the addition of a short targeting peptide
and spacing element that specifically targeted the gastrin release peptide receptor. When
incubated with receptor positive cell lines the new construct showed targeting capabilities
that were demonstrated by an enhanced amount of cellular uptake. Contrast agents
incubated with these cell lines were able to introduce gadolinium into the cells, which
was demonstrated by T1 weighted imaging of cell pellets.
To enhance the system for the future the following recommendations are
presented. 1) change the ELP guest residue position to create a stimulus responsive
particle system. This could potentially enhance relaxivity as well enhance cytotoxicity
through specific dissociation of the particles in certain conditions. 2) Introduce sitespecific crosslinking to better control the morphology of the crosslinked nanoparticles.
This can potentially enhance relaxivity by eliminating some of the non-specific
crosslinking that currently takes place. 3) Establish a range of therapeutics and their
partition coefficients in relation to changes in guest residue. This would create a library
of ELP / therapeutic combinations that could potentially be used in any number of
treatments. Along with the enhanced contrast agent properties these combinations would
prove to be an ideal theranostic system.
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This work demonstrated the ability to use micelles of ELPs as multifunctional
nanoparticles for theranostic applications. Features demonstrated include self-assembling
nanoparticle formation, MRI contrast, and active cancer cell targeting behavior. Taken as
a whole this represents a platform that can be manipulated in endless ways to truly
demonstrate the potential of elastin-like polypeptides.

187

BIBLIOGRAPHY
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: A Cancer Journal for
Clinicians. 2014;64(1):9-29.
2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics,
2014. CA-Cancer J Clin. 2014;64(4):252-271.
3. Sahoo S, Labhasetwar V. Nanotech approaches to delivery and imaging drug. Drug
Discov Today. 2003;8(24):1112-1120.
4. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional
nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science.
2012;338(6109):903-910.
5. Kelkar SS, Reineke TM. Theranostics: Combining imaging and therapy. Bioconjug
Chem. 2011;22(10):1879-1903.
6. Ryu JH, Lee S, Son S, et al. Theranostic nanoparticles for future personalized
medicine. Journal of controlled release : official journal of the Controlled Release
Society. 2014;190:477-484.
7. Kalia M. Personalized oncology: Recent advances and future challenges. Metab Clin
Exp. 2013;62, Supplement 1(0):S11-S14.

188

8. McGeough C, Bjourson A. Diagnostic, prognostic and theranostic genetic biomarkers
for rheumatoid arthritis. J Clin Cell Immuno. 2012;6(002):1-5.
9. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: The drawbacks
and advantages of vehicle selection for drug formulation. Eur J Cancer.
2001;37(13):1590-1598.
10. Cho K, Wang X, Nie S, Chen Z(, Shin DM. Therapeutic nanoparticles for drug
delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316.
11. Allen T, Cullis P. Drug delivery systems: Entering the mainstream. Science.
2004;303(5665):1818-1822.
12. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: An emerging treatment
modality for cancer. Nature Reviews Drug Discovery. 2008;7(9):771-782.
13. Brannon-Peppas L, Blanchette J. Nanoparticle and targeted systems for cancer
therapy. Adv Drug Deliv Rev. 2004;56(11):1649-1659.
14. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted
polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem
Soc Rev. 2012;41(7):2971-3010.
15. Zhang S, Li J, Lykotrafitis G, Bao G, Suresh S. Size-dependent endocytosis of
nanoparticles. Adv Mater. 2009;21(4):419-+.

189

16. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Controlled
Release. 2010;145(3):182-195.
17. Gratton SEA, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular
internalization pathways. Proc Natl Acad Sci U S A. 2008;105(33):11613-11618.
18. Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines
through particle design. Small. 2011;7(14):1919-1931.
19. Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol.
2007;25(10):1165-1170.
20. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles:
Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog
Lipid Res. 2003;42(6):463-478.
21. Torchilin VP. Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res.
2007;24(1):1-16.
22. Geng Y, Dalhaimer P, Cai S, et al. Shape effects of filaments versus spherical
particles in flow and drug delivery. Nat Nanotechnol. 2007;2(4):249-255.
23. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions.
Small. 2010;6(1):12-21.
24. Toy R, Bauer L, Hoimes C, Ghaghada KB, Karathanasis E. Targeted nanotechnology
for cancer imaging. Adv Drug Deliv Rev. 2014;76:79-97.

190

25. Doshi N, Prabhakarpandian B, Rea-Ramsey A, Pant K, Sundaram S, Mitragotri S.
Flow and adhesion of drug carriers in blood vessels depend on their shape: A study using
model synthetic microvascular networks. J Controlled Release. 2010;146(2):196-200.
26. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of
intravascularly injected particles. J Controlled Release. 2010;141(3):320-327.
27. Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular
trafficking, and cytotoxicity of nanomaterials. Small. 2011;7(10):1322-1337.
28. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of
anionic superparamagnetic nanoparticles as a function of their surface coating.
Biomaterials. 2003;24(6):1001-1011.
29. Dausend J, Musyanovych A, Dass M, et al. Uptake mechanism of oppositely charged
fluorescent nanoparticles in HeLa cells. Macromolecular Bioscience. 2008;8(12):11351143.
30. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins:
Implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv.
2011;8(3):343-357.
31. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the
stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27(24):4356-4373.
32. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug
Discov Today. 2005;10(21):1451-1458.

191

33. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: Nanosized
vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592-599.
34. Agnihotri S, Mallikarjuna N, Aminabhavi T. Recent advances on chitosan-based
micro- and nanoparticles in drug delivery. J Controlled Release. 2004;100(1):5-28.
35. Bala I, Hariharan S, Kumar M. PLGA nanoparticles in drug delivery: The state of the
art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422.
36. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by
using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A.
2008;105(7):2586-2591.
37. Soppimath K, Aminabhavi T, Kulkarni A, Rudzinski W. Biodegradable polymeric
nanoparticles as drug delivery devices. J Controlled Release. 2001;70(1-2):1-20.
38. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted
liposome design: Challenges and fundamental considerations. Trends Biotechnol.
2014;32(1):32-45.
39. Al-Jamal WT, Kostarelos K. Liposomes: From a clinically established drug delivery
system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res.
2011;44(10):1094-1104.
40. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical
applications. Adv Drug Deliv Rev. 2013;65(1):36-48.

192

41. Astruc D, Boisselier E, Ornelas C. Dendrimers designed for functions: From physical,
photophysical, and supramolecular properties to applications in sensing, catalysis,
molecular electronics, photonics, and nanomedicine. Chem Rev. 2010;110(4):1857-1959.
42. Kaminskas LM, Boyd BJ, Porter CJH. Dendrimer pharmacokinetics: The effect of
size, structure and surface characteristics on ADME properties. Nanomedicine.
2011;6(6):1063-1084.
43. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric
micelles in anticancer therapy: Targeting, imaging and triggered release. Pharm Res.
2010;27(12):2569-2589.
44. Http://Www.doxil.com/.
45. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar
erythrodysesthesia ('hand-foot') syndrome. incidence, recognition and management.
American journal of clinical dermatology. 2000;1(4):225-234.
46. Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with
doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer
Drugs. 2007;18(6):737-744.
47. Goto S, Ihara Y, Urata Y, et al. Doxorubicin-induced DNA intercalation and
scavenging by nuclear glutathione S-transferase pi. FASEB J. 2001;15(14):2702-2714.
48. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: Pharmacodynamics and
adverse effects. Pharmacogenetics and Genomics. 2011;21(7):440-446.

193

49. ROWINSKY E, DONEHOWER R. Drug-therapy - paclitaxel (taxol). N Engl J Med.
1995;332(15):1004-1014.
50. SPENCER C, FAULDS D. Paclitaxel - a review of its pharmacodynamic and
pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs.
1994;48(5):794-847.
51. Redis RS, Berindan-Neagoe I, Pop VI, Calin GA. Non-coding RNAs as theranostics
in human cancers. J Cell Biochem. 2012;113(5):1451-1459.
52. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281-297.
53. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of
micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc
Natl Acad Sci U S A. 2002;99(24):15524-15529.
54. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-ras-dependent lung
tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18(3):282-293.
55. Zhao J, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen
receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem.
2008;283(45):31079-31086.
56. Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and
chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun.
2008;377(1):114-119.

194

57. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumortargeting scFv deliver siRNA and miRNA for cancer therapy. Molecular Therapy.
2010;18(9):1650-1656.
58. Kim J, Yeom J, Ko J, et al. Effective delivery of anti-miRNA DNA oligonucleotides
by functionalized gold nanoparticles. J Biotechnol. 2011;155(3):287-292.
59. Oh Y, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev.
2009;61(10):850-862.
60. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed
siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science.
2008;319(5863):627-630.
61. Schiffelers RM, Storm G. ICS-283: A system for targeted intravenous delivery of
siRNA. Expert Opinion on Drug Delivery. 2006;3(3):445-454.
62. Barenholz Y(. Doxil (R) - the first FDA-approved nano-drug: Lessons learned. J
Controlled Release. 2012;160(2):117-134.
63. O'Brien M, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy
in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX (TM)/doxil (R))
versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann
Oncol. 2004;15(3):440-449.
64. Forssen EA, Ross ME. Daunoxome treatment of solid tumors: Preclinical and clinical
investigations. J Liposome Res. 1994;4(1):481-512.

195

65. Green MR, Manikhas GM, Orlov S, et al. Abraxane((R)), a novel cremophor((R))free, albumin-bound particle form of paclitaxel for the treatment of advanced non-smallcell lung cancer. Ann Oncol. 2006;17(8):1263-1268.
66. Kim T, Kim D, Chung J, et al. Phase I and pharmacokinetic study of genexol-PM, a
cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced
malignancies. Clin Cancer Res. 2004;10(11):3708-3716.
67. Maeda H, Greish K, Fang J. The EPR effect and polymeric drugs: A paradigm shift
for cancer chemotherapy in the 21st century. Adv Polym Sci. 2006;193:103-121.
68. Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced
permeability and retention (EPR) effects; what is the appropriate target? Theranostics.
2014;4(1):81-89.
69. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors
based on EPR effects. Adv Drug Deliv Rev. 2011;63(3):161-169.
70. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and
tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63(3):170-183.
71. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the
EPR effect in macromolecular therapeutics: A review. J Controlled Release. 2000;65(12):271-284.
72. Heldin C, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle
in cancer therapy. Nat Rev Cancer. 2004;4(10):806-813.

196

73. Maeda H. Vascular permeability in cancer and infection as related to macromolecular
drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
Proceedings of the Japan Academy Series B-Physical and Biological Sciences.
2012;88(3):53-71.
74. Moghimi S, Hunter A, Murray J. Long-circulating and target-specific nanoparticles:
Theory to practice. Pharmacol Rev. 2001;53(2):283-318.
75. Peer D, Karp JM, Hong S, FaroKHzad OC, Margalit R, Langer R. Nanocarriers as an
emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
76. Baselga J, Norton L, Albanell J, Kim Y, Mendelsohn J. Recombinant humanized antiHER2 antibody (herceptin (TM)) enhances the antitumor activity of paclitaxel and
doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer
Res. 1998;58(13):2825-2831.
77. Zhang X, Eden HS, Chen X. Peptides in cancer nanomedicine: Drug carriers,
targeting ligands and protease substrates. J Controlled Release. 2012;159(1):2-13.
78. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide
libraries. Nature. 1996;380(6572):364-366.
79. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling,
cyclodextrin polymer-based nanoparticle: From concept to clinic. Molecular
Pharmaceutics. 2009;6(3):659-668.
80. Http://Meetinglibrary.asco.org/content/32235-65.

197

81. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer
imaging and therapy. Theranostics. 2012;2(1):3-44.
82. Maloney D, GrilloLopez A, White C, et al. IDEC-C2B8 (rituximab) anti-CD20
monoclonal antibody therapy in patients with relapsed low-grade non-hodgkin's
lymphoma. Blood. 1997;90(6):2188-2195.
83. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med.
2004;350(23):2335-2342.
84. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab
plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
2004;351(4):337-345.
85. Nygren P. Alternative binding proteins: Affibody binding proteins developed from a
small three-helix bundle scaffold. Febs J. 2008;275(11):2668-2676.
86. Sudimack J, Lee R. Targeted drug delivery via the folate receptor. Adv Drug Deliv
Rev. 2000;41(2):147-162.
87. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer.
Curr Opin Chem Biol. 2009;13(3):256-262.
88. Watanabe K, Kaneko M, Maitani Y. Functional coating of liposomes using a folatepolymer conjugate to target folate receptors. International Journal of Nanomedicine.
2012;7:3679-3688.

198

89. Qian Z, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptormediated endocytosis pathway. Pharmacol Rev. 2002;54(4):561-587.
90. Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr C, Ehrhardt C. In vitro
assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation
therapy of lung cancer. European Journal of Pharmaceutical Sciences. 2006;29(5):367374.
91. Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr C, Ehrhardt C. In vitro
assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation
therapy of lung cancer. European Journal of Pharmaceutical Sciences. 2006;29(5):367374.
92. Reubi J. Peptide receptors as molecular targets for cancer diagnosis and therapy.
Endocr Rev. 2003;24(4):389-427.
93. Arias JL. Drug targeting strategies in cancer treatment: An overview. Mini-Reviews in
Medicinal Chemistry. 2011;11(1):1-17.
94. Haubner R, Wester H, Reuning U, et al. Radiolabeled alpha(v)beta(3) integrin
antagonists: A new class of tracers for tumor targeting. J Nucl Med. 1999;40(6):10611071.
95. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly(ethylene
glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J
Controlled Release. 2010;143(1):136-142.

199

96. Katsogiannou M, Peng L, Catapano CV, Rocchi P. Active-targeted nanotherapy
strategies for prostate cancer. Curr Cancer Drug Targets. 2011;11(8):954-965.
97. Http://Clinicaltrials.gov/show/NCT00031187.
98. Http://Clinicaltrials.gov/ct2/show?term=ASG-5ME&rank=1.
99. Polascik T, Oesterling J, Partin A. Prostate specific antigen: A decade of discovery what we have learned and where we are going. J Urol. 1999;162(2):293-306.
100. Chang S, Reuter V, Heston W, Bander N, Grauer L, Gaudin P. Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in
tumor-associated neovasculature. Cancer Res. 1999;59(13):3192-3198.
101. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced
internalization of prostate-specific membrane antigen. Cancer Res. 1998;58(18):40554060.
102. Xu W, Siddiqui IA, Nihal M, et al. Aptamer-conjugated and doxorubicin-loaded
unimolecular micelles for targeted therapy of prostate cancer. Biomaterials.
2013;34(21):5244-5253.
103. Hubert RS, Vivanco I, Chen E, et al. STEAP: A prostate-specific cell-surface
antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A.
1999;96(25):14523-14528.

200

104. Alves PMS, Faure O, Graff-Dubois S, et al. STEAP, a prostate tumor antigen, is a
target of human CD8(+) T cells. Cancer Immunology Immunotherapy. 2006;55(12):15151523.
105. Http://Clinicaltrials.gov/ct2/show/NCT01283373?term=DSTP3086S&rank=1.
106. Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim
Biophys Acta-Rev Cancer. 2006;1766(1):23-41.
107. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a
molecular target in experimental anticancer therapy. Annals of Oncology.
2007;18(9):1457-1466.
108. Beer M, Montani M, Gerhardt J, et al. Profiling gastrin-releasing peptide receptor in
prostate tissues: Clinical implications and molecular correlates. Prostate. 2012;72(3):318325.
109. Steinmetz NF, Ablack AL, Hickey JL, et al. Intravital imaging of human prostate
cancer using viral nanoparticles targeted to gastrin-releasing peptide receptors. Small.
2011;7(12):1664-1672.
110. Hosta-Rigau L, Olmedo I, Arbiol J, Cruz LJ, Kogan MJ, Albericio F.
Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing peptide
receptor of a tumor cell line. Bioconjug Chem. 2010;21(6):1070-1078.
111. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic
nanoparticles. Adv Drug Deliv Rev. 2010;62(11):1052-1063.

201

112. Debbage P, Jaschke W. Molecular imaging with nanoparticles: Giant roles for dwarf
actors. Histochem Cell Biol. 2008;130(5):845-875.
113. Choi KY, Jeon EJ, Yoon HY, et al. Theranostic nanoparticles based on PEGylated
hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer. Biomaterials.
2012;33(26):6186-6193.
114. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for
imaging, labelling and sensing. Nature Materials. 2005;4(6):435-446.
115. Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing
of HER2/neu gene via RNA interference. Biomaterials. 2007;28(8):1565-1571.
116. Derfus A, Chan W, Bhatia S. Probing the cytotoxicity of semiconductor quantum
dots. Nano Lett. 2004;4(1):11-18.
117. Shilo M, Reuveni T, Motiei M, Popovtzer R. Nanoparticles as computed
tomography contrast agents: Current status and future perspectives. Nanomedicine.
2012;7(2):257-269.
118. Liu Y, Ai K, Lu L. Nanoparticulate X-ray computed tomography contrast agents:
From design validation to in vivo applications. Acc Chem Res. 2012;45(10):1817-1827.
119. Zhu J, Zheng L, Wen S, et al. Targeted cancer theranostics using alpha-tocopheryl
succinate-conjugated multifunctional dendrimer-entrapped gold nanoparticles.
Biomaterials. 2014;35(26):7635-7646.

202

120. Rabin O, Perez J, Grimm J, Wojtkiewicz G, Weissleder R. An X-ray computed
tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat
Mater. 2006;5(2):118-122.
121. Zanzonico P. Principles of nuclear medicine imaging: Planar, SPECT, PET, multimodality, and autoradiography systems. Radiat Res. 2012;177(4):349-364.
122. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: Current status and
emerging strategies. Clin Radiol. 2010;65(7):500-516.
123. Jennings LE, Long NJ. 'Two is better than one'-probes for dual-modality molecular
imaging. Chem Commun. 2009(24):3511-3524.
124. Kao H, Lin Y, Chen C, et al. Evaluation of EGFR-targeted radioimmuno-goldnanoparticles as a theranostic agent in a tumor animal model. Bioorg Med Chem Lett.
2013;23(11):3180-3185.
125. Liu Y, Welch MJ. Nanoparticles labeled with positron emitting nuclides:
Advantages, methods, and applications. Bioconjug Chem. 2012;23(4):671-682.
126. Gambhir SS. Molecular imaging of cancer with positron emission tomography.
Nature Reviews Cancer. 2002;2(9):683-693.
127. Juweid M, Cheson B. Current concepts - positron-emission tomography and
assessment of cancer therapy. N Engl J Med. 2006;354(5):496-507.

203

128. Chen F, Hong H, Zhang Y, et al. In vivo tumor targeting and image-guided drug
delivery with antibody-conjugated, radio labeled mesoporous silica nanoparticles. ACS
Nano. 2013;7(10):9027-9039.
129. Toth E, Helm L, Merbach A. Relaxivity of MRI contrast agents. Contrast Agents i.
2002;221:61-101.
130. Tu C, Osborne EA, Louie AY. Activatable T (1) and T (2) magnetic resonance
imaging contrast agents. Ann Biomed Eng. 2011;39(4):1335-1348.
131. Botta M. Second coordination sphere water molecules and relaxivity of
gadolinium(III) complexes: Implications for MRI contrast agents. Eur J Inorg Chem.
2000(3):399-407.
132. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI
contrast agents. Chem Soc Rev. 2006;35(6):512-523.
133. Langereis S, de Lussanet QG, van Genderen MHP, Backes WH, Meijer EW.
Multivalent contrast agents based on gadolinium-diethylenetriaminepentaacetic acidterminated poly(propylene imine) dendrimers for magnetic resonance imaging.
Macromolecules. 2004;37(9):3084-3091.
134. CARR D, BROWN J, BYDDER G, et al. Gadolinium-dtpa as a contrast agent in mri
- initial clinical-experience in 20 patients. Am J Roentgenol. 1984;143(2):215-224.
135. Lauffer R, Parmelee D, Dunham S, et al. MS-325: Albumin-targeted contrast agent
for MR angiography. Radiology. 1998;207(2):529-538.

204

136. Yang JJ, Yang J, Wei L, et al. Rational design of protein-based MRI contrast agents.
J Am Chem Soc. 2008;130(29):9260-9267.
137. Xue S, Qiao J, Pu F, Cameron M, Yang JJ. Design of a novel class of protein-based
magnetic resonance imaging contrast agents for the molecular imaging of cancer
biomarkers. Wiley Interdiscip Rev -Nanomed Nanobiotechnol. 2013;5(2):163-179.
138. Qiao J, Li S, Wei L, et al. HER2 targeted molecular MR imaging using a de novo
designed protein contrast agent. Plos One. 2011;6(3):e18103.
139. Bruckman MA, Yu X, Steinmetz NF. Engineering gd-loaded nanoparticles to
enhance MRI sensitivity via T-1 shortening. Nanotechnology. 2013;24(46):462001.
140. Al-Jamal WT, Kostarelos K. Liposome-nanoparticle hybrids for multimodal
diagnostic and therapeutic applications. Nanomedicine (London, England). 2007;2(1):8598.
141. Kielar F, Tei L, Terreno E, Botta M. Large relaxivity enhancement of paramagnetic
lipid nanoparticles by restricting the local motions of the gd-III chelates. J Am Chem Soc.
2010;132(23):7836-+.
142. Kobayashi H, Brechbiel M. Nano-sized MRI contrast agents with dendrimer cores.
Adv Drug Deliv Rev. 2005;57(15):2271-2286.
143. Huang C, Nwe K, Al Zaki A, Brechbiel MW, Tsourkas A. Biodegradable
polydisulfide dendrimer nanoclusters as MRI contrast agents. Acs Nano.
2012;6(11):9416-9424.

205

144. Lam T, Pouliot P, Avti PK, Lesage F, Kakkar AK. Superparamagnetic iron oxide
based nanoprobes for imaging and theranostics. Adv Colloid Interface Sci. 2013;199:95113.
145. Mikhaylova M, Kim D, Bobrysheva N, et al. Superparamagnetism of magnetite
nanoparticles: Dependence on surface modification. Langmuir. 2004;20(6):2472-2477.
146. Lee C, Jeong H, Kim S, et al. SPION-loaded chitosan-linoleic acid nanoparticles to
target hepatocytes. Int J Pharm. 2009;371(1-2):163-169.
147. Uzun K, Cevik E, Senel M, et al. Covalent immobilization of invertase on PAMAMdendrimer modified superparamagnetic iron oxide nanoparticles. Journal of Nanoparticle
Research. 2010;12(8):3057-3067.
148. Lee H, Yu MK, Park S, et al. Thermally cross-linked superparamagnetic iron oxide
nanoparticles: Synthesis and application as a dual imaging probe for cancer in vivo. J Am
Chem Soc. 2007;129(42):12739-12745.
149. Moura CC, Segundo MA, das Neves J, Reis S, Sarmento B. Co-association of
methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for
theranostic application. International Journal of Nanomedicine. 2014;9:4911-4922.
150. Smejkalova D, Nesporova K, Huerta-Angeles G. Selective in vitro anticancer effect
of superparamagnetic iron oxide nanoparticles loaded in hyaluronan polymeric micelles.
Biomacromolecules. 2014;15(11):4012-4020.

206

151. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic
nanomedicine. Acc Chem Res. 2011;44(10):1029-1038.
152. Balasubramaniam S, Pothayee N, Lin Y, et al. Poly(N-isopropylacrylamide)-coated
superparamagnetic iron oxide nanoparticles: Relaxometric and fluorescence behavior
correlate to temperature-dependent aggregation. Chem Mat. 2011;23(14):3348-3356.
153. Grogna M, Cloots R, Luxen A, et al. Polymer micelles decorated by gadolinium
complexes as MRI blood contrast agents: Design, synthesis and properties. Polymer
Chemistry. 2010;1(9):1485-1490.
154. Jeong SY, Kim HJ, Kwak B, et al. Biocompatible polyhydroxyethylaspartamidebased micelles with gadolinium for MRI contrast agents. Nanoscale Research Letters.
2010;5(12):1970-1976.
155. Shiraishi K, Kawano K, Maitani Y, Yokoyama M. Polyion complex micelle MRI
contrast agents from poly(ethylene glycol)-b-poly(L-lysine) block copolymers having gdDOTA; preparations and their control of T-1-relaxivities and blood circulation
characteristics. J Controlled Release. 2010;148(2):160-167.
156. Kim KS, Park W, Hu J, Bae YH, Na K. A cancer-recognizable MRI contrast agents
using pH-responsive polymeric micelle. Biomaterials. 2014;35(1):337-343.
157. Liu T, Li X, Qian Y, Hu X, Liu S. Multifunctional pH-disintegrable micellar
nanoparticles of asymmetrically functionalized beta-cyclodextrin-based star copolymer

207

covalently conjugated with doxorubicin and DOTA-gd moieties. Biomaterials.
2012;33(8):2521-2531.
158. Rowe MD, Thamm DH, Kraft SL, Boyes SG. Polymer-modified gadolinium metalorganic framework nanoparticles used as multifunctional nanomedicines for the targeted
imaging and treatment of cancer. Biomacromolecules. 2009;10(4):983-993.
159. Yongjun L, Junsheng L. Theranostic polymeric micelles for the diagnosis and
treatment of hepatocellular carcinoma. Journal of Biomedical Nanotechnology.
2015;11(4):613-622.
160. URRY D, TRAPANE T, PRASAD K. Phase-structure transitions of the elastin
polypentapeptide water-system within the framework of composition temperature studies.
Biopolymers. 1985;24(12):2345-2356.
161. Urry DW. Physical chemistry of biological free energy transduction as demonstrated
by elastic protein-based polymers. J Phys Chem B. 1997;101(51):11007-11028.
162. Yamaoka T, Tamura T, Seto Y, Tada T, Kunugi S, Tirrell DA. Mechanism for the
phase transition of a genetically engineered elastin model peptide (VPGIG)(40) in
aqueous solution. Biomacromolecules. 2003;4(6):1680-1685.
163. Girotti A, Reguera J, Arias FJ, Alonso M, Testera AM, Rodriguez-Cabello JC.
Influence of the molecular weight on the inverse temperature transition of a model
genetically engineered elastin-like pH-responsive polymer. Macromolecules.
2004;37(9):3396-3400.

208

164. Alonso M, Reboto V, Guiscardo L, Mate V, Rodriguez-Cabello JC. Novel
photoresponsive p-phenylazobenzene derivative of an elastin-like polymer with enhanced
control of azobenzene content and without pH sensitiveness. Macromolecules.
2001;34(23):8072-8077.
165. Cho Y, Zhang Y, Christensen T, Sagle LB, Chilkoti A, Cremer PS. Effects of
hofmeister anions on the phase transition temperature of elastin-like polypeptides. J Phys
Chem B. 2008;112(44):13765-13771.
166. Xu W, Siddiqui IA, Nihal M, et al. Aptamer-conjugated and doxorubicin-loaded
unimolecular micelles for targeted therapy of prostate cancer. Biomaterials.
2013;34(21):5244-5253.
167. MacKay JA, Callahan DJ, FitzGerald KN, Chilkoti A. Quantitative model of the
phase behavior of recombinant pH-responsive elastin-like polypeptides.
Biomacromolecules. 2010;11(11):2873-2879.
168. Hrabchak C, Rouleau J, Moss I, et al. Assessment of biocompatibility and initial
evaluation of genipin cross-linked elastin-like polypeptides in the treatment of an
osteochondral knee defect in rabbits. Acta Biomaterialia. 2010;6(6):2108-2115.
169. Liu W, Dreher MR, Chow DC, Zalutsky MR, Chilkoti A. Tracking the in vivo fate
of recombinant polypeptides by isotopic labeling. J Controlled Release.
2006;114(2):184-192.

209

170. MacEwan SR, Chilkoti A. Applications of elastin-like polypeptides in drug delivery.
Journal of controlled release : official journal of the Controlled Release Society.
2014;190:314-330.
171. MacKay JA, Chen M, McDaniel JR, Liu W, Simnick AJ, Chilkoti A. Selfassembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish
tumours after a single injection. Nature Materials. 2009;8(12):993-999.
172. McDaniel JR, Bhattacharyya J, Vargo KB, Hassouneh W, Hammer DA, Chilkoti A.
Self-assembly of thermally responsive nanoparticles of a genetically encoded peptide
polymer by drug conjugation. Angewandte Chemie-International Edition.
2013;52(6):1683-1687.
173. Rincon AC, Molina-Martinez IT, de las Heras B, et al. Biocompatibility of elastinlike polymer poly(VPAVG) microparticles: In vitro and in vivo studies. Journal of
Biomedical Materials Research Part a. 2006;78A(2):343-351.
174. Martinez AW, Caves JM, Ravi S, Li W, Chaikof EL. Effects of crosslinking on the
mechanical properties, drug release and cytocompatibility of protein polymers. Acta
Biomater. 2014;10(1):26-33.
175. Nagapudi K, Brinkman WT, Leisen JE, et al. Photomediated solid-state crosslinking of an elastin-mimetic recombinant protein polymer. Macromolecules.
2002;35(5):1730-1737.

210

176. McHale MK, Setton LA, Chilkoti A. Synthesis and in vitro evaluation of
enzymatically cross-linked elastin-like polypeptide gels for cartilaginous tissue repair.
Tissue Eng. 2005;11(11-12):1768-1779.
177. Chung C, Lampe KJ, Heilshorn SC. Tetrakis(hydroxymethyl) phosphonium chloride
as a covalent cross-linking agent for cell encapsulation within protein-based hydrogels.
Biomacromolecules. 2012;13(12):3912-3916.
178. Lim DW, Nettles DL, Setton LA, Chilkoti A. In situ cross-linkinig of elastin-like
polypeptide block copolymers for tissue repair. Biomacromolecules. 2008;9(1):222-230.
179. Benitez PL, Sweet JA, Fink H, et al. Sequence-specific crosslinking of electrospun,
elastin-like protein preserves bioactivity and native-like mechanics. Advanced Healthcare
Materials. 2013;2(1):114-118.
180. McDaniel JR, Callahan DJ, Chilkoti A. Drug delivery to solid tumors by elastin-like
polypeptides. Adv Drug Deliv Rev. 2010;62(15):1456-1467.
181. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Chilkoti A. Thermal cycling
enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer
Res. 2007;67(9):4418-4424.
182. Moktan S, Perkins E, Kratz F, Raucher D. Thermal targeting of an acid-sensitive
doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy
compared with the parent compound in vivo. Molecular Cancer Therapeutics.
2012;11(7):1547-1556.

211

183. Shi P, Aluri S, Lin Y, et al. Elastin-based protein polymer nanoparticles carrying
drug at both corona and core suppress tumor growth in vivo. J Controlled Release.
2013;171(3):330-338.
184. Moktan S, Ryppa C, Kratz F, Raucher D. A thermally responsive biopolymer
conjugated to an acid-sensitive derivative of paclitaxel stabilizes microtubules, arrests
cell cycle, and induces apoptosis. Invest New Drugs. 2012;30(1):236-248.
185. Simnick AJ, Valencia CA, Liu R, Chilkoti A. Morphing low-affinity ligands into
high-avidity nanoparticles by thermally triggered self-assembly of a genetically encoded
polymer. ACS Nano. 2010;4(4):2217-2227.
186. Simnick AJ, Amiram M, Liu W, et al. In vivo tumor targeting by a NGR-decorated
micelle of a recombinant diblock copolypeptide. J Controlled Release. 2011;155(2):144151.
187. Hassouneh W, Fischer K, MacEwan SR, et al. Unexpected multivalent display of
proteins by temperature triggered self-assembly of elastin-like polypeptide block
copolymers. Biomacromolecules. 2012;13(5):1598-1605.
188. MacKay JA, Callahan DJ, FitzGerald KN, Chilkoti A. Quantitative model of the
phase behavior of recombinant pH-responsive elastin-like polypeptides.
Biomacromolecules. 2010;11(11):2873-2879.

212

189. Callahan DJ, Liu W, Li X, et al. Triple stimulus-responsive polypeptide
nanoparticles that enhance intratumoral spatial distribution. Nano Letters.
2012;12(4):2165-2170.
190. Hassouneh W, Nunalee ML, Shelton MC, Chilkoti A. Calcium binding peptide
motifs from calmodulin confer divalent ion selectivity to elastin-like polypeptides.
Biomacromolecules. 2013;14(7):2347-2353.
191. Frank S, Kammerer R, Mechling D, et al. Stabilization of short collagen-like triple
helices by protein engineering. J Mol Biol. 2001;308(5):1081-1089.
192. Du C, Wang M, Liu J, Pan M, Cai Y, Yao J. Improvement of thermostability of
recombinant collagen-like protein by incorporating a foldon sequence. Appl Microbiol
Biotechnol. 2008;79(2):195-202.
193. Ghoorchian A, Cole JT, Holland NB. Thermoreversible micelle formation using a
three-armed star elastin-like polypeptide. Macromolecules. 2010;43(9):4340-4345.
194. Ghoorchian A, Vandemark K, Freeman K, Kambow S, Holland NB, Streletzky KA.
Size and shape characterization of thermoreversible micelles of three-armed star elastinlike polypeptides. J Phys Chem B. 2013;117(29):8865-8874.
195. CHEN C, OKAYAMA H. High-efficiency transformation of mammalian-cells by
plasmid dna. Mol Cell Biol. 1987;7(8):2745-2752.

213

196. Bar M, Bar-Ziv R, Scherf T, Fass D. Efficient production of a folded and functional,
highly disulfide-bonded beta-helix antifreeze protein in bacteria. Protein Expr Purif.
2006;48(2):243-252.
197. Chilkoti A, Dreher MR, Meyer DE. Design of thermally responsive, recombinant
polypeptide carriers for targeted drug delivery. Adv Drug Deliv Rev. 2002;54(8):10931111.
198. McPherson DT, Xu J, Urry DW. Product purification by reversible phase transition
following escherichia coli expression of genes encoding up to 251 repeats of the
elastomeric pentapeptide GVGVP. Protein Expr Purif. 1996;7(1):51-57.
199. Meyer D, Chilkoti A. Quantification of the effects of chain length and concentration
on the thermal behavior of elastin-like polypeptides. Biomacromolecules. 2004;5(3):846851.
200. Urry DW, Luan CH, Parker TM, et al. Temperature of polypeptide inverse
temperature transition depends on mean residue hydrophobicity. J Am Chem Soc.
1991;113(11):4346-4348.
201. Meyer DE, Chilkoti A. Purification of recombinant proteins by fusion with
thermally-responsive polypeptides. Nat Biotechnol. 1999;17(11):1112-1115.
202. Meyer DE, Trabbic-Carlson K, Chilkoti A. Protein purification by fusion with an
environmentally responsive elastin-like polypeptide: Effect of polypeptide length on the
purification of thioredoxin. Biotechnol Prog. 2001;17(4):720-728.

214

203. Yu S, Liu Y. Expression and one-step purification of a beta-galactosidase by fusion
with elastin-like polypetides. Process Biochem. 2012;47(7):1108-1114.
204. Fong BA, Wu W, Wood DW. Optimization of ELP-intein mediated protein
purification by salt substitution. Protein Expr Purif. 2009;66(2):198-202.
205. Chow D, Dreher M, Trabbic-Carlson K, Chilkoti A. Ultra-high expression of a
thermally responsive recombinant fusion protein in E-coli. Biotechnol Prog.
2006;22(3):638-646.
206. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro
testing of conventional tablets and capsules. J Pharm Sci. 1969;58(10):1253-&.
207. Yang W, Jones LM, Isley L, et al. Rational design of a calcium-binding protein. J
Am Chem Soc. 2003;125(20):6165-6171.
208. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic
fibrosing dermopathy and nephrogenic systemic fibrosis? (vol 21, pg 1104, 2006).
Nephrol Dial Transplant. 2006;21(6):1745-1745.
209. Clogston JD, Patri AK. Detecting and measuring free gadolinium in nanoparticles
for MRI imaging. Characterization of Nanoparticles Intended for Drug Delivery.
2011;697:101-108.
210. Nagaraja TN, Croxen RL, Panda S, et al. Application of arsenazo III in the
preparation and characterization of an albumin-linked, gadolinium-based macromolecular
magnetic resonance contrast agent. J Neurosci Methods. 2006;157(2):238-245.

215

211. Woods M, Pasha A, Zhao P, et al. Investigations into whole water, prototropic and
amide proton exchange in lanthanide(III) DOTA-tetraamide chelates. Dalton
Transactions. 2011;40(25):6759-6764.
212. Barge A, Cravotto G, Gianolio E, Fedeli F. How to determine free gd and free
ligand in solution of gd chelates. A technical note. Contrast Media Mol Imaging.
2006;1(5):184-188.
213. ALLEN T, CHONN A. Large unilamellar liposomes with low uptake into the
reticuloendothelial system. FEBS Lett. 1987;223(1):42-46.
214. Mieszawska AJ, Mulder WJM, Fayad ZA, Cormode DP. Multifunctional gold
nanoparticles for diagnosis and therapy of disease. Mol Pharm. 2013;10(3):831-847.
215. Li S, Goins B, Zhang L, Bao A. Novel multifunctional theranostic liposome drug
delivery system: Construction, characterization, and multimodality MR, near-infrared
fluorescent, and nuclear imaging. Bioconjug Chem. 2012;23(6):1322-1332.
216. Chen Z, Yu D, Liu C, et al. Gadolinium-conjugated PLA-PEG nanoparticles as liver
targeted molecular MRI contrast agent. J Drug Target. 2011;19(8):657-665.
217. Talelli M, Rijcken CJF, van Nostrum CF, Storm G, Hennink WE. Micelles based on
HPMA copolymers. Adv Drug Deliv Rev. 2010;62(2):231-239.
218. Caldorera-Moore ME, Liechty WB, Peppas NA. Responsive theranostic systems:
Integration of diagnostic imaging agents and responsive controlled release drug delivery
carriers. Acc Chem Res. 2011;44(10):1061-1070.

216

219. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular parameters and
increasing magnetic field strength on relaxivity of gadolinium- and manganese-based
T(1) contrast agents. Contrast Media & Molecular Imaging. 2009;4(2):89-100.
220. URRY D, HAYNES B, HARRIS R. Temperature-dependence of length of elastin
and its polypentapeptide. Biochem Biophys Res Commun. 1986;141(2):749-755.
221. Alonso M, Reboto V, Guiscardo L, Mate V, Rodriguez-Cabello J. Novel
photoresponsive p-phenylazobenzene derivative of an elastin-like polymer with enhanced
control of azobenzene content and without pH sensitiveness. Macromolecules.
2001;34(23):8072-8077.
222. Park J, Won J. Thermal behaviors of elastin-like polypeptides (ELPs) according to
their physical properties and environmental conditions. Biotechnology and Bioprocess
Engineering. 2009;14(5):662-667.
223. McDaniel JR, Callahan DJ, Chilkoti A. Drug delivery to solid tumors by elastin-like
polypeptides. Adv Drug Deliv Rev. 2010;62(15):1456-1467.
224. Betre H, Setton L, Meyer D, Chilkoti A. Characterization of a genetically
engineered elastin-like polypeptide for cartilaginous tissue repair. Biomacromolecules.
2002;3(5):910-916.
225. Rao G, Balamurugan S, Meyer D, Chilkoti A, Lopez G. Hybrid bioinorganic smart
membranes that incorporate protein-based molecular switches. Langmuir.
2002;18(5):1819-1824.

217

226. Asai D, Xu D, Liu W, et al. Protein polymer hydrogels by in situ, rapid and
reversible self-gelation. Biomaterials. 2012;33(21):5451-5458.
227. Meyer D, Chilkoti A. Genetically encoded synthesis of protein-based polymers with
precisely specified molecular weight and sequence by recursive directional ligation:
Examples from the elastin-like polypeptide system. Biomacromolecules. 2002;3(2):357367.
228. Hanaoka K, Lubag AJM, Castillo-Muzquiz A, Kodadek T, Sherry AD. The
detection limit of a Gd3+-based T-1 agent is substantially reduced when targeted to a
protein microdomain. Magn Reson Imaging. 2008;26(5):608-617.
229. Ghoorchian A, Holland NB. Molecular architecture influences the thermally induced
aggregation behavior of elastin-like polypeptides. Biomacromolecules.
2011;12(11):4022-4029.
230. Yamaoka T, Tamura T, Seto Y, Tada T, Kunugi S, Tirrell D. Mechanism for the
phase transition of a genetically engineered elastin model peptide (VPGIG)(40) in
aqueous solution. Biomacromolecules. 2003;4(6):1680-1685.
231. GILL S, VONHIPPEL P. Calculation of protein extinction coefficients from aminoacid sequence data. Anal Biochem. 1989;182(2):319-326.
232. Barge A, Cravotto G, Gianolio E, Fedeli F. How to determine free gd and free
ligand in solution of gd chelates. A technical note. Contrast Media & Molecular Imaging.
2006;1(5):184-188.

218

233. Clogston JD, Patri AK. Detecting and measuring free gadolinium in nanoparticles
for MRI imaging. Characterization of Nanoparticles Intended for Drug Delivery.
2011;697:101-108.
234. Xu X, Smith AE, McCormick CL. Facile 'one-pot' preparation of reversible,
disulfide-containing shell cross-linked micelles from a RAFT-synthesized, pH-responsive
triblock copolymer in water at room temperature. Aust J Chem. 2009;62(11):1520-1527.
235. Li Y, Lokitz B, McCormick C. RAFT synthesis of a thermally responsive ABC
triblock copolymer incorporating N-acryloxysuccinimide for facile in situ formation of
shell cross-linked micelles in aqueous media. Macromolecules. 2006;39(1):81-89.
236. Osborne JL, Farmer R, Woodhouse KA. Self-assembled elastin-like polypeptide
particles. Acta Biomaterialia. 2008;4(1):49-57.
237. Gianolio E, Giovenzana GB, Longo D, Longo I, Menegotto I, Aime S. Relaxometric
and modelling studies of the binding of a lipophilic gd-AAZTA complex to fatted and
defatted human serum albumin. Chem -Eur J. 2007;13(20):5785-5797.
238. Nicolle G, Helm L, Merbach A. S-8 paramagnetic centres in molecular assemblies:
Possible effect of their proximity on the water proton relaxivity. Magn Reson Chem.
2003;41(10):794-799.
239. Luk BT, Fang RH, Zhang L. Lipid- and polymer-based nanostructures for cancer
theranostics. Theranostics. 2012;2(12):1117-1126.

219

240. Kozlowska D, Foran P, MacMahon P, Shelly MJ, Eustace S, O'Kennedy R.
Molecular and magnetic resonance imaging: The value of immunoliposomes. Adv Drug
Deliv Rev. 2009;61(15):1402-1411.
241. Peer D, Karp JM, Hong S, FaroKHzad OC, Margalit R, Langer R. Nanocarriers as
an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2(12):751-760.
242. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol.
2008;26(24):4012-4021.
243. Caravan P, Ellison J, McMurry T, Lauffer R. Gadolinium(III) chelates as MRI
contrast agents: Structure, dynamics, and applications. Chem Rev. 1999;99(9):2293-2352.
244. Lee GY, Qian WP, Wang L, et al. Theranostic nanoparticles with controlled release
of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano.
2013;7(3):2078-2089.
245. Li NK, Quiroz FG, Hall CK, Chilkoti A, Yingling YG. Molecular description of the
LCST behavior of an elastin-like polypeptide. Biomacromolecules. 2014;15(10):35223530.
246. Rembert KB, Paterova J, Heyda J, Hilty C, Jungwirth P, Cremer PS. Molecular
mechanisms of ion-specific effects on proteins. J Am Chem Soc. 2012;134(24):1003910046.
247. Reile H, Armatis PE, Schally AV. Characterization of high-affinity receptors for
bombesin/gastrin releasing peptide on the human prostate-cancer cell-lines pc-3 and du-

220

145 - internalization of receptor-bound (125)i-(tyr(4)) bombesin by tumor-cells. Prostate.
1994;25(1):29-38.
248. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogs and
bombesin/gastrin-releasing peptide antagonist rc-3095 inhibit the growth of human
glioblastomas in-vitro and in-vivo. Cancer Res. 1994;54(22):5895-5901.
249. Roebroek AJM, Martens GJM, Duits AJ, et al. Differential expression of the gene
encoding the novel pituitary polypeptide 7b2 in human-lung cancer-cells. Cancer Res.
1989;49(15):4154-4158.
250. Migneault I, Dartiguenave C, Bertrand MJ, Waldron KC. Glutaraldehyde: Behavior
in aqueous solution, reaction with proteins, and application to enzyme crosslinking.
BioTechniques. 2004;37(5):790-+.
251. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast
agents and nephrogenic systemic fibrosis. Radiology. 2007;242(3):647-649.

221

APPENDIX

Figure A-1: Incubation of Doxorubicin loaded ELP-THO nanoparticles with cells.
Nanoparticles were incubated with both PC3 and U87 cells at different concentrations
and for different time periods. There is clearly an increase in interaction with the cells
with increasing in incubation time as well as protein concentration.
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